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Gene delivery vectors that are safe, efficient and affordable could significantly 
enhance the prospects for genetic-based therapies. Here we describe an approach to such 
vectors, using new variants of polyphosphazene materials and describe the synthesis of a 
series of degradable polyphosphazenes with both cationic and anionic side-chains, and 
report their use as mixed polyelectrolyte complexes for DNA and RNA delivery to 
glioblastoma cells in vitro and in vivo. Precursor poly(allylamino-phosphazene)s were 
converted to cationic and anionic derivatives via α, ω-thiolated alkylamines and 
alkylcarboxylates, respectively. Simultaneous co-incubation of alkylamine- and 
alkylcarboxylate-poly(phosphazenes) with nucleic acids generated polyelectrolyte 
complexes which were more compact than poly(alkylamino-phosphazene):DNA 
analogues but with similar positive surface charges. Screening of a series of these 
complexes for transfection of U87MG glioblastoma cells, showed that 
6-mercaptohexanoic acid substituted poly(phosphazene)s mixed in the polycation/DNA 
complexes resulted in the highest luciferase expression in the cells. These data were 
consistent with an increased buffering capability of the 6-mercaptohexanoic acid 
substituted polymer across the early endosomal pH range in comparison with other 
anionic side-chain substituted polymers. Transfection assays in 3D spheroid models and 
in subcutaneous xenograft U87MG tumours confirmed higher transgene expression for 
these mixed cationic and anionic poly(phosphazene)s compared to the related 
poly(alkylamino-phosphazene)-DNA complexes, and also to PEI-DNA complexes. 
Extension of the approach to siRNA delivery showed that the mixed cationic and anionic 




tumour progression (DYRK1A), resulting in a reduced renewal ability of U87MG cells 








Los vectores de administración de genes seguros, eficientes y asequibles podrían 
mejorar significativamente las perspectivas de las terapias génicas. Aquí describimos un 
enfoque para el desarrollo de tales vectores, usando nuevas variedades de 
polifosfacenos. Específicamente, describimos la síntesis de una serie de polifosfacenos 
degradables con cadenas laterales tanto catiónicas como aniónicas, y mostramos su uso 
como complejos polielectrolíticos mixtos para la administración de ADN y ARN a 
células de glioblastoma in vitro e in vivo. Los poli(alilamino-fosfacenos) precursores se 
convirtieron en derivados catiónicos y aniónicos a través de  αὠ-alquilaminas -tioladas 
y ácidos carboxílicos, respectivamente. La co-incubación simultánea de alquilaminas y 
alquilcarboxilatos de polifosfaceno con ácidos nucleicos generó complejos de 
polielectrolíticos más compactos que los poli (alquilamino-fosfacenos) -ADN análogos, 
pero con cargas superficiales positivas similares. Un cribado de los complejos 
sintetizados en base a la transfección de células de glioblastoma U87MG, mostró que el 
polifosfaceno sustituido con ácido 6-mercaptohexanoico mezclado en los complejos de 
policatión/ADN dio como resultado la expresión de luciferasa más alta en las células. 
Estos datos fueron en consonancia con una capacidad de tamponamiento incrementada 
del polímero sustituido con ácido 6-mercaptohexanoico en el rango de pH del endosoma 
temprano en comparación con otros polímeros sustituidos de cadena lateral aniónica. 
Los ensayos de transfección en modelos 3D de esferoides y en tumores de xenoinjerto 
subcutáneo U87MG confirmaron una mayor expresión del transgen para estos 
polifosfacenos aniónicos y catiónicos mixtos en comparación con los complejos de 




ampliación del enfoque a la administración de ARNi mostró que los polifosfacenos 
catiónicos y aniónicos mixtos fueron capaces de silenciar un gen que codifica una 
quinasa implicada en la progresión tumoral (DYRK1A), promoviendo una reducción en 
la capacidad de renovación de células U87MG in vitro y un retraso del crecimiento 
tumoral en un modelo de xenoinjerto. 
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I. Antecedentes y Introducción  
Administración de genes mediante vehículos poliméricos para el desarrollo de 
terapias frente al cáncer  
El cáncer se ha convertido en la mayor causa de muerte del siglo XXI y varias 
limitaciones de las terapias convencionales llevan consigo una baja eficacia terapéutica 
y un bajo índice de supervivencia en los pacientes tratados1-3. Este conjunto de 
enfermedades van frecuentemente ligadas a desórdenes genéticos y han desarrollado 
mecanismos para su autoprotección, como las mutaciones que confieren 
multirresistencia a fármacos y previenen la apoptosis, las capacidades de 
auto-renovación y metástasis, resultando en tratamientos ineficaces y bajos índices 
terapéuticos4-6. Esta elevada mutación genómica pone de relevancia la importancia de 
la terapia génica5. Los éxitos recientes en ensayos clínicos y un gran número de nuevas 
terapias emergentes basadas en polinucleótidos están suscitando una urgente demanda 
de vehículos de genes más seguros y eficientes7-9. A pesar de que la administración de 
genes mediante vehículos virales es el método más avanzado en cuanto al número de 
ensayos clínicos10, todavía existen preocupación acerca de la seguridad a largo plazo 
de estos vectores, y muchos de los nuevos polinucleótidos son más fácilmente 
integrables en vehículos no virales. Entre estos vehículos, los sistemas basados en 
polímeros presentan varias ventajas frente a los vectores virales, como su potencial 
seguridad, la facilidad de producción a gran escala, y su fácil preparación y 
modificación, como evidencian los resultados prometedores en ensayos clínicos11. Sin 
embargo siguen existiendo varias limitaciones para la aplicación práctica de estos 
vehículos poliméricos12-15, incluyendo una administración eficiente en los tejidos 
dianas así como un adecuado balance entre la protección de los ácidos nucleicos y su 
Resumen in extenso 
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posterior liberación una vez en el lugar de acción. La administración de genes 
mediante policationes toma ventaja de la tendencia de las cargas electrostáticas a pasar 
a través de las membranas celulares e incluso asociarse a estas, dando lugar a un tráfico 
intracelular adecuado16,17. Sin embargo, esta carga positiva de los policationes también 
puede provocar la disrupción de las membranas celulares dando lugar a efectos tóxicos 
indeseados, y una lenta disociación de los ácidos nucleicos que conlleva una baja 
eficiencia de transferencia génica18. En conjunto, los criterios de diseño que aún no han 
sido conseguidos por la mayoría de los vehículos de genes incluyen: (a) estabilidad, 
biocompatibilidad y biodegradabilidad, (b) una biodistribución selectiva y una 
adecuada farmacocinética, (c) la habilidad para traspasar barreras de tejido y 
extracelulares, (d) transporte a través de barreras intracelulares y liberación específica 
en orgánulos celulares.   
 
La necesidad de crear complejos de poliiones híbridos para terapia génica 
 
Para el ensamblaje electrostático de complejos para uso en terapia génica, se 
requiere que polímeros catiónicos y ácidos nucleicos con carga negativa sean 
mezclados adecuadamente construyendo vehículos similares a nanopartículas. La 
polietilenimina (PEI) es el polímero más ampliamente utilizado y puede formar 
complejos con pDNA cuando el ratio N/P ≥ 3, pero para conseguir una transfección 
significativa in vitro, estudios previos en varias líneas celulares tumorales han 
mostrado que se requieren ratios N/P ≥10 PEI/ácidos nucleicos. Este exceso molar de 
PEI es necesario para facilitar la internalización y la liberación intracelular del material 
genético, sin importar si esta PEI en exceso estaba libre en solución o fuera añadida 
previamente con el complejo PEI a N/P=3. En esta transfección "mediada por 
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polímeros", estos polímeros catiónicos adicionales promueven la transfección pero 
también pueden causar efectos secundarios no deseados. Además, este exceso de 
policationes no es eficaz in vivo, dado que los polipéptidos no unidos pueden ser 
retirados por fluidos intersticiales o atascados en la matriz extracelular19. En esta tesis, 
proponemos una estrategia para evitar los efectos secundarios derivados de un exceso 
de polímeros catiónicos, mediante la utilización de complejos de polímero/gen bien 
condensados formados a través de la mezcla de policationes con polianiones, llamados 
“poliplexos mixtos” como alternativa a los complejos de policatión tradicionales. 
 
Extensión de la flexibilidad de los polifosfacenos biodegradables 
 
Los polifosfacenos  son considerados como materiales prometedores para la 
administración de genes ya que combinan biodegradabilidad con una gran flexibilidad 
química para alcanzar los criterios mencionados anteriormente. Se ha especulado que 
dicha flexibilidad sería ideal para generar cribados de química combinatoria para 
optimizar la estructura de los polímeros. Sin embargo, su aplicación para 
administración de genes ha sido relativamente escasa dado que la ruta sintética 
principal para la modificación de estos polímeros, la sustitución nucleofílica del 
precursor polidiclorofosfaceno, es problemática para la mayoría de los derivados de 
interés. La causa es que los grupos funcionales con varios centros nucleofílicos (ej. 
aminas, hidróxidos, ácidos carboxílicos, etc.) usados en terapia génica tienen la 
capacidad de entrecruzar el polímero precursor. Inspirados por estudios recientes20 que 
proponen la potencial introducción de radicales click en polifosfacenos  (PPZs), en 
esta tesis demostramos que la introducción de un grupo vinilo a través de la formación 
de un polímero precursor secundario, alilamino-polifosfacenos  (AAPPZ), permite su 
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modificación sencilla con grupos funcionales de interés para administración de genes 
mediante reacciones de adición tiol-eno. Mediante este método, se pueden sintetizar 
PPZs con aminas primarias sin necesidad de utilizar una reacción de desprotección, y 
se ha generado una pequeña librería de otros derivados con aminas terciarias o ácidos 
carboxílicos como radicales, generando varios policationes y polianiones para la 
formación de “complejos mixtos” como vehículos para aplicación en terapia génica. El 
proceso de síntesis y evaluación biológica ha dado lugar a relaciones 























































































Esquema I. Polimerización de anillo-abierto de polifosfacenos  y su funcionalización 
mediante adición click tiol-eno para aplicación en terapia génica. Adición tiol-eno de 
alquilamina (4-5) y mezcla de alquilamina y alquil imidazol (6), mezcla de alquilamina 
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y tiol-eno terminal modificado (7), y diferentes longitudes de alquilcarboxilato en el 




Sobre la base de los conocimientos explicados, elaboramos las siguientes hipótesis: 
1. Administración factible a través de tratamientos locales para GBM 
 
En este estudio, nos centramos en cánceres altamente agresivos y malignos, 
Glioblastoma Multiformes (GBM) que están clasificados como grado IV por la 
Organización Mundial de la Salud (OMS) debido a la alta tasa de recurrencia. La 
cirugía es el tratamiento clínico más común si los tumores pueden extirparse, lo que 
permite que las administraciones locales de fármacos terapéuticos sean otro medio 
factible para tratar las células tumorales GBM remanentes o las células tumorales 
iniciales (TIC) después de la extirpación de los tumores principales. 
 
2. Administración sistémica de genes y superación de las trampas endosómicas 
 
En general, la composición de los vehículos de terapia génica se optimiza en base 
a su eficacia de transfección en cultivos celulares 2D in vitro. Sin embargo, algunas 
publicaciones sugieren que la optimización de las formulaciones en cuanto a su 
eficacia de transfección in vitro puede no ser eficiente. En estos estudios, se usan 
relaciones N/P más altas para conseguir una transfección génica más eficiente, pero 
muchas veces la transfección resulta incrementada por policationes no unidos debido a 
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efectos en la internalización y el escape endosomal21-23. En la presente tesis, 
seleccionamos varios polianiones sensibles al pH como un excipiente para la 
formación de complejos binarios poliiones/gen con una estabilidad óptima en medios 
complejos, donde la estabilidad de poliplexos altamente catiónicos se vería 
comprometida. Además, hipotetizamos que estos polianiones sensibles al pH ayudarían 
a los nanocomplejos a escapar de los compartimentos endo-lisosómicos mediante el 





Esquema II. Polianiones sensibles a pH,  el polifosfaceno (PPZ) aniónico se mezcla 
con los complejos de PPZ catiónico para facilitar el escape de los compartimentos 
endosomales y liberar el ácido nucleico. 
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3. Minimizar la citotoxicidad y facilitar la liberación de los vehículos 
 
Como se ha descrito anteriormente, dos inconvenientes de los vehículos 
poliméricos en la administración intracelular son la toxicidad inducida por el policatión 
y la difícil disociación completa de los policationes y cargas génicas incluso después 
del escape endosómico. De la co-formulación de policationes con polianiones puede 
esperarse la neutralización parcial del exceso de cargas positivas de los nanocomplejos 
antes de la internalización, evitando daños graves a la membrana celular. Además, 
después de la endocitosis, el ambiente ligeramente ácido en los compartimentos 
endosomales sería amortiguado por los complejos poliméricos mixtos, reduciendo 
además la neutralización de los polianiones debido a la protonación, aumentando así 
las cargas positivas de los nanocomplejos así como aumentando la hidrofobicidad de 
los polianiones, estableciendo por tanto dos mecanismos para la disrupción de la 
membrana celular (Esquema II). En este trabajo hipotetizamos que esta acción dual de 
los complejos mixtos resultará en un aumento del escape endosomal así como una 
mejora en la eficacia de transfección. 
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III. El objetivo de esta tesis 
Los polímeros catiónicos se diseñaron para complejar ácidos nucleicos cargados 
negativamente con el objetivo de construir vehículos de terapias génicas similares a 
nanopartículas a través de interacciones electrostáticas hace algunas décadas. Sin 
embargo, la falta de suficiente estabilidad del complejo polimérico y la liberación 
controlada de los ácidos nucleicos en los lugares diana son las dos principales razones 
que limitan su aplicación en clínica. Aquí, proponemos una estrategia para complejos 
de polímero/gen bien condensados a través de la mezcla de policationes con 
polianiones en comparación con complejos de policatión tradicionales.  
 
Obj I. Sintetizar polifosfacenos policatiónicos y polianiónicos para su uso en terapia 
génica  
 
Obj II. Elaborar complejos mixtos policatión-polianión con ácidos nucleicos, analizar 
su nanoestructura y caracterizar sus propiedades fisicoquímicas.  
 
Obj III. Evaluar potenciales polianiones en base a su capacidad tamponante de 
protones y discutir las propiedades de los complejos poliméricos para el escape 
endosomal mediante efectos de esponja de protones y/o disrupción de membrana. 
 
Obj IV. Optimizar estos complejos a base de poli-iones binarios en base a su eficacia 
de transfección en modelos in vitro.  
 
Obj V. Evaluar el potencial de los vehículos a base de poli-iones binarios como 
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agentes de transfección en modelos bio-relevantes, incluyendo modelos de esferoides 
3D (modelos de GBM para mimetizar tumores recurrentes en estadíos tempranos) y 
modelos xenograft. 
 
Obj VI. Realizar una prueba de concepto de la eficacia de silenciamiento de los 
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IV. Resultados y discusión 
La estrategia para la síntesis de varios polifosfacenos sustituídos fue mediante la 
polimerización de anillo-abierto térmica del monómero cíclico hexaclorofosfaceno (1) 
y la reacción del poli(diclorofosfaceno) resultante con alilamina bajo condiciones 
básicas para permitir las cadenas laterales vinílicas20. Las ventajas de este precursor 
AAPPZ residen en su fácil derivatización tiol-eno, y aquí utilizamos esta reacción para 
dar lugar a una serie de policationes (4-5) y polianiones (8) (Esquema I). Para esta 
reacción, se obtuvieron altos grados de conversion (cadena lateral/grupo alílico) 
≧90% y altos rendimientos de reacción (≧71%) mediante reacciones tiol-eno. 
 
Varias cadenas laterales funcionales fueron añadidas exitosamente a los 
polifosfacenos. Comparados con los complejos basados únicamente en policationes 
(Policatión/pDNA, diámetro 80 nm, +40 mV), los complejos mixtos 
(Policatión/polianión/pDNA) presentaron una estructura nanométrica más compacta y 
una reducción de -10 mV en su carga superficial. En cultivos 2D en monocapa de 
células U87MG, se hizo un cribado de varias longitudes de cadenas laterales alifáticas 
en el polímero aniónico, obteniéndose la expresión más alta de luciferasa para el 
polímero sustituido con ácido 6-mercaptohexanoico en los complejos policatiónicos 
(Figura I-a). Estos resultados son consistentes con la más alta capacidad tampón del 
ácido 6-mercaptohexanoico dentro del rango de pH del endosoma temprano en 
comparación con las otras cadenas aniónicas. Además, la toxicidad del complejo mixto 
en 2D fue reducida en comparación con los otros complejos, probablemente debido a 
la neutralización de la carga. Por otro lado, la mayor parte de los PPZ polianiónicos no 
consiguieron aumentar la eficacia de los nanocomplejos para la liberación de genes, 
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con excepción del 6MHA-PPZ. Esto es probablemente debido a la capacidad 
específica de la estructura del 6MHA-PPZ para tamponar protones. Al analizar el 
mecanismo detrás del mejor funcionamiento de estos nanocomplejos, nuestros estudios 
han mostrado que la presencia de 6MHA-PPZ en el nanocomplejo, resulta en una 
menor co-localización con los compartimentos endosómicos (Figura I-b). Este 
eficiente escape endosomal está probablemente ligado a la capacidad de 6MHA-PPZ 
para romper las membranas celulares en el ambiente ácido de los endosomas tal y 
como hemos confirmado mediante tests de hemólisis (Figura I-c). En este trabajo, 
complejos integrando 6MHA-PPZ fueron los únicos que presentaron un efecto 
hemolítico despreciable a pH neutro, pero un efecto hemolítico comparable con 
poli-L-lisina (PLL) a pH ácido. Este efecto de rotura de membrana puede ser mediado 
por la hidrofobización de 6MHA-PPZ ya que este polímero pierde sus cargas mediante 
protonación entre los pH fisiológicos y endosomales. Es interesante mencionar que 
6MHA-PPZ parece también capaz de mejorar la transfección celular en combinación 
con policationes estándar con bajas capacidades de escape endosomal como la PLL.  
 
En comparación con los cultivos en monocapa 2D, los cultivos 3D constituyen 
mejores modelos de la arquitectura tisular (e.g. extracellular matrix, cell interactions)24 
y los patrones de expresión génica25. A día de hoy, pocos estudios han investigado la 
administración de ácidos nucleicos en esferoides tumorales a pesar del hecho de que 
constituyen adecuados modelos previos a los estudios in vivo. Según se obseva 
mediante imagen fluorescente tomográfica, los complejos CA-/6MHA-PPZ:pDNA, 
dieron lugar a una mayor transfección de los esferoides de U87MG en comparación 
con los compejos CA-PPZ:pDNA y los complejos de referencia PEI:pDNA; esto fue 
particularmente remarcable a la dosis más baja de  2 µg/mL (Figura II-a). Esta 
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eficacia incrementada fue también acompañada de una toxicidad mínima. Esta 
observación podría deberse a las propiedades fisicoquímicas de los complejos 
CA-/6MHA-PPZ:pDNA, cuyas cargas catiónicas parcialmente neutralizadas an pH 
fisiológico podrían apantallar al sistema de una unión indiscriminada a la matriz 
extracelular en los esferoides tumorales. Aunque los datos fueron más difíciles de 
interpretar debido a los niveles de transfección no homogéneos entre el sitio de 
inyección y los sitios más distales, estos resultados van en consonancia con los del 
experimento in vivo (Figura II-a).  
 
Siguiendo las mismas condiciones del experimento piloto in vivo con 
GFP-pDNA, utilizamos la misma formulación optimizada para la liberación de una 
secuencia de siRNA con actividad conocida para suprimir las células iniciantes de 
glioblastoma (siRNA contra DYRK1A, siDYR)26. La formulación 
CA-/6MHA-PPZ:siDYR fue evaluada en un modelo xenograft U87MG de ratón, en un 
esquema terapéutico que incluye el co-tratamiento con el quimioterapéutico de primera 
línea temozolamida. Este experimento encontró un retraso significativo en la 
progresión del tumor en los ratones que recibieron TMZ y CA-/6MHA-PPZ:siDYR vs 
los ratones que recibieron TMZ y CA-/6MHA-PPZ complejado a una secuencia 
siRNA no funcional (Figura II-b). Por lo tanto, nuestros resultados sugieren un 
beneficio terapéutico en combinar la terapia génica CA-/6MHA-PPZ:siDYR con el 
tratamiento farmacológico estándar de glioblastoma. Futuros ensayos serán necesarios 
para elucidar el posible impacto clínico de esta terapia combinada en modelos más 
avanzados y mediante un análisis fenotípico adicional de los tumores.  
 
 




Figura I. Optimización y estudios mecanísticos de los complejos PPZ iónicos en cultivos 2D 
en monocapa de U87MG. (a) Expresión de luciferasa mediante cuantificación de las RLU/μg 
proteína obtenidas después de la transfección de células U87MG con los complejos 
CA-PPZ:pDNA (8:1 N/P ratio) y los complejos CA-PPZ/polianiónicos PPZ:pDNA (N/C/P 
ratio of 8:4:1, dosis de pDNA 1 μg/cm2). Se muestra la transfección con PEI:pDNA como un 
control interno. (b) Actividad metabólica celular 48h después del tratamiento con diferentes 
concentraciones de los mismos complejos (c) Imágenes de microscopía confocal mostrando la 
localización intracelular del pDNA (Rojo) administrado en complejos poliméricos, con 
respecto al endosoma (Verde). (d) Estudiode hemólisis de los diferentes complejos 
poliméricos.  
 




Figura II. Eficacia de los complejos PPZ en modelos de esferoide in vitro y en un modelo 
xenograft in vivo. (a) Imágenes tomográficas 3D de esferoides transfectados con GFP tomadas 
mediante LSFM y transfección en tumores U87MG subcutáneos mediante IVIS. (b) Volumen 
tumoral relativo en un modelo xenograft de U87MG tratado con CA-PPZ/6MHA-PPZ 
complejando una secuencia de siRNA terapéutica (siDYR) o scrambled (siCtrl) (16 µg por 
tumor) y terapia combinada con la inyección intraperitoneal de TMZ 5 mg/kg con 4 
tratamientos en total. 
 










Hemos desarrollado una estrategia sintética sencilla para la preparación de una 
pequeña librería de polifosfacenos de interés para administración de genes, basada en 
la generación de un polímero precursor con asas click, y su posterior derivatización 
mediante adiciones tiol-eno. Esta estrategia nos ha permitido testar una variedad de 
compuestos y llevar a cabo relaciones estructura/función. Basándonos en los cribados, 
hemos seleccionado un polímero con presencia de aminas primarias (CA-PPZ) y un 
polifosfaceno aniónico análogo (6MHA-PPZ) para la administración de pDNA. Estos 
complejos binarios poliión/gen mostraron una eficacia de transfección 
significativamente mayor que el sistema padre con sólo policatión en cultivos 
monocapa 2D, esperoides de U87MG 3D y un modelo xenograft subcutáneo, debido a 
un mejor transporte intratumoral y a unas mejores características de tráfico intracelular. 
Este sistema optimizado también mostró indicaciones de una mejor eficacia en 
comparación con complejos PEI “gold-standard”, particularmente en modelos 
tumorales 3D. Cuando se usaron para terapias de RNA interferente, los complejos 
CA-PPZ/6MHA-PPZ consiguieron liberar el siRNA contra DYRK1A en células 
U87MG, induciendo una reducción significativa en la capacidad de auto-renovación in 
vitro y un efecto anti-tumoral significativo en un modelo de glioblastoma in vivo. En 
conclusión, estos datos describen un nuevo sistema de liberación de genes polimérico, 
biodegradable y versátil basado en polifosfacenos con una capacidad remarcable para 
la transfección celular, la penetración de tumores y con un buen perfil de acción in 
vivo.  
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I. Background and Introduction 
 
Polymer-gene delivery in need for cancer therapy 
 
Cancer has become a leading death cause in the 21th century and several 
limitations and issues in conventional therapies, currently causing poor therapeutic 
efficacy and low survival rate of treated patients1. This highly gene-disorder disease 
developed own self-protection mechanisms, like multi-drug resistance and 
anti-apoptosis mutation, self-renewal and metastatic capacities, resulting in ineffective 
anticancer treatments and discounting therapeutic index2-4. Herein, their genomic 
mutation emphases the importance of gene therapy5. Current successes in clinical trials 
and many emerging novel therapies based on polynucleotides are driving an urgent 
demand for more efficient and safer gene carriers6-8. While viral-based gene delivery is 
the most advanced in terms of number of clinical trials9, there are still concerns over 
long-term safety of viral vectors, and many of the new polynucleotides are easier to 
integrate in non-viral gene delivery systems. Among them, polymer-based gene 
systems have several advantages over viral vectors, such as their potential safety, 
large-scale production, and easy preparation and modification, providing a number of 
promising results in clinical trials10. However, there remain several limitations for 
polymer-based gene vehicles in practical applications11-14, including efficient delivery 
to targeting locations and a trade-off between gene protection before and unloading of 
nucleic acids after arriving at the destinations. Polycation-mediated gene delivery takes 
advantages on electrostatic charging tendency to pass through cell membranes and 




the polycation-driven membrane disruption brings unwanted toxic effects and slow 
dissociation of polycations and nucleic acids with reduced gene-transferring 
efficiency17. Taken together, design criteria that are yet unfulfilled in most synthetic 
polymer-gene carriers include: (a) stability, biocompatibility and biodegradability, (b) 
selective biodistribution and adequate pharmacokinetics, (c) ability to surmount tissue 
and extracellular barriers, (d) transport across intracellular barriers and 
organelle-specific release. 
 
The needs for hybrid polyions complexes in gene delivery 
 
For electrostatic assembly of complexes in gene delivery applications, cationic 
polymers and negatively charged nucleic acids are required to be mixed properly to 
construct nanoparticle-like vehicles. Polyethylenimine (PEI) is the most intensively 
investigated polycation and can complex with pDNA when N/P ratio ≥ 3, but for 
significant in vitro transfection prior reports have shown that ratios of N/P ≥ 10 for 
PEI/nucleic acids are needed for efficacy in several tumour cell lines 18,19. These excess 
PEI is necessary to facilitate internalisation and intracellular delivery, no matter 
whether the excess PEI is free in solution or added in advance with the PEI-complex at 
N/P = 3. In this “polymer-mediated” transfection, the extra cationic polymers promote 
transfection but can also cause unwanted side effects. More importantly, excess 
polycation is not such effective in vivo, as unbound polycations may be sequestered by 
interstitial fluids or be retained in extracellular matrices20. In this thesis, we have 
proposed a strategy for avoiding excess polycation-mediated side effects by utilising 
well-condensed polymer/gene complexes formed via mixing polycation with synthetic 
anionic polymers in addition to the polyanionic nucleic acids, and have compared these 





Extension of biodegradable polyphosphazene flexibility 
 
Polyphosphazenes have been considered promising materials for gene delivery 
since they combine biodegradability and great chemical flexibility for meeting those 
above-mentioned criteria. It was envisaged that such flexibility would be ideal for 
generating combinatorial chemistry screens to optimize polymer structure. Still, their 
application for gene delivery has remained relatively scarce because the main synthetic 
route for polymer modification, the nucleophilic substitution of the precursor 
poly(dichlorophosphazene), is problematic for most derivatives of interest. The reason 
is that functional groups with several nucleophilic centres (i.e. amines, hydroxides, 
carboxylic acids, etc.) used in gene therapy will cross-link the precursor polymer. 
Inspired by recent reports21 that proposed the potential introduction of click handles in 
PPZs, this thesis further demonstrates that introduction of a vinyl group through the 
formation of a secondary polymer precursor, allylamino-poly(phosphazene) (AAPPZ), 
enables its simple modification with functional groups of interest for gene delivery 
using a thiol-ene addition reaction. By this method, PPZs with primary amines can be 
synthesized without any protection/deprotection processes, and a small library of other 
derivatives with tertiary amines or carboxylic acid pendent groups (Scheme I). The 
streamlined synthetic process has drawn interesting structure/performance 
relationships. The scheme showed all functional polymers derived from allyl-modified 
PPZ we synthesized, but only cationic (4, 5) and anionic (8) side-groups introduced 

























































































Scheme I. Ring-opening polymerisation of polyphosphazene and functionalisation by 
thiol-ene click addition for gene delivery applications. Thiol-ene addition of 
alkylamine (4-5) and mixing alkylamine and alkyl imidazole (6), mixing alkylamine 
and thiol-ene modified terminals (7), and different lengths of alkylcarboxylate on 








On the basis of general knowledge in clinical use and pharmaceutical science, we set 
out the following hypotheses to test: 
 
1. Feasible administration via local treatments for GBM 
 
In this study, we focus on highly aggressive and malignant cancers, Glioblastoma 
Multiformes (GBM), which are classified as grade IV by the World Health 
Organization (WHO) due to their high rate of recurrence3. Surgery is the most typical 
clinical treatment if the tumours can be excised, allowing local administrations of 
therapeutic drug to treat leftover GBM tumour cells or tumour initial cells (TIC) after 
primary tumour excision. As this accessible administration, we design an 
intra-tumoural injection of our polymeric gene vehicles for gene therapy application. 
 
2. Systemic gene delivery and overcome endosomal traps 
 
In general, the best formulation composition ratios of polymer gene-carriers are 
usually defined from the highest transfection efficiencies obtained in 2D in vitro 
cultures. However, some literature reports have indicated problems for formulation 
optimization regarding in vitro transfection. Higher N/P ratios are used for higher 
efficiency of gene transfection until dose-induced toxicity, in which unbound 
polycations however facilitated the carriers for internalisation and endosomal 
escape.18,19,22 Herein, we screen various pH-responsive polyanions as an excipient to 




complexes and their stability in complex media where highly positively-charged 
conventional polymer complexes would be sub-optimal. In addition, we hypothesize 
that these pH-responsive polyanions would help the nanocomplexes to escape from 
endolysosomal compartments via a ‘proton-sponge’ mechanism and membrane 
disruption (Scheme II). 
 
 
Scheme II. pH-sensitive polyanionic polyphosphazene (PPZ) mixing into polycationic 
complexes for facilitating escape from endosomal compartments and release of nucleic 
acids. 
 
3. Minimize cytotoxicity and release efficiency from vehicles 
 
As described above, two drawbacks of current polymers in used for nucleic acid 
delivery are polycation-induced toxicity and the difficulty in ensuring complete 




Co-formulation of polycations as well as polyanions can be expected to neutralize 
partially the excess positive charges on the nanocomplexes before internalisation, 
avoiding serious damages to cell membrane. Furthermore, after endocytosis, the 
acidified environments in the intracellular digestive endosomal compartments would 
be buffered by mixed polyanion/polycation complexes as well as reduce neutralization 
by the polyanions due to protonation, increasing the positive charges on the polymeric 
complexes as well as enhancing the hydrophobicity of the polyanions, thus establishing 
two mechanisms for disrupting intercellular membranes (Scheme II). We hypothesize 
that this dual action of the mixed complexes will result in enhancement of endosomal 





III. The objective of this thesis 
In general, cationic polymers that designed for complexation with negatively 
charged nucleic acids to construct nanoparticle-like gene vehicles via electrostatic 
interactions are well-established in the pharmaceutical science literature. However, the 
lack of systemic stability of conventional polymer-gene complexes and controlled 
release of the nucleic acid cargo once at the targeting locations are two of the main 
reasons for delay in clinical applications18,19. Herein, we propose a strategy for 
enhanced efficacy of polymer/gene complexes through the mixing of polycations with 
additional polyanions during the complexation stage with nucleic acids.  
 
Obj I. To synthesize polycationic and polyanionic polyphosphazenes via 
click-chemistry addition for use in polymeric gene delivery 
 
Obj II. To establish mixed polycation and polyanion nanocomplexes with nucleic 
acids and to analyse their nanostructure and particle characterisation. 
 
Obj III. To evaluate potential polyanions as suggested by proton-buffering capacity 
and to discuss that facilitated polymeric complexes escaping from endosomal 
compartments through proton-sponge effects and/or membrane disruption. 
 
Obj IV. To optimize these binary-polyions gene complexes by transgene efficiency in 
vitro models. 
 




bio-relevant models, including 3D spheroid models (GBM models for mimicking early 
stage tumour in recurrence) and xenograft models. 
 
Obj VI. To provide a proof-of-concepts for gene silence therapy by using the optimal 
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Abbreviated name Full name 
1H-DOSY 1H Diffusion-ordered spectroscopy 
7-AAD 7-Aminoactinomycin D 
AAPPZ Allylamino-substituted polyphosphazene (3) 
3MPA-PPZ 3-Mercaptopropanoic acid introduced on AAPPZ (x=2 at structure 8) 
4MBA-PPZ 4-Mercaptobutanoic acid introduced on AAPPZ (x=3 at structure 8) 
6MHA-PPZ 6-Mercaptohexanoic acid introduced on AAPPZ (x=5 at structure 8) 
8MOA-PPZ 8-Mercaptooctanoic acid introduced on AAPPZ (x=7 at structure 8) 
CA-PPZ Cysteamino-introduced on AAPPZ (4) 
CA-PPZ complex Complexes of CA-PPZ with pDNA 
CA-/6MHA-PPZ 
complex 
Complexes of CA-PPZ and 6MHA-PPZ with pDNA 
Cy3 ; Cy5 Cyanine 3; Cyanine 5 
Diglyme Diethylene glycol dimethyl ether 
DLS Dynamic light scattering 
DMAES-PPZ 2-(dimethylamino)ethanethiol side-chain addition on AAPPZ 
DYRK1A Dual specificity tyrosine-phosphorylation-regulated kinase 1A 
ECM Extracellular matrix 
EGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
FRET Förster resonance energy transfer 
GBM Glioblastoma multiforme 
GICs glioblastoma initiating cells 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IVIS In Vivo Imaging Instruments 
KCPs Kilo counts per second, which is an unit of total derived count  
LSFM  Light-sheet based fluorescent microscopy 
RBC Red blood cells 




N/C/P ratio The ratio of polycationic amines (N), polyanionic carboxylates (C) 
and negative DNA phosphates (P) 
NTA Nanoparticle Tracking Analysis 
PDCP Poly(dichlorophosphazene) 
pDNA Plasmid DNA 
PEI Polyethylenimine 
PLL Poly-L-lysine 
PPZ  Polyphosphazene 
RLU Relative luminometer units 
ROIs The regions of interest 
siCtrl a scramble sequence of siRNA as control 
siDYR siRNA against DYRK1A 
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 Gene delivery is one of the most ancient processes on earth, as it is central to the 
lifecycle of all organisms. In addition, viruses and bacteria utilise certain aspects of 
gene delivery for infection of higher organisms. Synthetic gene delivery is of particular 
importance for medical applications, and a wide range of different vectors have been 
used to enhance delivery of therapeutic gene. Viral-based gene carriers have been the 
most investigated vectors in clinical trials, but the drawbacks of viral vectors still limit 
the range of medical applications. Non-viral gene vehicles, particularly lipid-based 
vehicles or polymeric carriers have advantages in gene delivery because of their 
low-risk of immunogenicity and carcinogenicity compared to viral counterparts. In this 
chapter, we firstly introduce the general field of gene therapy and its clinical progress, 
and then we focus on polymeric gene delivery and discuss the related challenges of 
non-viral gene delivery in practice. 
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1.1 Gene delivery 
Gene delivery involves the transfer of foreign nucleic acids to host cells, and 
therapies based on this concept hold promise for gene-associated human diseases, such 
as cancers, neurodegenerative disorders and cystic fibrosis. However, there are many 
biological barriers that significantly hinder delivery of exogenous nucleic acids to target 
locations and the nucleic acids (DNA, RNA) themselves are fragile and rapidly 
degraded by enzymes (e.g. nucleases). There is a clear motivation for developing 
materials or carriers that can protect nucleic acids during formulation, administration to 
the body, and in transit across the many biological barriers before precisely delivering 
therapeutic genes to their targets. These gene carriers, or vectors can be generally 
divided to two main classes, i.e. viral vectors and non-viral carriers, and both methods 
have been applied for systemic delivery in clinical trials 1,2.  
 
Viruses are one of the most ancient biological agents and have evolved over 
billions of years on earth, developing highly efficient approaches to deliver their 
genomes to many different host cells. Scientist have employed viruses as vehicles for 
gene delivery since the 1970s3 and engineered various viruses as gene carriers including 
adenoviruses, adeno-associated viruses (AAVs), lentiviruses, and retroviruses. In the 
last decade, around 70% of clinical trials in gene therapy have utilised viral vehicles4. 
As shown in Figure 1-1, adenoviruses are the most commonly used vehicle in the 
data-base, with an early example being a treatment for the genetic disorder ornithine 
transcarbamylase deficiency. However, in this particular case, a young patient died due 
to severe inflammation and multi-organ failures5. After that, problems relating to 
pre-existing immune response, the effectiveness of certain viruses integrating into the 
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human genome, and long-term safety have increased concerns relating to viral-based 
gene therapy. In addition, although recent vectors of lentivirus and adeno-associated 
virus (AAV) have shown improved clinical safety1, several innate drawbacks of viral 
gene vectors still remain. These include immunogenicity and carcinogenicity, low 
genetic payloads, and the high cost of viral vector production at scale. These limitations 
are driving research into synthetic nucleic acid carriers.  
 
 
Figure 1-1 Gene vehicles used in clinical trials from 1989 to 2012.4 [Reproduced from 
Ginn et al, J Gene Med 2013; 15: 65–77, with a Creative Commons license.]. 
 
Non-viral gene delivery approaches generally include two categories based either 
on physical or chemical methods (Figure 1-2)6. In terms of the physical methods, jet 
injection, ultrasound and biolistics have all been used to generate transient holes in cell 
membranes or on tissue boundaries, allowing gene transfer directly into the cytoplasm 
of host cells. Fine needle puncture and electric impulses have also been employed for 
bypassing the known barriers to delivery, and have been very effective for single or 
multiple cells. However, the low amount of delivered nucleic acids and the high costs of 
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a delivery method which is difficult to use in large-scale have limited clinical 
applications to date.  
 
Chemical methods of gene delivery have advantages relative to viral vectors, 
including safety profile, higher gene loading capacity, and potential for large-scale 
production. In general, for these vectors, cargos of DNA or RNA are condensed or 
packaged in complexes / encapsulates via electrostatic interactions and the resulting 
‘polyplexes’ are able to pass through cell membranes via a range of endocytic pathways. 
Materials used for gene carriers of this type include natural molecules, such as cationic 
lipids (which form so-called Lipoplexes) and both synthetic and natural polymers which 
form polyelectrolyte complexes (Polyplexes) with polyanionic nucleic acids. Other 
complexes can be formed by addition of the nucleic acids to inorganic salts containing 
di- or multivalent cations such as calcium phosphates.  
 
Polyelectrolyte formulations from these polycation-nucleic acid complexes can be 
produced as suspensions of virus-sized particles (< 100 nm) but with low-risks of 
immunogenicity and carcinogenicity. These artificial nanoscale carriers are able to 
upload larger amount of genetic payloads and various kinds of gene sequences than 
viral analogues 7,8. In addition, the risk of those artificial gene carriers in human tests 
can be evaluated prior to clinical trials, an advantage compared with viral vectors. 
However, poor efficiency in delivery, attributable to the inability to cross all the 
biological barriers in routes to target cells and organelles, is still a problem for non-viral 
vectors, promoting scientists and engineers to endeavour to address those issues9. 
 
 





Figure 1-2. General summary of gene delivery vehicles and categorized by synthesis 
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1.2 Nanoparticle-based gene delivery 
In terms of chemical gene delivery methods, nanoparticle-based gene delivery 
systems are defined as nanoscale (1-200 nm) vehicles loaded nucleic acids. 
Nanoparticles of this type exhibit large surface area-to-volume ratios, and with 
appropriate surface chemistries can display prolonged half-life, and increasing 
bioavailability11. In the last decade, many formulations or agents have been developed 
for gene delivery, including organic materials (lipid-based and polymer-based vehicles, 
dendrimers, etc.) and inorganic carriers (calcium phosphate precipitation, gold/silver 
particles, etc.). Herein, we focus on introduction of lipid-based and polymer-based 
carriers, which have had promising results in clinical studies in the recent years 9.  
 
Lipid-based nanoparticles (LNP) contain cationic lipids, and form micelle-like or 
liposome-like structures, for example the cationic lipid DOTMA 
(1,2-di-O-octadecenyl-3-trimethylammonium propane) is used in LipofectinTM and 
DOSPA 
(2,3-Dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l-propanaminium 
trifluoroacetate) is one of components in LipofectAMINETM, as shown in Scheme 1-1. 
By virtue of these cationic lipids, the positively charged LNP can condense various 
nucleic acids plasmid DNA (pDNA), small interfering RNA (siRNA), microRNA 
(miRNA), antisense oligonucleotides (ODNs), etc., and protect their gene cargos from 
degradation by nucleases, forming a nanoscale carrier (≥ 200 nm in diameter). Within 
commercial reagents for in vitro transfection, LipofectAMINETM series are the most 
commonly used LNP as transfection reagents. In clinical trials, LNP formulations have 
shown advances, for example Patisiran (ALN-TTR02) which recently completed a 
Chapter I / Capítulo I 
54 
 
clinical study in phase III for patients with Transthyretin (TTR)-Mediated Amyloidosis, 
and commenced Expanded Access Protocol Study  
 
As shown in Table 1-1, polymer-based gene delivery is a term referring to polymer 
mediated targeting gene in host cells, using synthetic polymers, such as 
polyethylenimine (PEI), polyethylene glycol (PEG), poly-L-lysine (PLL)12, 
poly(β-amino ester) (PBAE)13, poly[(2‑dimethylamino) ethyl methacrylate] 
(pDMAEMA) 14, polyamidoamine (PAMAM) dendrimers 15, or natural macromolecules, 
like protamine, chitosan16, etc. (Scheme 1-1).8 The general principle is that cationic 
polymers condense negatively charged nucleic acids via ionic attraction, forming 
nanoparticle-like carriers. Among the first cationic polymer employed for condensing 
DNA for gene delivery was PLL, which is a biodegradable polypeptide and readily 
available polypeptide 17. However, relatively low transfection efficiencies of some 
PLL/pDNA vehicles were found, attributable to trapping of PLL/pDNA in endosomes 
and lysosomes18. One of the reasons is that PLL polymers lack amine groups with 
appropriate buffering capacity for the endosomal range (pH7.4 - 5.5), as shown in 
Figure 1-3.  
 
Polyethylenimine (PEI) is recognized as one of the most widely-used cationic 
polymers. Although the repeating units are simple, PEI as commercially available 
contains primary, secondary, and tertiary amines, providing different buffering 
capacities across different pH environments, which included those of endosomal 
compartments (Figure 1-3). In light of the simple repeating structure of PEI and desired 
outcomes of endosomal escape, PEI has become one of gold standard agents for in vitro 
transfection. However, PEI/gene complexes also have their limitations: firstly, the lower 
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stability of PEI-gene vehicles compared to PLL-complexes may limit protection of 
nucleic acids from nuclease degradation during delivery. It is especially important when 
PEI complexes carry siRNA, in comparison with pDNA19-21. Secondly, PEI is a 
non-degradable polymer, with potential side effects resulting from intracellular 
accumulation. Thirdly, a stoichiometric excess of PEI polymer is usually necessary in 
gene transfection for facilitating internalisation and endosomal escape, but this excess 
causes unwanted toxicity 22. Despite those drawbacks, poly(ethylenimine) derivatives 
have inspired many studies, such as conjugation of repeating units of ethylenimine on 
biodegradable polymers for facilitating endosomal escape. For examples, Prof. Kataoka 
and his co-workers found conjugation of even numbers of ethylenimine units (two or 
four repeat units) on biodegradable polyaspartamides can improve gene-transferring 
efficiency due to endosomolytic effects 23. Crosslinking of PEI polymer chains via 
disulfide bonds can stabilize the complexes in physiological ionic strength solution 24 
and reduce PEI-caused toxicity25. Moreover, glucose has also been conjugated with four 
ethylenimine repeating units for significantly reducing cytotoxicity and those structures 
of glucose-linked ethylenimines are identical to the commercial reagent (GlycofectTM) 
26.  
 
Although there are many doubts regarding non-degradable PEI, PEI-based gene 
carriers still account for most clinical trials of polymeric gene delivery (Table 1-1). 
PEI-related reagents for in vitro transfection or in vivo experiments are also 
commercially available, such as linear PEI commercial reagent (Jet-PEI) or 
saccharide-conjugated repeating ethylenimines (GlycofectTM). In preclinical studies, 
intratumoral injection of PEI/DNA complexes showed promising luciferase gene 
transferring efficiency 27. In human studies (Table 1-1), PEI/DNA complexes (BC-819 
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from BioCancell) are in phase II trials for bladder cancer via local administration. The 
preliminary results showed both safety and efficacy: BC-819/PEI complexes were 
well-tolerated and showed ability to regress tumours in 72% patients. Furthermore, 
EGEN-001 (an IL-12 plasmid) delivered by PEG–PEI–cholesterol lipo-polymer treated 
patients with platinum-resistant recurrent ovarian cancer and combined 
chemotherapeutic drugs for colorectal-cancer patients following cytoreductive surgery 
and hyperthermic intraperitoneal chemotherapy therapy (HIPEC). 
 
Taken together, there are potentially promising clinical trials of lipid-based and 
polymer-based gene delivery ongoing. In comparison with viral gene delivery, 
nanoparticle-based vehicles can reduce unwanted severe acute toxicity and unexpected 
long-term side effects, but still lack efficient delivery and transfection potency to desire 



















































































 Scheme 1-1 Common-used materials in lipid-based and polymer-based gene carriers 
Abbreviation: DOTAP (1,2-dioleoyl-3-trimethylammonium-propane); DOTMA 
(1,2-di-O-octadecenyl-3-trimethylammonium propane); DOGS 
(Di-octadecyl-amido-glycyl-spermine); DOSPA 
(2,3-Dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l-propanaminium 
trifluoroacetate); PEI (polyethylenimine); PLL (poly-L-lysine); PBAE (poly(β-amino 
ester)); pDMAEMA (poly[(2-dimethylamino) ethyl methacrylate]); chitosan. 
 
  





Figure 1-3. Potentiometric titration curves of various polycations. [Reproduced from Li, 
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Table 1-1. Selected promising clinical trials of lipid-based and polymer-based gene 
therapies2,8,9. 













































































































Note: TTR: transthyretin.; IP: intraperitoneal injection. 
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1.3 Difficulties in polymeric gene delivery 
Although most clinical trials in gene therapies are based on viral vectors, the desire 
for scalable low-cost manufacturing for effective and safe gene therapies has led to the 
development of synthetic vehicles to deliver nucleic acids to target cells 29-31. However, 
there still remain a number of challenges on the delivery routes for practical 
applications32-35. In Figure 1-4, administrations through circulation system (e.g. 
intravenous administration, IV) to whole body, eligible gene vehicles should be able to 
protect nucleic acid cargos from degradation by serum endonucleases and immune 
detection before arriving at targeting tissues. In the circulation, avoidance of clearance 
by the hepatic mononuclear phagocyte system (MPS) and renal excretion are major 
barriers limiting effectiveness of vectors following intravenous administrations. For 
minimizing the non-specific interactions (e.g. with opsonin protein) and to avoid the 
clearance in short term, polyethylene glycol (PEG) is commonly used as a nanoparticle 
coating polymer and enables nanoscale carriers to have “stealth properties”. However, 
PEGylation of gene carriers also significantly reduces the interaction with target cells, 
causing a dilemma in terms of formulation design36. There is substantial literature data 
regarding innate excretion systems, in which macromolecules and gene delivery 
nanoparticles have chances to passively enter tumours or inflammation tissues via the 
enhanced permeability and retention (EPR) effect37. However, despite many successes 
for exploiting EPR-medicated nanoparticle gene delivery in murine models, a number 
of tumour types lack significant EPR effects in clinical cases, and the extent of EPR 
effects are considerably dependent to individual patients 38. It is also important to note 
that even after the vehicles have entered tumour tissues via EPR effects, they still face 
other obstructions prior to successful delivery of gene cargos39. For example, while 
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malignant tumour cells are proliferating and spreading, abnormal structures of 
vasculatures in the tumour cause interstitial areas to form dense and complicated 
crosslinked matrices, containing cancer-associated fibroblasts, and interlinked 
hyaluronan and collagen biopolymers, etc39. These tumour interstitial matrixes can 
efficiently impede diffusion of “nanoscale” particles and separate therapeutic vehicles 
from tumour cells39,40. As a result, an effective penetration over normal organs and 
throughout tumour tissues is one of the most necessary requirements in gene delivery, 
especially in GBM cancers, which are usually infiltrative to neighbouring tissues 41. 
 
In addition, from the perspectives of the various active pharmaceutical ingredients 
(API) in nanocarriers for anticancer administrations, for example chemo-, gene-, or 
radioisotope- therapeutic agents, the nucleic acid cargos are the most challenging one 
because of several additional criteria. In comparison with these three delivery systems, 
small chemotherapeutic drugs can still diffuse into cells even if their carriers are 
retained in the interstitial matrix of tumour tissues. For radionuclide cargos, therapeutic 
isotopes with high-penetration radiation (e.g. β-particle emitting radionuclides 188Re, 
131I, 90Y) are only required to be close to tumours, or stayed in tumour tissues and 
capable to offer therapeutic effects, even without release from their carriers or without 
internalization of tumour cells.42,43 However, for nucleic acid delivery, gene cargos 
have to be delivered into cells, released from the carriers themselves, and activated by 
certain enzymes. Nevertheless, while gene delivery has its own difficulties, it is still 
likely to be the best option especially for chemotherapeutic drug-resistant, 
radiotherapy-resistant patients, or gene-disorder diseases. 
 
Chapter I / Capítulo I 
62 
 
Even across through tumoral and vessel interstitial matrixes, gene vehicles usually 
internalize target cells via endocytosis pathways44,45. Endocytosis mechanisms are the 
most common approaches for mammalian cells to access nutrients and manage 
signalling regulators, including macro-scale phagocytosis (cell eating) and pinocytosis 
(cell drinking), and micro-scale endocytic processes (clathrin- and caveolae/lipid 
raft-dependent endocytosis, etc.)46. For most cancer cells, nanoscale particles are 
usually internalised via micro-scale endocytic processes, which involve 
clathrin-dependent and clathrin-independent endocytosis (Figure 1-5), but there is no 
unambiguous evidence to prove which mechanisms are the main pathways for 
internalisation of nanovehicles, because of strong cell-type dependence and 
insufficiently specific agents used for inhibiting endocytic pathways44,47. However, 
except for phagocytosis, which is a common pathway for macrophages, nanocarriers 
entered through cell membranes via the other endocytic mechanisms have to pass 
through multiple endosomal compartments and then arrive the final destination at 
lysosomes for degradation and hydrolysis. Importantly, the degradation of nucleic acid 
cargos in lysosomes is one of the main obstacles to efficient non-viral gene delivery. A 
previous study employed lipid-based vehicles carrying siRNA-linked 
gold-nanoparticles (siRNA-AuNP) as cargos to offer direct evidence in quantification 
assay. Through in vitro and in vivo studies, only 1-2% of siRNA-AuNP in lipid-based 
carriers can escape from multiple endosomal compartments into the cytosol, even 
though the lipid/siRNA vehicles still have high efficient down-regulation of GFP 
expression48. Taken together, gene vehicles escaping from endosomal stage before 
lysosomal stage have become an important research topic in non-viral gene delivery. 
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After escape from endosomal/lysosomal compartments, the gene cargos should 
unload from vehicles and further arrive at destinations or be activated with specific 
proteins or enzymes8. For instance, plasmid DNA (pDNA) should be further 
transported to nucleus and then follow transcription and translation processes for gene 
expressions. siRNA and miRNA should integrate with the RNA-induced silencing 
complex (RISC) to activate RNA interference (RNAi) pathway. However, dissociation 
of gene cargos from the carrier vehicles is also one of the most difficult steps in 
polymeric gene delivery. For example, polycation-delivered plasmid (via PEI) can be 
efficiently transported to nuclei but nearly ten-times less gene-transferring expression 
than lipid-mediated transfection (via Lipofetamine) at the same dose. This is likely 
caused by difficultly complete separation between the plasmid and PEI49. For 
lipid-delivered pDNA (Lipofectamine/pDNA), high levels of reporter gene expression 
have found in transfected cells under active dividing period (late S/G2 phase), while 
polycation-delivered pDNA (PEI/pDNA) are not clearly statistic association with cell 
circle periods50. The PEI-mediated pDNA has a tendency to locate at nucleus 
membrane, likely driven by positive surface charge of the polycation/pDNA complex. 
This high tendency to target on nucleus may provide high efficacy on gene transfection, 
but poor dissociation of polycation and pDNA discount the amount of pDNA entering 
nucleus. In this thesis, we not only attempt to design a polymeric carrier for endosomal 
escape (slight acidic environment) but also try to address the issue for release of gene 
cargo in cytoplasm (physiological pH). 
 
  





Figure 1-4. Diagram for nanoparticle-based gene delivery from IV administration to 
their own destinations. [Reproduced from Yin, H., et al. (2014). Nature reviews. 
Genetics8 with permission] 
 
  





Figure 1-5. Mechanisms of endocytosis and general intracellular transport. 
Nanocarriers (green dots) are taken by cells via endocytosis. Macropinosomes (MP), 
early endosomes (EE), multivesicular bodies/ late endosomes (MVB), lysosomes (Lys), 
recycling endosomes (RE) [Reproduced from Iversen, T.-G., et al. (2011). Nano 
Today44 with permission]. 
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Considering their possibilities including biodegradability and versatility, 
polyphosphazenes were selected as the polymeric backbone for gene delivery. 
However, there is a limitation on the classical side-chain substitution of 
polyphosphazene, which cannot react with compounds having more than one 
nucleophilic terminal group without protection/deprotection procedures. A 
breakthrough to overcome that limitation would be a simple, selective and efficient 
method to add directly side chains to the backbone. Herein, we employed a thiol-ene 
addition reaction to synthesize cationic and anionic side-chain polyphosphazenes. 
Concretely, we reacted a polyphosphazene precursor with α, ω-aminoalkanethiols and 
α, ω−carboxylatoalkanethiols to yield amine side-group polyphosphazenes, as 
polycations, and carboxylate side-chain polyphosphazenes, as polyanions. After that, 
we designed complexes composed of cationic and pH-sensitive anionic 
polyphosphazenes. Based on physicochemical characterisation and transfection 
screening with a pDNA encoding GFP/Luciferase, polyphosphazene with primary 
amines derived from cysteamine were chosen the most efficient cationic materials, 
while polyphosphazenes with alkylcarboxylic acids derived from 6-mercaptohexanoic 
acid were the most efficient anionic materials. Through the optimization of binary 
polyionic gene complex on the 2D monolayer model in vitro in this chapter, we can 
further investigate gene-release mechanisms and evaluate effects of the selected 
“mixed complexes” on the 3D-culture and in vivo situations in the following chapters. 
 
  










2.1.1 Basic chemical properties of polyphosphazene 
Polyphosphazene is a general term for polymers having a backbone made of 
repeating units of phosphazene, phosphorus-nitrogen alternative arrangement, which 
can be configured as circle or linear species. In general, the linear polyphosphazenes 
were N=PR1R2, and as shown in Figure 2-1a, the structure of polyphosphazenes is built 
by phosphorus covalently linked to nitrogen via σ-σ bond and σ-π bond alternatively, 
but differing with the familiar bonds in carbon-based compounds. Each phosphorus 
atom offers five electrons and each nitrogen provides another five electrons, forming 
alternatively saturated and unsaturated bonds on the backbones. Among of them, two 
electrons of phosphorus are used for side chain conjugation, and two electrons of 
nitrogen remained of a lone-pair (Figure 2-1 b). Although the linear backbone 
contained unsaturated bonds, the dπ(P)−pπ(N) bond is expected flexible rotation, 
because several 3d orbitals of phosphorus provide more chances to hybrid with the pz 
orbital of nitrogen once the π bond undergoes torsions (Figure 2-1 c)1. As the 
calculation suggested, the bond energy of inherent torsional barrier in the phosphazene 
backbone is as low as only 100 cal per bond.2,3 Moreover, such hybridisation brings 
delocalization-stabilization effects similar to aromatic compounds pπ(C)−pπ(C). 
 
In the molecular conformation, linear polyphosphazenes are significantly 
influenced by their side groups (i.e. Cl, OCH2CF3, etc.). In general, the phosphazene 
skeleton is easily distorted by its side groups, occupying a trans-trans planar or cis-trans 
planar conformation4. Theoretically, most of polyphosphazenes are favour to be as 
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cis-trans planar form, in view that the side chains can keep maximum distance to each 
other, minimizing the internal repulsions (Figure 2-1 d)1,5. Taken the 
poly(dichlorophosphazene) as an example, the Cl∙∙∙N attractions and Cl∙∙∙Cl repulsions 




Figure 2-1. General structures of polyphosphazene (a), electron arrangement in the 
phosphazene bond (b) and its orbital hybridisation in (c), in which phosphorus provides 




2.1.2 Synthesis of polyphosphazene and nucleophilic substitution 
Although the inaugural synthesis of polyphosphazene had been reported by Stokes 
at 1897, the product was polymerised at high-temperature and long time for formation 
of insoluble elastomers known as inorganic rubber. The first stable synthesis of 
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polyphosphazene and its use for biomedical application were reported by Prof. Allcock 
group6, starting several broad interest from the research community and from industry. 
In the most general procedure for non-crosslinked polyphosphazene synthesis, the 
precursor poly(dichlorophosphazene) (PDCP) is prepared in a first step, and then the 
final polymer is formed by nucleophilic substitution of desired side chains. Based on the 
raw monomers, synthetic methods of PDCP can be classified in those starting from 
cyclic trimers (i.e. hexachlorocyclotriphosphazene) and those starting from non-cyclic 
monomers (i.e. dichlorophosphinoyl-iminotrichloro phosphorene, Cl3P=N-P(O)Cl2, or 
trichloro(trimethylsilyl)phosphoranimine, Cl3P=NSiMe3).7 In the former method, the 
polymerisation is typically thermo-initiated and ring-opening reaction propagates 
towards linear PDCP (Figure 2-2 a). Many advanced technologies for PDCP synthesis 
by this general method have been published recently including catalysed 
polymerisation8,9 and solvent-mediated stabilization10. Although the mechanism of this 
ring-opening polymerisation is still open to debate, the most broadly accepted 
mechanism is that one phosphorus-chloride bond of the cyclic trimer would be cleaved 
by heating above 250-260 ºC, inducing the opening of next cyclo-triphosphorazene and 
starting the chain propagation reaction (Figure 2-2 a). In the terminal step, the reactive 
head of the polyphosphazene chain (~N=PCl2+) can recapture the chloride anion as the 
reaction temperature decreases. However, the reaction is extremely sensitive to 
contamination of water or other nucleophiles, which cause unwanted cross-linking, 
precipitation of an insoluble material (i.e. Stokes’ “inorganic rubber”) and lack of 
reproducibility between batches regarding physical properties. For avoiding water 
contamination and simplifying the synthesis process, a solvent-free polymerisation 
(melt polymerisation reaction) would be more suitable than a polymerisation in solvent9. 
In addition, for achieving high-yield polymerisation of PDCP, which can omit further 
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purification in the first polymerisation and directly conjugate with side chains via 
nucleophilic substitution, proper catalysts were reported as a necessary compartment in 
this reaction8,9. Boron trichloride (BCl3) and aluminium chloride (AlCl3) are strong 
Lewis acids that facilitate the extraction of the chloride on the trimers and act as 
catalysts for cyclic trimer activation (Figure 2-3)8. Boron trichloride may have the 
additional advantage of reducing the possibility of crosslinking by eliminating trace 
amounts of water in the polymerisation by forming B(OH)3. Sohn et al. also reported 
that aluminium chloride can be used as a catalyst in polyphosphazene polymerisation to 
yield PDCP with a Mw range between 10K and 100K Da, which could be suitable in 
many biomedical applications, especially drug delivery9. The combination of 
solvent-free polymerisation with the efficient catalyst make PDCP a more 
easy-accessible polymer material, even laboratories only with basic facilities for organic 
chemical synthesis. 
 
Another method to synthesize PDCP was via living-cationic polymerisation using 
phosphorus pentachloride (PCl5) as the initiator (Figure 2-2 b)11. In this approach, the 
polymer products would have narrow polydispersity (Mw/Mn), and the reaction can be 
carried out at room temperature. Other advantages of this reaction are its control over 
the molecular weight. The monomer Cl3P=N-Si(CH3)3, however is not available in 
standard commercial vendors and the catalyst, PCl5, is a dangerous compound classified 
as third level health hazard. 
 
 




Figure 2-2. Synthesis mechanisms for polyphosphazene polymerisation. (a) 
Ring-opening polymerisation of cyclo-triphosphorazene and (b) living-cationic 


































































Figure 2-3. Lewis acid, Boron trichloride (BCl3) as a catalyst for ring-opening 
polymerisation of linear PDCP. 





Figure 2-4. Two dominant classes of nucleophile to substitute chlorides by functional 
side chains, including amines or alkoxides. 
 
 
2.1.3 Nucleophilic substitution and click-chemistry addition extension 
Following polymerisation of PDCP, this polymer can be recognized as a precursor, 
which can derive different polyphosphazenes via nucleophilic substitution 
reactions.6,12,13 PDCP provides an easy-coupling platform for conjugation with potential 
side-chain candidates, in which nucleophile terminals can substituted chlorine of PDCP 
to attach on the polyphosphazene backbone. There are two main classes of nucleophile 
terminal groups to substitute the chloride to desired side chains, generally either amines 
or alkoxides (Figure 2-4). However, side-chain candidates with more than one 
hydrophilic or nucleophilic terminal group cannot be added directly on the backbone. In 
other words, the candidates having over two functional groups (amines, imines, thiols, 
acids, or polar amino acids etc.) need to go through protection/deprotection procedures 
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for the nucleophilic substitution step. Otherwise, the excess nucleophilic terminal group 
would cause crosslinking due to double substitutions on intra-macromolecules or 
between macromolecules. Fortunately, a library of polyphosphazenes have extensively 
developed14,15, including several nucleophilic substitutions of alkene, alkyne, or vinyl 
series on the polyphosphazene backbone, such as allylamine14,15, 2-Aminoethyl 
methacrylate16, allyl glycinate17, methacrylic acid18,19, and propargylamine20 (Figure 
2-5). In the previous studies, most double-bond introductions on PPZ backbone were 
usually utilised for radical photo-polymerisation to form hydrogel or to improve the 
mechanical strengthens.16,17,19,21 Only few studies from Prof. Qian, Y. C. and Huang, X.J. 
groups reported thiol-ene and azide/alkyne click reactions for conjugating biomolecules 
(i.e. glucose) on polyphosphazenes15,22. These modifications bring additional versatility 
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Figure 2-5 Potential “side-chain” added polyphosphazenes for thiol-ene, thiol-yne, and 
azide/alkyne click addition reactions. 
 
2.1.4 Biodegradable of poly(organophosphazenes) 
Poly(organophosphazene)s are a class of polymers derived from a backbone of 
repeated phosphazenes and having organic functional side groups. The main advantages 
of poly(organophosphazenes) are derived from its structural flexibility derived from the 
different side chains that can be linked, and interestingly tunable biodegradability of the 
backbones. Regarding this, the mechanism for hydrolysis of polyphosphazene is also 
controversial but three hypothetic mechanisms have been put forward (Figure 2-6)23-25. 
In the same mechanisms, the side groups might react with the phosphazene backbone 
and accelerate polymer hydrolysis while in other cases the side chains of 
polyphosphazenes may be eliminated from their backbone first, and finally the 
backbone would be hydrolysed to phosphates and ammonia12. What is clear is that 
unlike other biodegradable polymers, the degradation rate of polyphosphazenes is 
extremely dependent on the substituting side groups and their ratio if there is more than 
one type26. For example, among amino-acid ester polyphosphazenes in solid-state 
hydrolysis tests, the degradation of different amino acids attached polyphosphazenes is 
governed by hydrophobicity and steric hindrance of the side chains. For examples, the 
degradation rate of side-chain PPZ: ethyl glycinate (degradation half time, T1/2 ~3 
months) < alanine (T1/2 ~6 months) < valine (T1/2 ~ 1 year) ≦ phenylalanine ethyl ester 
(T1/2 ~1 year).12,27,28 When analysing two water-soluble polyphosphazenes with the same 
terminal functional side group, a tertiary amine, but linked to the polyphosphazene 
backbone by an different nucleophile group, the authors found that alkoxide-substituted 
Chapter II / Capítulo II 
83 
 
poly(2-dimethylamino-ethoxy)phosphazene (T1/2 ~7days) was degraded faster than the 
amine-substituted poly(2-dimethylaminoethylamino)phosphazene (T1/2 ~ 24 days)29.  
 

































































































Figure 2-6. The three common hypotheses of poly(amino acid ester)phosphazenes for 
degradation mechanisms. [Adapted from Allcock, H. R. et al. 30, Polymer Chemistry 
2012, with permission] 
 
 
2.1.5 Applications of polyphosphazene 
In views of plentiful candidates of side chain attaching to repeating phosphazene 
units, there are more than 700 different polyphosphazenes derived from this backbone, 
providing wide ranges of applications (Table 2-1)27. As an inorganic-organic polymer, 
polyphosphazene has some advantages over organic polymers, such as higher ultraviolet 
or gamma-radiation stability as well as better thermal stability. Broadly potential 
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candidates as side groups generated different physical and chemical properties in this 
material family, for examples from elastomeric to glass states (Tg from -105 to >180ºC), 
from water-soluble to super hydrophobic properties, from bio-inert to bio-active 
modifications3. 
 
As mentioned in chemical properties (Section 2.1.1), the phosphazene-composed 
backbone is flexible due to the orbital hybridisation of dπ(P)−pπ(N), giving rise to 
potential in elastomeric characters3. The first polyphosphazene used in commercial 
elastomer is a mixture of at least two side-chains attached on the backbone, which are 
including CF3CH2ONa and CHF2(CF2)xCH2ONa31. Through these fluoroalkoxy side 
groups, they offer highly random distribution in the structure, reducing the chances of 
inter-chain alignment and crystallinity, creating more “free volume” inside elastomers 
for polymer movement and dislocation once the materials received distortional 
deformation32. From industrial needs, polyphosphazenes have been used in fire-resistant 
or heat-, electrical-, and sound-insulation materials. Poly(aryloxyphosphazene) was 
employed as heat- and sound-insulation rubber tube and fire-resistant composite 
materials are utilized in circuit boards3. Poly[bis(trifluoroethoxy)phosphazene] was 
made as super-hydrophobic materials for water-proofing surface coating. 
Poly[bis(methoxyethoxyethoxy)phosphazene), MEEP, was used as solid solvents for 
lithium salts in battery industry. The side chains of MEEP are oligo(ethylene oxide), 
whose oxygen atoms can help separate ion-pair, and cations and anions can early 
migrate to negative and positive electrode under applied electric current, respectively33. 
Poly(ethylene oxide) is also potential in ionic conduction but the reason why MEEP is 
superior to poly(ethylene oxide) is that the non-/low-crystalline MEEP do not form 
microcrystalization to interrupt ionic conductor, yielding a high ionic conductivity. 




In biomedical application, polyphosphazenes have attracted particular interests due 
to versatile side chains, tunable bio-erodible and bio-stable properties, including 
drug/gene/protein delivery, tissue engineering, vaccine delivery, and bio-inert 
elastomers for dental treatments30,34. Nowadays hundreds of derivatives have been 
synthesized and formulated to various products in biomedical applications. For example, 
amino acid ester polyphosphazenes have been widely studied30 and applied to prepare 
fibres or scaffolds by electrospinning for bone tissue engineering35; amphiphilic 
polyphosphazenes have been used for the preparation of nanoscale polymeric carriers in 
controlled drug delivery36,37. For vaccine delivery the most advanced prototypes are 
based on polyphosphazenes with carboxylic acids side chains, being the most 
poly[di(carboxylatophenoxy)-phosphazene]. This materials has been used as a vaccine 
adjuvant, showing effective immune-stimulating activity in a variety of in vitro and in 
vivo models27,38. Moreover, recent studies have shown that polyphosphazenes can 
effectively deliver small drugs, proteins and nucleic acids in a number of therapeutic 
settings39-45. The versatility of polyphosphazene chemistry is also important from 
scale-up and manufacture perspectives15,43,46. For many industrial applications, it is 
desirable to have ‘platform’ materials that can be manufactured in bulk and adapted or 
modified for specific purposes. For pharmaceutical applications, a single precursor 
polymer that can be tailored for different therapies would be highly advantageous. 
 
In this chapter, we have optimised a polyphosphazene platform, which have 
substituted by allylamines for preparation of a series of cationic and anionic derivatives 
via thiol-ene grafting chemistries using α, ω-aminoalkanethiols (4 & 5) and 
α, ω−carboxylatoalkanethiols (7 to 10) in Figure 2-7). The resulting cationic 
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polyphosphazenes were of appropriate charge to bind nucleic acids into polyelectrolyte 
complexes suitable for gene delivery, while the carboxylic acid functionalized 
polyphosphazene derivatives displayed varying degrees of anion content dependent on 
environmental pH. By combining these materials in the presence of nucleic acids, we 
aimed to generate mixed polyelectrolyte complexes with sufficient positive charge to 
retain stability in extracellular environments, but with induced changes in charge and 
hydrophobicity once inside acidic intracellular compartments. 
 
 
























































































































(7) 3MPA-PPZ (10) 8MOA-PPZ(8) 4MBA-PPZ (9) 6MHA-PPZ  
 
Figure 2-7. A small library of ionic polyphosphazene. (a) Ring-opening 
polymerisation of polyphosphazene and (b) functionalization by thiol-ene click 
addition for controlled gene delivery. 
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2.2 Materials and methods 
 
2.2.1 Materials 
Hexachlorocyclotriphosphazene (99%), Aluminium chloride (99.99%), 
triethylamine (TEA), cysteamine, 2-(dimethylamino)ethanethiol hydrochloride 
(DMAES), 2,2-dimethoxy-2-phenylacetophenone (DMPA), branched 
poly(ethyleneimine) 25K (PEI), 3-mercaptopropionic acid (3MPA), 4-mercaptobutyric 
acid (4MBA), 6-mercaptohexanoic acid (6MHA), 8-mercaptooctanoic acid (8MOA), 
heparin sodium salt (from porcine intestinal mucosa), anhydrous tetrahydrofuran 
(THF), 2,2,2-trifluoroethanol (TFE), anhydrous diethylene glycol dimethyl ether 
(Diglyme), Ethidium bromide (EtBr), Poly-L-lysine (Mw 30K-70K) were all 
purchased from Sigma-Aldrich and used as received. 
 
2.2.2 Synthesis of the precursor poly(allylamino-phosphazene) 
Poly(dichlorophosphazene) (PDCP) was prepared as previously described.9 A 
pre-dried flask was loaded with 5.0 g (14.4 mmol) of hexachlorocyclotriphosphazene 
and aluminium chloride as a catalyst. The reactor was filled with high-purity nitrogen 
and heated to an initial temperature of 240-250 °C. After the polymerization for 3 hours, 
the reactor was cooled to 120 °C, and 8mL of diglyme was injected into the reactor to 
solubilize the crude product and to minimize crosslinking10. The aluminium chloride 
was removed by centrifugation (7000 g at -10 °C. The product identity was confirmed 
by 31P-NMR in a co-solvent of diglyme/deuterated chloroform (1:3). Subsequent 
nucleophilic substitution at the chlorine phosphorus centres18 was performed by 
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transferring the product supernatant into a pre-dried flask containing 50 mL of 
anhydrous THF, where TEA (3 eq to chlorine) and allylamine (3 eq to chlorine) were 
added. The reaction was carried out in ice for 24 hours and then for an additional 24 
hours at room temperature. For purification, the mixture of raw products was filtered to 
remove the trimethylamine hydrochloride and the desired polymer in THF was 
precipitated in double-volume water (THF:water 1:2), then in pure water. The 
precipitated polymer, poly(allylamino-phosphazene) (AAPPZ), was collected and dried 
in vacuo. (Yield~4.61 g, 68 %). 
 
2.2.3 Synthesis of cationic and anionic polyphosphazenes by thiol-ene reactions 
After synthesis of the precursor AAPPZ, we introduced two different amine 
side-chains (cysteamine and DMAES) with different composition ratios, to provide 
cationic functionality, via thiol-ene addition reaction of the thiol termini of both 
compounds with the alkenyl side chains of the allyl repeat units. Analogous reaction to 
install various carboxylic acid groups were carried out using 3-mercaptopropionic acid 
(3MPA), 4-mercaptobutyric acid (4MBA), 6-mercaptohexanoic acid (6MHA) and 
8-mercaptooctanoic acid (8MOA). Firstly, AAPPZ (100 mg, 0.637 mmol) in 
trifluoroethanol (TFE, 8 mL) was mixed with the designated mercaptoalkyl amine or 
mercaptoalkyl carboxylic acid (3 eq. to allyl group) and flushed with nitrogen gas 
before adding 2,2-dimethoxy-2-phenylacetophenone (0.05 eq. to allyl groups). The 
thiol-ene reaction was initiated under UV irradiation (λ=365 nm) for 3 hours, and then 
the crude product was directly dialysed against an aqueous solution (molar mass cut-off 
7 kDa) until the resulting solution became completely clear. The products were 
recovered by freeze-drying from aqueous solution as powdery solids. The polymers 
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were analysed by 1H and 31P NMR spectra, and purity and molecular weight were 
measured by 1H-DOSY.  
 
2.2.4 Formation of polyphosphazene-based complexes 
A plasmid DNA (pDNA) is a bi-functional coding for enhanced green fluorescent 
protein (EGFP) and luciferase from firefly photinus pyralis was used throughout this 
thesis, except for confocal imaging because of minimum background fluorescence. In 
this pDNA, wild-type EGFP was modified to enhance the fluorescence excitation and 
emission at 488 nm and 507 nm, respectively. Photinus pyralis luciferase was chosen 
as it emits yellow-green light with maximum at 560 nm during across the pH range of 
7.5-8.5. Cationic polyphosphazenes with the varying side-chain ratios of cysteamine 
and DMAES were dissolved in 10 mM HEPES pH 5.0. The anionic side-chain 
polyphosphazenes were dissolved in 10 mM HEPES pH 8.2 and the pDNA was in pure 
water. Complexation was performed under intense vortex mixing for 30 second at 
various ratios of positively-charged amine moieties on the polymer to 
negatively-charged phosphates on the pDNA (N/P ratio). In the case of the mixed 
cationic and anionic polyphosphazenes, the polycationic PPZ condensed both the 
anionic polymers and the pDNA in one step. These polymeric complexes were 
characterized by their stoichiometric composition ratio, in terms of positive amines (N), 
negative carboxylates (C) and negative DNA phosphates (P), i.e. N/C/P ratio. 
 
2.2.5 Characterization  
 
2.2.5.1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
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1H and 31P NMR spectra were recorded on a Bruker 400 and DRX-500 
spectrometers. 1H Diffusion-ordered spectroscopy (1H-DOSY) was recorded on Varian 
Inova 750 (750MHz). Solvents used were CDCl3, D2O, MeOD or Acetone-d6. All 
chemical shifts are reported in parts per million (ppm) relative to tetramethylsilane 
(TMS) or known solvent peak positions. 
 
2.2.5.2 Gel Permeation Chromatography (GPC)  
Molar masses of polymers were determined via gel permeation chromatography 
using a Shimadzu Prominence UPLC system fitted with a DGU-20A5 degasser, 
LC-20AD, CBM-20A LITE system controller, SIL-20A autosampler, CTO-20A oven 
and RID-10A refractive index detector. Separations were performed on a series of 
Aquagel 30-40-50 (300 x 7.8 mm, 5 mm bead size, Agilent UK) columns fitted with a 
matching guard column (50 x 7.8 mm). The mobile phase was acidic buffer solution (1M 
acetic acid and 0.3 M NaH2PO4) at 1 mL/min flow rate and separations were performed 
at 37 ºC. Column calibration was achieved using Poly(2-vinylpyridine) Easi Vials (2 
mL) standards (668 Da–211k Da, Polymer Standards Service, USA). 
 
2.2.5.3 Dynamic light scattering (DLS) and Zeta Potential Measurements 
Dynamic light-scattering and zeta potential measurements were performed using a 
Nanosizer ZS instrument (Malvern, UK) at 25 ºC, equipped with a He-Ne laser (λ=633 
nm) with a backscatter angle of 173º. For zeta potential, measurements were performed 
in 1 mM KCl. Hydrodynamic radii distributions were calculated with Malvern software. 
From standard auto correlation functions, diffusion coefficients were related to particle 
hydrodynamic radius via the Stokes Equation:  
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RH = κBT/6π η D                                             (Eq. 2-1) 
 
Where RH is the hydrodynamic radius, κB is the Boltzmann constant, T is the 
temperature, and η is the viscosity of the solvent. In addition, it was assumed that 
particles were spherical and non-interacting. 
 
2.2.5.4 Electron Microscopy 
The morphologies of the polymeric complexes were probed by transmission 
electron microscopy (JEOL JEM-2010) in negative staining mode using 
phosphotungstic acid (PTA, 2 % w/v). The complex suspensions (10 μL of solutions at 
a plasmid concentration of 62.5 μg/mL) were dropped onto a TEM grid (Carbon Film 
CF400, Electron Microscopy Sciences) and left for 5 min for attaching on the grid, and 
then residual solution was blotted away by capillary force. Afterwards, the PTA 
solution was added to the grid for 1 min and then the grids were washed with pure 
water and dried under low-pressure prior to TEM imaging. 
 
2.2.6 Potentiometric titration, gel electrophoresis 
The buffering capacities of cationic and anionic polyphosphazenes were 
determined by initial dissolution of the polymer in MilliQ water to give a concentration 
of 50 mM of side-chain units. The anionic polymer solutions (0.5 mL) were adjusted to 
pH 11 with 1 N NaOH and then titrated with 1 N HCl. In between each addition, the 
polymers were agitated under vortex for 30 second and allowed to stabilize for another 
30 second prior to pH measurement. For cationic polymers, solutions of the same 
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concentration were adjusted to pH 2 with 1 N HCl then titrated with 1 N NaOH using 
the same method as for the anionic polymers. pKa calculation was performed by 
Henderson-Hasselbalch equation (Eq 2-2) based on the data of potentiometric titration curves. 
The titration curve data were re-plotted to scatter diagrams by pH against Log ([A-]/[HA]), and 
pKa was obtained by a linear fitting between pH 8 and pH 5. Protonation degree (α) vs. pH 
was calculated from the potentiometric titration curves. Herein Alpha (α) represented 
the percentage of protonated carboxylic acid groups or amine groups in the whole 
anionic/cationic polyphosphazene, and the calculation of α was shown below35,37,38: 
 
𝑝𝑝 = 𝑝𝑝𝑝 + 𝐿𝐿𝐿([𝐴
−]
[𝐻𝐴]





∑ (𝐶𝐻𝐶𝐻 − C[H+]) − C[𝑂𝐻−]𝑛𝑖=0
𝐶𝐴
�                     (Eq 2-3) 
 
Here, taking anionic polymers as an example, CA denotes total concentration of 
alkyl-carboxylic side groups in the polyanionic solution; Cp denotes the concentration 
of protonated alkyl-carboxylic acid groups; CHCl denotes each addition of HCl 
concentration; C[H+] is the concentrations of free [H +], which can be measured by pH 
meter, and C[OH-] is the concentration of initial [OH-] in the test solution, adjusted by 
NaOH in the beginning for ensuring all carboxylic acids in the de-protonation state; 
i=0 is the initial point, where we defined 0 % as the protonated alkyl-carboxylic acid 
groups around pH 11; n is the number of HCl additions. There is an assumption that 
the total volume keeps a constant during the titration (the volume percentage of each 
addition of HCl is 0.004 of total volume). 
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For estimating the binding efficiency of pDNA complexation, gel electrophoresis 
was performed using 1 % agarose containing (0.5 μg/mL) ethidium bromide (EtBr) at 
110 V for 50 min. Each sample was prepared to a 30 μL volume containing 1 μg 
plasmid. In heparin displacement tests, each polymer/DNA complex sample was 
challenged with different mass ratios of heparin to plasmid, using samples at a fixed 
volume (30 μL) and incubated for 1 hour at 37 ºC. 
 
2.2.7 Preparation of Cy3-CA-PPZ and Cy5-pDNA for FRET 
For tracking and investigating polymer and pDNA in vitro and in vivo, we 
labelled cyanine 3 (Cy3) and cyanine 5 (Cy5) on the polycation CA-PPZ and blank 
pDNA, respectively. Firstly, for labelled CA-PPZ, 0.5 mg of Cy3-NHS (from GE) was 
dissolved in DMSO and 8.2 mg of CA-PPZ was suspended in 0.5 mL HEPES pH 8.2 
and diluted to 3.5 mL with DMSO. The Cy3-NHS solution and CA-PPZ solution are 
mixed in an amber vial and stirring for reaction overnight under light protection. The 
purification is via dialysis against pure water for 72 hours with renewing water 
frequently. After that, the Cy3-labelled CA-PPZ was dried by lyophilisation and 
stocked in -20 ºC.  
 
For Cy5-labelled pDNA preparation, we used the Cy5 Label IT® kit (Mirus), 
following with the manufacturers’ instructions. Briefly, pDNA was added to Label IT® 
reagent at the ratio of 0.25 µL to 1 µg pDNA. The reaction was performed under 
shaking at 37 ºC for 1 hour. Afterwards, 0.1 volumes of 5 M sodium chloride and 2 
volumes of cold 100% ethanol were added into the reaction and the mixture was left 
for at least 30 min at -20 ºC. The Cy5-labelled pDNA was isolated by centrifugation 
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into a pellet. For removing possible impurities, the pellet was washed with 70% 
ethanol and re-suspended in pure water. The complexation of Cy3-CA-PPZ and 
Cy5-pDNA was described above and loaded in 96-well plates. The fluorescent 
intensity was measured by Fluorimetry (Synery H1, Biotek) with excitation / emission 
wavelengths set at 500 nm / 565 nm for Cy3 and at 645 nm / 676 nm for Cy5. The 
FRET efficiency is calculated by the equation: FRET efficiency = I(Ex500-Em676) / 
I(Ex500-Em565). 
 
2.2.8 Transfection and cytotoxicity 
For 2D transfection and cytotoxicity studies, U87MG or GBM1 cells were 
cultured in Dulbecco's Modified Eagle Medium (DMEM, Sigma) containing 10 % 
fetal bovine serum, 2 mM Glutamine and 100 mg/L penicillin-streptomycin and 
maintained at 37 ºC under a 5 % CO2 atmosphere. For 2D cultures, the cells were 
seeded at a density of 25000 cells/cm2 in 24-well plates and incubated 24 h prior to 
transfection. Then, polymer:pDNA complexes were added at various pDNA 
concentrations in Opti-MEM for 4 h. After this time, the formulations and cells were 
incubated with fresh growth medium for additional 48 h. The transfected cells in 
24-well plates were evaluated via fluorescence microscopy and quantified by 
Luciferase assay kits (from Promega). Cytotoxicity was evaluated by MTT assays 
(Promega). Briefly, the transfected cells were treated with 10 µL 12 mM MTT/PBS 
solution and incubated with 100 µL phenol-red free media in each well for 4 h. After 
the supernatant was removed, 50 µL DMSO aliquots were added to the wells of 
MTT-labelled cells, and then mixed and incubated for 10 min before being analysed in 
a plate reader with absorbance wavelength at 540 nm.  
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2.3 Results and discussion 
 
2.3.1 Synthesis of the precursor Allylamino-attached polyphosphazene 
The strategy for syntheses of various substituted polyphosphazenes was via 
conventional thermal ring-open polymerisation of cyclic monomer 
hexachlorophosphazene (1) and reaction of the resultant poly(dichlorophosphazene) 
with allylamine under basic conditions to afford vinylic side-chains15. Firstly, the 
ring-opening polymerisation was initialised by high temperature (~240 ºC) with catalyst 
Aluminium chloride (AlCl3) and without any solvents. In traditional solvent-free 
polymerisation for polyphosphazene, the product easily crosslinked by traces of water, 
forming a rubber-like solid. In the present time, the catalyst (AlCl3) would help in 
minimizing crosslinking because of its high affinity to water and reacts forming 
hexahydrate [Al(H2O)6]Cl3. In addition, it significantly speeded up the reaction time to 3 
hours, because the catalyst effectively takes chloride away from the trimer at the 
beginning of the reaction, facilitating the initiation of the polymerisation and 
contributing to a decline in the molecular weight distribution (PI) and molecular weight 
of poly(dichlorophosphazene) (2, PDCP)9. For subsequent thiol-ene click chemistry, we 
chose the simplest allyl-terminal group as side chain, which is allylamine (Figure 2-8). 
In view of minimum water pollution, we designed a simple and effective purification 
procedure after the melt polymerisation. Once the polymerisation is completed, the 
reactor would be cooled to approximately 120 ºC and anhydrous diethylene glycol 
dimethyl ether (diglyme) was injected into the reactor. The solvent is known to minimise 
crosslinking of PDCP and to stabilise the crowd product PDCP as well as for stabilising 
the crude product10. However, if the temperature of the reactor dropped below 100 ºC, 
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the crude polymer started solidifying and precipitating even addition of diglyme. After 
suspension in diglyme, the crude product will be chilled to -10 ºC in an ice bed (ice plus 
salt). The low temperature minimised crosslinking but also significantly reduced the 
solubility of aluminium chloride, which could be precipitated efficiently by centrifuge. 
Therefore, the main advantages to this synthesis protocol are that they allow purification 
from the catalyst and other impurities in a streamlined way while optimising polymer 
stability. After ring-opening polymerisation, the crude products were transferred to a 
super-dry reactor with THF as solvent for nucleophilic substitution of allylamine. 
Following that, the product was purified via filtration to remove TEA-Cl, and then, 
precipitated in water. In this study, we attempted to simplify chemical synthesis and 
minimise the use of organic solvents, but diglyme and THF are still used. Future 
research might try to replace THF with water or alcohol to move this chemistry towards 
a greener approach. 
 
The final product AAPPZ should not be completely dried by lyophilisation likely 
because of its crystallization that renders a product that can be re-dissolved in only few 
solvents (i.e. TFE and 5-10 % phosphoric acid solution). For the polymer 
characterisation, the polymer samples were dried at low pressure overnight. PDCP was 
characterized by 31P-NMR and nucleophilic substitution at the P-Cl bonds with 
allylamine to generate the key precursor polymer. As shown in Figure 2-8, the major 
single peak shifted from 21.2 ppm to -16.0 ppm in the 31P-NMR spectra, confirming that 
hexachlorocyclotriphosphazene has been polymerised to PDCP. Also, the single peak of 
PDCP shifts to 3.6 ppm after the allylamine substitution reaction, confirming that 
allylamine has substituted chlorine and its nitrogen atom has bound to the phosphoric 
atom on the backbone. In the 1H-NMR spectra, there are two peaks at 5.80 ppm and 5.09 
Chapter II / Capítulo II 
99 
 
ppm corresponding to protons of the allyl group, which provided a second confirmation 
of the successful introduction of allyl groups in the polyphosphazene. Furthermore, an 
NMR-DOSY experiment confirmed that allylamino-polyphosphazene (AAPPZ) 







































Figure 2-8. Synthesis and characterization of the polyphosphazenes. a) Synthesis of 
ionic polyphosphazenes via thermal ring-open polymerisation, nucleophilic 
substitution and thiol-ene click chemistry. (b) 31P-NMR spectra of 
hexachlorocyclotriphosphazene, Poly(dichlorophosphazene) (PDCP), and 
allylamino-polyphosphazene (AAPPZ). (c) 1H-NMR-DOSY of AAPPZ. 
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2.3.2 Synthesis of ionic polyphosphazene via thiol-ene click addition 
The advantages of this precursor AAPPZ is that it is amenable to thiol-ene 
derivatisation, and here we applied this reaction to yield a series of polycations (4-6) and 
polyanions (7-10) (Figure 2-7). Firstly, we introduced the different cationic side chains 
on the backbone via thiol-ene click chemistry (4-6). For cysteamine-introduced 
polyphosphazene (4), high conversion rate (cationic moiety/allyl group) ≧90% and the 
high reaction yields (≧71%) were achieved by one direct thiol-ene reaction in TFE. 
However, the conversion efficiency of when introducing both cysteamine and DMAES 
or only DMAES in the solvent as TFE was lower 60-70%. We hypothesized that this 
reduction in the efficiency was caused by charge-repulsion of the tertiary amine of 
DMAES. To address this issue, we prepared a home-made buffer, sodium phosphite 10 
mM and sodium sulfate 50 mM pH 8.2 as reaction media where we expected the sulfate 
ions to shield the ionic repulsion of the tertiary amine47. Using this customized aqueous 
buffering solution as reaction medium, the conversion rate from allyl group to cationic 
groups was improved to ≧96% (Figure 2-9a). In the 1H-NMR spectra, the peaks of the 
allyl group almost disappeared after the thiol-ene reaction, whereas the two peaks at 1.83 
ppm and 1.29 ppm attributed to the protons from −S−CH2−CH2−CH2− (peak b’) and 
−S−CH(CH3)− (peak b’’) confirmed the successful addition of thiol groups on the 
precursor. Furthermore, the ratio of protonation of the amine groups would be affected 
by the chemical shifts of neighbouring protons, especially for tertiary amines. For 
cationic polyphosphazene, we adjusted pH of deuterium oxide to around pH 9-10, 
inducing the peak (g) of −S−CH2−CH2−N(CH3)2 shifting to around 2.35 ppm, for 
accurate calculation of the primary to tertiary amine ratio.  The intensity of the peak at 
2.35 ppm (g) increased with increasing ratio of DMAES introduced on the backbone, 
which indicates the increasing ratio of tertiary amines introduced to the backbone. 
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 A range of different anionic (7-10) side-chains polymers were also generated from 
AAPPZ via thiol-ene click chemistry. Reactions proceeded to a high degree (≧99% 
substitution of the allyl groups by the cationic side-chains) and good overall yield 
(≧71%). Product identities were confirmed by 1H-NMR (Figure 2-9b). 
 
 
Figure 2-9. Proton-NMR of ionic polyphosphazenes. (a) Proton-NMR of cationic 
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functionalized polyphosphazenes with cysteamine and/or 
2-(dimethylamino)ethanethiol (DMAES) at the ratios of 100:0, 50:50, and 0:100, 
prepared via thiol-ene addition. The polymers were dissolved in D2O, pH 9-10. (b) 
Proton-NMR of anionic functionalized polyphosphazenes with aliphatic chains of 
diverse lengths, prepared via thiol-ene addition. 
 
For further confirming the structure of cationic polyphosphazene, correlation 
spectroscopy (COSY) and Heteronuclear Single-Quantum Correlation spectroscopy 
(HSQC) were performed (Figure 2-10). COSY is a two-dimensional NMR spectrum for 
a homonuclear correlation, here for 1H to 1H correlation. The cross peaks on diagonal 
line represent the correlation of the protons with themselves and generate the same peaks 
as the regular proton spectrum. The other cross peaks are symmetric against the 
diagonal and correspond to two nuclei coupling. When we analysed the cationic 
polymers by COSY, we could easily identify a spin group of the peak b’ with its 
neighbouring peaks c’ and d, and another one with peaks i and e. More interestingly, 
there is a small cross peak derived from a coupling pair of peaks c’ and d, indicating 
that the c’ (–P−NH−CH2−) is located at higher chemical shift than the peak i 
(H2N−CH2−CH2−) around pH 7, even though their chemical shifts are very close. 
Since most of these groups are formed by the thiol-ene addition of the allyl group, 
these provided further proof of the final structure of the compounds. 
 
On the other hand, HSQC presents heteronuclear correlations that separate 
between one single bond. In HSQC, we can separate low chemical shifted carbons 
corresponding to those having C−S and C−C bonds and high chemical shifted carbons 
(i.e. C−N bonds) (Figure 2-10b). These spectra allowed us to confirm that peaks (i) 
Chapter II / Capítulo II 
104 
 
and (c’) are associated to C−N protons, further supporting our molecular assignment. It 
also should be carefully considered the effect of pH on the proton NMR chemical 
shifts of ionic polymers causing a satellite peak near to peak (c’). 
 
 
Figure 2-10. 2D spectra of high-Mw CA-PPZ. (a) 1H-1H COSY spectra and (b) 1H-13C 
HSQC spectra. 
 
Although the literatures indicate that the molecular weight of PDCP can be 
adjusted by the feeding ratio of catalyst (AlCl3), the reported Mn range of 
polyphosphazene was from 10K to 100K, hardly of any significance when coupled 
with large polydispersity. Herein, we measured the molecular weight of cationic 
polyphosphazenes instead of AAPPZ, because the crystallization of completely dried 
AAPPZ caused issues of solubility, while cationic polyphosphazenes are much easier 
dissolved in aqueous buffer15. In addition, the purification after click addition to 
cysteamines on the backbone is through dialysis by cut-off Mw 7K, which may 
influence the molecular weight of the final product. We focused our characterization on 
cysteamino-introduced polyphosphazene (CA-PPZ) which is the most important 
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cationic material in this study (Table 2-2 and Figure 2-11). We observed that by 
changing catalyst addition rate (5 wt% and 10 wt% to monomer) we could prepare 
CA-PPZ with low MW (~26KDa) and high (~36KDa). In both cases, the 
polydispersity was narrow, likely due to the effective purification after the 
ring-opening polymerisation by the centrifuge method and filtration after thiol-ene 
click reaction, which both had removed highly crosslinked fractions from the raw 
products. 
 
Table 2-2. Molecular weight and distribution measured by GPC (n=3) 
Cationic PPZ Mw Mn PI 
HMw CA-PPZ 35921 ± 3936 24515 ±6622 1.54 ±0.36 
LMw CA-PPZ 25954 ± 2387 16693 ±1864 1.56 ±0.05 
 
 
Figure 2-11. The molecular weight distribution of high and low molecular weight 
CA-PPZ. The molecular weight distribution was measured by GPC and column 
calibration was achieved using Poly(2-vinylpyridine) standards. 
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2.3.3 Acid-base buffering capacity of ionic polyphosphazenes 
The polymers were intended as nucleic acid carriers, for which their abilities to 
act as ‘proton-sponges’ and/or membrane disruptors48 would be highly dependent on 
their ability to accept protons and to change their hydrophilic / lipophilic balance 
across intracellular pH ranges. The protonation profiles of the polycations were thus 
determined by potentiometric titrations (Figure 2-12 a,d). As expected, the amine 
side-chain polymers remained protonated across cytosolic and endolysosomal pH 
ranges and their buffering ranges were higher than pH 8. However, the various 
aliphatic acid side-chain polymers, derived from 3-mercaptopropanoic acid (3MPA), 
4-mercaptobutanoic acid (4MBA), 6-mercaptohexanoic acid (6MHA), and 
8-mercaptooctanoic acid (8MOA) exhibited buffering regions across the range of pH 8 
to pH 5 (Figure 2-12 f). For these anionic polymers, the titration was performed from 
high to low pH, and in this process, the polymers became hydrophobic due to 
protonation of alkylcarboxylic acid and precipitated at certain point. Because of this 
precipitation, we only can obtain “apparent pKa” for these pH-sensitive polyanions. 
The pKa values were calculated by Henderson-Hasselbalch equation, by which the 
titration data was re-plotted to scatter diagrams and then fitted with linear regression. 
As shown in (Figure 2-12 b,e), the apparent pKa of alkylcarboxylate side-chain PPZ 
increased while the alkane section of side chains extended. This is likely that longer 
alkane chain on the alkylcarboxylate-PPZ presents more hydrophobic features once 
their carboxylate groups are protonated. In light of this, we screened different 
alkylcarboxylates as side chains on the PPZ backbone based on the process and clearly 
shows that those polyanions possess high pH-sensitivity and the capacity to change 
their aggregation behaviour around endosomal pH. 
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 For further understanding of their buffering capacity, these titration curves were 
converted to line charts plotting protonation degree (α) against pH (Figure 2-12 c,f). 
The largest shift in the proportion of ionized side chains over the critical physiological 
pH to early endosomal pH (pH 7.4 to 6.0) was exhibited by 6MHA-PPZ, with an 
overall change in protonation of 61.9±3.6%. This was significantly higher than the 
other anionic polymers (Table 2-3). 
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Figure 2-12. Protonation profiles of ionic polyphosphazenes analysed by 
potentiometric titration curves. (a) Potentiometric titration curves of cationic 
polyphosphazenes, only primary amines attached (P100%) (CA-PPZ), half primary 
and half tertiary amines attached (P50% T50%) CA-/DMAES-PPZ, and only tertiary 
amine attached (T100%) (DMAES-PPZ). (b) pKa calculation of polycations by a 
scatter diagram of Log [P/PH+] against pH. [P] represents the concentration of amine 
side-groups on the PPZ and [PH+] is the concentration of protonated amine-side groups. 
(c) Protonation degree (α) of different cationic polymers against pH. (d) Potentiometric 
titration curves of anionic polyphosphazenes with different lengths of alkylcarboxylic 
acid. (e) pKa calculation of polyanions by a scatter diagram of Log [A-/HA] against pH. 
[A-] represents the concentration of carboxylate side-groups on the PPZ and [HA] is 
the concentration of protonated carboxylic acid side groups. (f) The protonation degree 
of different anionic polyphosphazenes against pH. 
 
 
Table 2-3. Apparent pKa and percentage of protonation between pH 7.4 and 6.0 of 
anionic polyphosphazenes. Data derived from potentiometric titrations (n≧3). 
Polyanion 3MPA 4MBA 6MHA 8MOA 
Apparent pKa 5.56±0.09 5.89±0.07 6.55±0.08 7.14±0.10 
△α (pH 7.4 – 6.0) 19.7%±3.2% 29.1%±4.0% 61.9%±3.6% 29.7%±2.6% 
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2.3.4 Particle characterization of polyionic gene complexes 
For the characterization of ionic polyphosphazene complexes, we screened how 
several factors affected the physicochemical properties of the complexes. The factors 
analysed were N/P ratio of polycation/pDNA complex, addition of anionic 
polyphosphazenes, and the ratio between cationic and anionic polyphosphazenes. In the 
whole screening, every complex was loaded with same amount of pDNA. Here, we 
abbreviated the composition ratio of polymeric complexes between polycationic 
amines (N), polyanionic carboxylates (C), and negative DNA phosphates (P) to N/C/P. 
Firstly, the cationic polymers (CA-PPZ) were screened for polyelectrolyte complex 
formation with plasmid DNA (pDNA) at varying N/P ratios (Figure 2-13a). From N/P 
ratio 1:1 to 2:1, the surface charge of the complexes undergoes inversion from -15 mV to 
net positive values, showing that at N/P ratio 1:1 the plasmid is not completely covered 
by the cationic polyphosphazene. At N/P = 8, the diameters of the complexes were all 
close to 80 nm and the zeta potentials close to +40 mV, and these characteristics did not 
increase with further additions of polycation.  
 
When CA-PPZ complexes were formed in the presence of the various PPZ 
polyanions (at the 8:4 ratio of amines to carboxylic acids in the mixture), the diameters 
increased to ~100 nm and the zeta potential decreased to approximately +30 mV 
(Figure 2-13b), indicating further neutralization of the CA-PPZ. The characteristics of 
the complexes, however, did not change by introducing alkylcarboxylate-PPZ with 
different aliphatic chains. In addition, the size of the complexes did not significantly 
increase with the addition of higher amounts of the polyanion 6MHA-PPZ, but the total 
derived count rate in the light scattering experiments increased over one order of 
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magnitude compared to the same complexes without the anionic PPZ. This indicated 
that tighter particulate complexes were formed in the presence of polyanionic PPZs 
(Figure 2-13c). 
 
For further investigation on our binary polyionic complexes, we employed 
Nanoparticle Tracking Analysis (NTA, from Malvern) to measure particle size 
distribution and concentration. In Figure 2-14, the three-axis scatter charts showed that 
the scattered light intensity increased with increasing 6MHA-PPZ mixing ratio. This 
change is particularly visible when comparing intensity distributions between 8:0:1 and 
8:1:1 complexes, but the change was maintained at compositions with higher amounts 
of 6MHA-PPZ. Despite of that, NTA experiments determined that all polymer 
complexes, independent on the introduction of higher amounts of 6MHA-PPZ, had 
similar amounts of particle numbers (Figure 2-14). Trying to reconcile these results 
with the intensity plots and the DLS, we suggest that the introduction of 6MHA-PPZ in 
the complexes only increased particle density, making more compact complexes, 
instead of generating a higher amount of particles. 
Another tool for nanocomplex characterization is Transmission Electron 
Microscopy (TEM) imaging, which could help us understand the morphology of the 
different polymer complexes (Figure 2-15). Both CA-PPZ:pDNA and 
CA-/6MHA-PPZ:pDNA complexes are spherical. Compared to CA-PPZ:pDNA, 
6MHA-PPZ mixing in CA-PPZ complexes show more defined boundaries when 
imaged by TEM. This might be a further indication of a more compact structure in 
complexes having 6MHA-PPZ, and would support the hypothesis on PPZ complex 
structure put forward by DLS and NTA data. 
 




Figure 2-13. Characterisation of ionic PPZ gene complexes. Hydrodynamic size and 
zeta potential of CA-PPZ:pDNA with different N/P ratios in a) and of CA-PPZ:pDNA 
complexes mixed with different polyanions in b) and at a ratio of CA-PPZ amines, 
anionic PPZ carboxylates and pDNA phosphorous (N/C/P) of 8:4:1 was used. c) The 
particle sizes and total derived counts (KCPs) of CA-PPZ:pDNA complexes (8:1 N/P 
ratio) mixed with increasing amounts of 6MHA-PPZ (from 8:0 to 8:4 N/C ratio). 
 




Figure 2-14. Nanoparticle Tracking Analysis of polyionic complexes. A fixed ratio of 
polycation CA-PPZ condensed various ratios of polyanion 6MHA-PPZ and the same 
amount of pDNA. In the green scatter graph (up) showed the relationship between 
particle size (X-axis) and light scattering intensity (Y-axis). For the 3D graphs (down), 
the three-axes represented particle size (X-axis), light scattering intensity (Y-axis) and 
concentration (particle number/mL in Z-axis). The quantification of particle size and 
concentration above were shown in the bar chart graph. 
 
 




Figure 2-15 TEM images of CA-PPZ:pDNA and CA-/6MHA-PPZ:pDNA complexes 
in three independent experiments. 
 
 
2.3.5 Binding efficiency of polyionic gene complexes  
Following the physicochemical particle characterisation, we investigated the 
pDNA-binding efficiency of polymeric complexes and pDNA release in the presence 
of a competitor. Agarose gel electrophoresis experiments were performed in the 
absence and presence of the competing strong polyelectrolyte heparin to test the ability 
of the different polyplexes for retaining pDNA. The data indicated that tertiary-amine 
PPZ complexes, particularly 100% tertiary amine groups quickly released their pDNA 
cargo by incubation with heparin, as shown by pDNA bands migrating from the 
loading location (Figure 2-16a). Indeed, these experiments indicate that complexes 
loose efficiency in pDNA-binding as primary amines are substituted by tertiary-amines. 
This conclusion is supported by other references from the literature.49,50 Complexes of 
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CA-PPZ:pDNA and CA-/6MHA-PPZ:pDNA were also analysed by agarose gel 
electrophoresis and then challenged with heparin under simulated endosomal (pH 5) 
and standard physiological (pH 7.4) conditions (Figure 2-16 b). There was less pDNA 
release from both CA-PPZ:pDNA and CA-/6MHA-PPZ:pDNA complexes at pH 5 than 
at pH 7, reasonably due to increased protonation of polyions in the more acidic 
environments. When competing with heparin at pH 5, increasingly-protonated 
CA-PPZ:pDNA complex showed stronger binding of pDNA, and even a 4-fold mass 
ratio excess of heparin is not enough to release the pDNA escape. In comparison, the 
loading bands of CA-/6MHA-PPZ:pDNA complexes at pH 5 were apparent from 
2-fold heparin excess, indicating that the structure is loose enough to allow ethidium 
bromide (EtBr) intercalation, but clear release was evident starting from 4-fold heparin 
excess. At pH 5, both complexes would be protonated and induced more positively 
charged amines to bind with pDNA, but this loose structure of CA-/6MHA-PPZ:pDNA 
complexes might be related to the hydrophobicity of protonated 6MHA-PPZ at pH5, 
and the reduction of the its interaction between the cationic polymers and nucleic 
acids.  
 




Figure 2-16. Binding efficiency test. (a) Gel retardation and heparin-displacement 
tests of complexes prepared with PPZs having 100% primary amines (P100%), P50% 
or P0% (8:1 N/P ratio). The remaining substitutes of each polymer corresponded to 
tertiary amines: T0%, T50% and T100%, respectively. (b) Gel electrophoresis and 
heparin-displacement tests of CA-PPZ:pDNA complexes and CA-/6MHA-PPZ:pDNA 
(8:4:1 N/C/P ratio) complexes at pH 7.4 and pH 5. 
 
To obtain further information on the molecular interactions between CA-PPZ, 
6MHA-PPZ,  nucleic acids, and the competitive binding with strong anionic 
polyelectrolyte (e.g. Heparin sulfate or Dextran sulfate)51. Hetero-Förster resonance 
energy transfer (FRET) techniques were utilized for understanding of this 
complexation. To perform these experiments, two pH-independent fluorescent dyes 
that were a well-known fluorescent pair for FRET were selected: cyanine 3 (Cy3) and 
Chapter II / Capítulo II 
117 
 
cyanine 5 (Cy5)51,52. FRET has been employed to measure dynamic association or 
dissociation between donor fluorophore (Cy3) and accepter fluorophore (Cy5) at the 
nanometre scale. When the donor and acceptor are very close, the emission spectra of 
donor partly overlap with the excitation spectra of acceptor; thus, the emission of 
donor would transfer partial energy to the acceptor, and the transferring efficiency 
would be inversely proportional to the distance between the donor and acceptor. In this 
study, CA-PPZ was conjugated with Cy3 as donor and pDNA was labelled by Cy5 as 
acceptor, and then formed a binary fluorescently labelled nanocomplex. By the way, 
through this fluorescent probe (Cy5) labelled on pDNA, we can further evaluated how 
much pDNA can be loaded in the polymer complexes, using a high-speed centrifuge to 
separate unbound Cy5-pDNA from polymeric Cy5-pDNA nanocomplex53. The 
association efficiency of Cy5-pDNA loaded in PEI, CA-PPZ, and CA-/6MHA-PPZ 
complexes were 82±1.4%, 85±8%, and 97±2%, respectively, based on the fluorescent 
intensity measurement. 
 
In Figure 2-17a, the Cy5 maximum emission spectra at around 676 nm showed 
an increase in intensity with higher amounts of 6MHA-PPZ in the system. Indeed, 
compared to CA-PPZ:pDNA (CA-plex), mixing of complexes CA-PPZ, 6MHA-PPZ, 
and the same amount of pDNA (Mix-plex) revealed increasing Cy5 intensity until N/C 
8:3 ratio, and a saturation of the effect between N/C ratios of 8:3 and 8:4. This data 
clearly indicated that 6MHA-PPZ compacts CA-PPZ:pDNA complexes. On the other 
hand, low FRET efficiency of CA-PPZ:pDNA complexes indicate some distance 
between these components inside the nanoparticles. Although CA-PPZ complex 
showed higher capacity to counteract the presence of an electrostatic competitor for 
pDNA (i.e. heparin sulfate or dextran sulfate) than CA-/6MHA-PPZ complexes 
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(Figure 2-16b), this capacity does not seem related to a more compact structure but 
rather to the capacity of the “positively charged” CA-PPZ to also condense heparin 
until full neutralisation is achieved. In Figure 2-17b, CA-PPZ complexes showed 
increasing intensities of the Cy5 emission peak as they are incubated with more 
dextran sulfate up to a mass ratio of 0.4 with respect to pDNA, indicating further 
nanocomplex reticulation. As this threshold ratio was surpassed with higher amounts of 
dextran, CA-PPZ complex showed a significant decrease in FRET efficiency as it was 
observed with CA-/6MHA-PPZ complex. This process can be attributed to the 
dissociation and displacement of the CA-PPZ:pDNA interaction, causing an increase in 
the distance between acceptor (Cy5-pDNA) and donor (Cy3-CA-PPZ). The advantage 
of FRET is to measure the proximity between donor and acceptor at small nanometric 
scale (i.e. 1 nm to ~10 nm). However, this technique does not inform reliably about 
distances above this range and therefore, it does not constitute a definitive 
conformation of pDNA release from the cationic complexes, yet presenting the 
interaction of polycation and pDNA in the early stage when strong polyanion displaced 
pDNA from the complexes. For further understanding of the release mechanism, we 
analysed intercellular distributions of polycation and pDNA using confocal 
microscopic images (in Chapter 3.3.2). 
 




Figure 2-17. FRET evaluation of molecular interaction between Cy3-labelled CA-PPZ 
and Cy5-labelled pDNA. (a) Scanning emission spectra of Cy3-CA-PPZ complexed 
with Cy5-pDNA (CA-plex) or Cy3-CA-plex mixing polyanion 6MHA-PPZ (Mix-plex) 
at different mole ratios of amines on the CA-PPZ to carboxylic acids on 6MHA-PPZ. 
(b) Spectra and (c) FRET efficiency (%) of either CA-plex or Mix-plex incubating 
with various mass ratios of dextran sulfate. 
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2.3.6 Optimisation of polyionic complexes by in vitro transfection 
Complexes based on cationic PPZs were initially assessed for their ability to 
transfect U87MG glioblastoma cells when cultured as adherent monolayers. Here 
PPZ-based complexes were loaded with pDNA encoding GFP and luciferase sequences. 
GFP was used for qualitative observation of transfection, while luciferase was used to 
quantify this process. To select the optimal formulations, the transfection efficiency 
and the toxicity of different formulations were measured. In the first screening (Figure 
2-18 a, b), the most favourable compromise between transfection efficiency and cell 
viability occurred at N/P ratio (8:1) of primary amine-PPZ:pDNA with high molecular 
weight (36k Da). Albeit of the highest gene-transferring expression at N/P16, the 
toxicity at this ratio was deemed too severe. For low molecular weight of CA-PPZ, the 
best condition for transfection was at N/P 24, but the high amount of cationic polymer 
induced cell death. Considering the effectiveness and cytotoxicity, the high molecular 
weight of CA-PPZ at N/P 8 was chosen in the following studies. 
 
In the screening of PPZ with different cationic side chains, polymers substituted 
with cysteamines (primary amine) were more effective for inducing gene expression 
than DMAES (tertiary amine). This results was similar to that of previous study54 
where random poly(methacrylate) copolymers with different ratios of tertiary to 
primary amines were analysed for gene transfection. In this work, the most efficient 
polymer was also the one with only primary amines. The main reason may be that the 
primary amine group can offer tightly binding with the plasmid, whereas the two 
methyl groups of DMAES could generate steric hindrance, reducing binding efficiency 
with pDNA (Figure 2-16 a). Another reason might be that polymers with tertiary 
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amines such as    poly(2-(dimethylamino)ethyl methacrylate) (pDMAEMA) seem to 
require higher molecular weight to achieve their highest efficiency of gene-transfer55. 
The minimum Mw of pDMAEMA to have the optimal transfection with pDNA in the 
COS-7 and OVCAR-3 cell-line is 300 KDa; in contrast, low Mw pDMAEMA (Mw 
≦63 kDa) had 5 times less transfection efficiency than the optimal condition. The 
importance of high Mw in pDMAEMA was explained by more effective condensation 
of pDNA and by a capacity to avoid nanocomplex collapsed prior to internalisation. 
However, we had selected PPZ platform with only Mw 10K-100K in views of the 
transfection data obtained previously, and of their easier degradation and minimum 
polymer-induced toxicity. In light of this, the low binding capability of tertiary amines 
may not be a suitable gene delivery based on this low-Mw PPZ platform. 
 
In order to provide for an endosomal escape mechanism and release of nucleic 
acid cargos, we prepared CA-PPZ:pDNA complexes integrating carboxylate side-chain 
PPZs (3MPA-, 4MBA-, 6MHA-, or 8MOA-PPZ), with buffering capacities at different 
pH range (Figure 2-12). Luciferase expression assay were run in U87MG monolayers 
using these complexes as gene carriers and PEI:pDNA complexes at the same N/P 
ratios as positive control (Figure 2-19). The mixing CA-/6HMA-PPZ:pDNA complex 
showed the highest level of transgene expression and a neat reduction in cytotoxicity 
compared to the parent CA-PPZ:pDNA complex. Similar enhancements in transfection 
were not observed in the mixed complexes with the other polyanionic PPZs, in view of 
the unique effect that we attributed to the significant change in protonation of 
6MHA-PPZ at endosomal pH as described earlier. Besides this effect, all polyanionic 
PPZs reduced the cytotoxicity of the complexes, which can be attributed to partial 
shielding of the cationic charges of CA-PPZ. The transfection enhancing effect of 
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6MHA-PPZ is also effective with other cationic polymers with similar structure such 
as poly-L-lysine (PLL), and translates to other clinically relevant glioblastoma models 
such as the primary cell model GBM1 with remarkable efficacy56 (Figure 2-20). It is 
interesting to note that 6MHA-PPZ seems also capable of improving cell transfection 
in combination with another common-used polycation (PLL), which are also low 
endosomal escape properties. Although 6MHA-PPZ mixing in CA-PPZ complexes 
seem to be particularly efficient (Figure 2-20), which likely attributed to our above 
optimization of this cationic PPZ platform. 
  





Figure 2-18. (a, b) Optimisation of polycationic complexes via luciferase expression 
and cell viability of CA-PPZ/pDNA complexes with low molecular weight (LMw 26K) 
and high molecular weight (HMw 36K) at different N/P ratios. (c) Luciferase 
expression upon transfection with complexes of different polycationic PPZs (T0%, 
T50%, T100%) and pDNA (1 µg/cm2 pDNA dose and 8:1 N/P ratios). (d) Cell viability 









Figure 2-19. Optimisation of CA-PPZ complexed with various anionic polymers. (a) 
Luciferase expression by quantification of relative luminescence unit (RLU)/μg protein 
obtained upon transfection of U87MG cells with CA-PPZ:pDNA complexes (8:1 N/P 
ratio) and different CA-PPZ/polyanionic PPZ:pDNA complexes (N/C/P ratio of 8:4:1, 
pDNA dose 1 μg/cm2). Transfection with PEI:pDNA is shown as an internal control. (b) 









Figure 2-20. Investigation of optimized polyanion boosting luciferase expression upon 
cell transfection with various polycations (CA-PPZ or poly-L-lysine). A comparison 
was performed between at alone (8:1 N/P ratios) and after mixing with 6MHA-PPZ 
(8:4:1 N/C/P ratio). Data obtained in U87MG and in the primary cell line GBM1. 
  





A versatile polymeric gene delivery system platform was established based on 
polyphosphazenes modified by thiol-ene addition reactions. Based on these materials, a 
small library of cationic or anionic gene-delivery polymers was screened for optimized 
physicochemical properties, gene-binding efficiency, low cytotoxicity, and high gene 
transfection. The optimal system was generated with polyphosphazene modified with 
primary amines (CA-PPZ) and mixed with another polyphosphazene with the anionic 
polymer (6MHA-PPZ) and pDNA. This system showed transfection efficiency/toxicity 
ratios above one order of magnitude higher than the parent polycation:pDNA system. 
This improved transfection can be explained by the high buffering capacity and the 
pH-induced hydrophobicity of 6MHA-PPZ in the endosomal environment. Besides, 
DLS, NTA, FRET and TEM indicated that the addition of 6MHA-PPZ generates more 
compact complexes that efficiently release their gene cargo once in the presence of 
another strong anionic polyelectrolyte. The nanocomplexes based on the 
CA-/6MHA-PPZ:pDNA mixture were considered of sufficient interest for further 
studies in more advanced disease models. 
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Following efforts on screening a small library of potential side chains for 
enhanced polyphosphazene formulation (CA-/6MHA-PPZ complex) by pDNA 
transfection in 2D culture, this chapter would cover several potential mechanisms for 
6MHA-PPZ facilitated endosomal escape. For understanding intracellular distribution, 
Cy5-labelled pDNA was delivered by either CA-PPZ or mixing CA-PPZ with 
6MHA-PPZ to the U87MG cells and then analysed for intracellular locations related to 
lysotracker (late-endosomal and lysosomal markers). Through ImageJ analysis, it was 
shown that pDNA in CA-/6MHA-PPZ complexes are better able to escape from 
endolysosomal compartments than the CA-PPZ-only analogue. The release of pDNA 
after endosomal escape was also confirmed by confocal microscopy images, further 
confirming that the 6MHA-PPZ helped release of pDNA as well. Through optimisation 
and mechanistic analysis, further transfection experiments were performed in 3D 
culture spheroid models, which provide bio-relevant microenvironments related to in 
vivo tumour models and which also preserve genetic profiles of the tumour cells. On 
the basis of GFP expression, CA-/6MHA-PPZ complexes showed high transfection 
efficiencies in U87MG spheroids of sizes up to with 250 μm diameter. Tomographic 
imaging also demonstrated that CA-/6MHA-PPZ complexes transferred gene cargos 
through the core of the spheroids and were able to transfect cells at lower doses, 
compared to the polycation-only complexes, CA-PPZ and PEI. Finally, the polymeric 
complexes were tested in xenograft models on mice. These in vivo transfection 
evaluations were through intra-tumoral injection of CA-/6MHA-PPZ complexes, and 
luciferase expression in these experiments was similar to those of PEI/nucleic acid 
complexes. The H&E stained images of transfected tumours indicated no significant 
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sign of cell death in all polymer-nucleic acid complex treatments. Taken together, the 
gene-transfer studies in 2D, 3D in vitro models and xenograft models in vivo, 
demonstrated that the addition of 6MHA-PPZ enhanced transfection efficiency of 
polycations-nucleic acid complexes and many be considered promising for further 
gene therapy experiments. 
  





3.1.1 Endocytosis of polymeric gene-carriers and endosomal escape 
 
Endocytosis is a term used to describe a series of pathways by which cells obtain 
nutrients, control inter- and intra-cellular signalling, and regulate receptor expressions. 
Endocytic pathways are also primary routes for nanoscale vehicles to cross plasma 
membrane.1,2 Endocytosis mechanisms include macro-scale endocytic processes 
(phagocytosis and macropinocytosis) and micro-scale endocytic processes 
(clathrin-mediated, caveolin-dependent/independent endocytosis, and 
dynamin-dependent/ independent endocytosis, etc.). For polymeric gene complexes, 
Wagner group reported that the internalisation of PEI complexes into mammal tumour 
cell-lines was strongly dependent on the particle sizes. Thus, small PEI complexes 
were internalised via caveolae/raft-dependent routes3, and large aggregated PEI 
complexes (diameter <1 μm) by clathrin-independent pathways or macropinocytosis 
pathways.4,5 In nearly all cases, most of the complexes were found in endosomal 
compartments6 which is the normal fate for most nanocarriers following internalisation 
via endocytosis. Escape from endosomal compartments is one of the pivotal challenges 
for endocytosis-related intracellular gene delivery7-9, because if the carriers are 
retained in these vesicles as the late endosomes mature to lysosomes, enzymes in the 
resultant acidic environment can very efficiently degrade any nucleic acid cargos. 
Although the mechanisms of endosomal escape are still not entirely clear now, many 
hypotheses have been proposed and scientific experiments designed to test the 
concepts10. However, it is generally accepted that endosomal environments are 
gradually acidified by ATP-driven transport during the process of endocytosis, and this 
acidification can be exploited by pH-responsive polymers. These materials can 
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destabilize endosomal membranes through the “proton-sponge effect”11,12, 
endosomolysis13, or membrane fusion14 as shown in Figure 3-1. In all cases, the 




Figure 3-1.  The common of hypotheses for endosomal escape for nanocarriers. 
[reproduced from Martens, T. F., et al. (2014). Nano Today10 with permission] 
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3.1.2 Buffering capacity for endosomal escape 
 
For the proposed mechanisms of nanocarriers escaping from endosomal 
compartments, the most well-known mechanism is the “proton-sponge” effect. After 
formation of early-endosomal vesicles, V-type proton ATPases continue to pump 
protons across the endosomal membrane during vesicular maturation until lysosomal 
compartments are formed with a pH range of 5.0 - 4.5, and during this process, 
counter-ions cross the transmembrane channel to balance electric potential15. When 
polymeric-based or lipid-based gene carriers, containing excess un-protonated 
functional groups with pKa values close to the endosomal pH range, they can be 
protonated and thus buffer the active-transported protons. Through absorbed excess 
protons and accumulation of counter-ions (e.g. Cl- or SO4-) inside endosomes, the 
increasing osmotic gradient causes hypotonic shocks, thus inducing the influx of H2O, 
which in turn causes swelling of endosomal compartments. The high osmotic pressure 
contributes to endosomal destabilization, triggering endosomal rupture and release of 
cargos inside. It should be emphasised that this is not the only pathway2,16 and 
mechanisms of endosomal escape strongly depend on differences in the design of 
carriers. When the endosomal compartments became acidified, there are several effects 
on the endosomal leakage. Firstly, increasingly protonated polycations provide higher 
positively charged surfaces of nanoparticles, which cause the cationic carriers to repel 
each other and favour interactions with the negative endosomal membranes. This 
causes membrane damages and pore formation17, as demonstrated by histidine-rich 
peptide H5WYG 18 and GALA 19 and other polymers with pKa values between 7.0 to 
5.5.20 Secondly, it is known that certain viruses escape from endosomal traps via 
pH-sensitive proteins, such as HA-2 subunits21, which expose hydrophobic α-helical 
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domains in slightly acidic environments in order to disrupt endosomal membranes22. 
Two other well-known examples of membrane disruptors are the anionic amphiphilic 
peptides are INF7 and E5WYG 10,22. Thirdly, for lipid-based vehicles or amphiphilic 
materials, a fusion of the introduced amphiphiles and phospholipid-based membranes 
can happen, especially in the case of which cationic lipids undergo association with 
negatively-charged membranes10,18. Through membrane fusions, the cargos in the 
nanocarriers can be introduced to the cytosol and released directly23 (Figure 3-1). 
 
3.1.3 pH-sensitive polyanions for endosomal escape 
 
On the basis of the potential mechanisms above, many strategies have proposed 
buffering functional groups into cationic polymer chains, like poly- or oligo-histidine20, 
aminoethylene repeats24, diisopropylamino side groups.25 However, those buffering 
side chains are located on nitrogen atoms as potential positively charged functional 
groups, but there are very few designs utilizing anionic side chains or polyanions for 
improving buffering capacity of nanocarriers. Although some studies have employed 
anionic polymers to mix with or to coat on cationic complexes for protein delivery26 
and gene delivery27, most of the polycation/polyanion complexes to date have been 
used for nanoparticle construction. Of these, only a few of them have been designed to 
utilise stimuli-responsive polyanions, especially for endosomal pH responsiveness. In 
general, designs of pH-sensitive polyanions can be classified into four strategies, 
including cleavable anionic side chains28,29, pH-sensitive zwitterionic polymers30,31, 
poly(propylacrylic acid)-copolymers (PPAA)32-35, and poly(β-malic acid) (PMLA) 
copolymers 36,37, as shown in Figure 3-2.  
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Firstly, the cleavable anionic side-chains are designed by intramolecular 
nucleophilic amides and neighbouring carboxylic acid groups. Once in slightly acidic 
environments, the amide groups are cleaved by acid-catalysed hydrolysis, generating 
free amine groups, resulting in the terminal side chains switching from negatively 
charged carboxylates to positively charged amines38 (Figure 3-2a). However, these 
charge-reversal polymers have only used to date for small-molecule chemotherapeutic 
drugs. Secondly, for pH-sensitive zwitterionic polymers, anionic terminal groups were 
introduced on tertiary amines, elaborately designing the pKa of the carboxylic acid 
groups at outmost layer to target the slight acidic tumour microenvironment (pH 6.9－
6.5)30,31 (Figure 3-2b). However, this well-designed formulation was only used as a 
carrier for hydrophobic drugs and would be difficult to manipulate in the gene carriers 
because the negatively charged nucleic acids would perturb the ordering of the 
zwitterionic polymers, likely causing nanoparticular structures collapse.  
 
The Hoffman and Stayton groups have utilised PPAA-copolymers for 
endosomolysis since 1999 32,39. They screened a library of substituted poly(acrylic 
acid)s with different hydrophobic chain sections, finding specific pH-inducing 
hydrophobic poly(acrylic acid)s which possessed membrane disruption ability at 
slightly acidic environments via haemolysis studies. Furthermore, advanced 
endosomolytic block-co-polymers were synthesized by controlled reversible addition 
fragmentation chain transfer polymerisation (RAFT) of PPAA and butyl methacylate 
(BMA) and cationic side-chain monomers for siRNA delivery (Figure 3-2c). Although 
these PPAA copolymers introduced polyanions in gene delivery, the non-biodegradable 
polymer backbone and complicated synthesis procedures may obstruct pharmaceutical 
applications, but the strategy indeed inspired further studies. A recent example is a 
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membranolytic PMLA copolymer, which is a biodegradable polyanion containing 
abundant carboxylic terminal groups. However, without further chemical modification, 
PMLAs do not have membrane disruption capacity due to low pKa (~3.5) and high 
hydrophilicity. As a result, some studies have optimized the amphiphilicity of PMLA 
conjugated with hydrophobic peptides for pH-sensitive membrane disruption36. After 
the optimisation, only conjugation with a short peptide (triple leucine) on PMLA 
backbone is significantly capable to rupture liposomal membranes at pH 5. In this 
strategy, a biodegradable backbone PMLA conjugated with tri-leucine as side chains 
for successfully breaking liposomal membranes. PMLA is also widely used for 
covalent nanoconjugation with antibody (antiEGFR)37,40 or chemotherapeutic drugs 
(e.g. temozolomide)41. To sum up, there are few reports that have used related 
polymers in nanoformulations for gene therapy applications.  
 
As noted above, although some studies have utilized polyanions or anionic 
terminal groups of zwitterionic polymers to enhance endosomal escape, there are rare 
uses of anionic groups for co-formulation with polycations in order to minimise side 
effects and maximise gene-transfer efficiency to date. The reasons for this include 
biodegradation capabilities, as complicated synthetic polymers are of less interest for 
the human-use, due to a lack for prior validation in clinical trials and in PICS/GMP 
production. In addition, it can be troublesome using zwitterionic polymers for 
polymer-gene nanocomplex systems, because when zwitterionic polymers are 
condensed with anionic nucleic acids, it is difficult to control and maintain zwitterionic 
sections at the outer layer and polycation sections with complexed nucleic acids in the 
core. This is likely why the zwitterionic polymers are frequently used for delivery of 
hydrophobic drugs, in which van der Waals interaction provide the driving forces for 
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forming nanoscale particles29,30. 
 
According to the previous chapter, the optimal cysteamine-attached 
poly(phosphazene)s (CA-PPZ) was selected by in vitro transfection studies, while the 
carboxylic acid functionalized poly(phosphazene) derivatives possessed varying 
degrees of anion content dependent on environmental pH. By combining these 
materials in the presence of nucleic acids, we expected the mixed binary polyionic 
complexes to escape more effectively than conventional polycation/nucleic acid 
complexes from endolysosomes, which have been considered to be the most significant 
intracellular barriers to effective gene delivery.42-45 
 
  





Figure 3-2. Chemical structures of pH-sensitive polyanions in the literatures. a) 
Cleavable anionic side chains; b) pH-sensitive zwitterionic polymers; c) 
poly(propylacrylic acid)-co-block polymers; d) nanoconjugate poly(β-malic acid) 
(PMLA) copolymers with linear trimers of leucine. 
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3.1.4 Three dimensional in vitro cultures  
 
Traditional two-dimensional cell mono-layers have been used for formulation 
screening for several decades but also have been questioned due to lack of clinical 
validation and whether they are representative for physiologically relevant situations 
46,47. Three-dimensional cultures are better able to provide tissue-like architecture (e.g. 
extracellular matrix)48 and fundamental tumour microenvironments, like nutrient and 
oxygen gradients 49, cell-cell interactions, and gene expression profiles50. Engineered 
3D tumour models can be derived from simple mono-/multiple-cellular spheroids (cell 
aggregation) to complicated microfluidic scaffold systems or larger scale bioreactors. 
For establishing simple spheroid models, the predominant method is growing tumour 
cells or co-culture specific cells in a limited space to force them to gather and attach to 
each other, which then results in the cells forming a sphere-like aggregate. The common 
protocols are designed to limit cells in specific spaces, including using hydrogels, 
scaffolds, cell culture dishes or plates with non-adherent coatings, or suspending cells in 
hanging drops51. Dependent on the models, additions of growth factors and small 
molecular signals are necessary52 and the scale of spheroid diameter is approximately 
from few millimetres to sub-millimetres53. Other 3D models utilising microfluidic 
devices or bioreactors can set-up large scale multi-cellular objects (~several 
centimetres), develop vascular lumens54 or endothelial cell layers55 for bio-relevant tests 
in pharmaceutical applications (Figure 3-3).  
 
In this thesis, we employed a liquid-overlay method to produce spheroids, which 
used ultra-low attachment U-shape plates to maintain cells in aggregates while they 
formed sphere-like tumour-mimetic clumps. This model has previously been shown to 
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simply generate, with good reproducibility and efficient screening of large numbers of 
formulations56,57. These kinds of spheroid models have been used in screening 
anticancer drug or related formulations, but a few studies have utilised spheroids to 
evaluate nucleic-acid delivery. In addition, more importantly for this study, the 
3D-culture spheroids are more capable to retain the genomic profiles of GBM cell-lines 
than 2D counterparts50. In this study, we tested transgene expression in spheroids of 
GBM cells before in vivo studies. Consequently, in 2D cell monolayer, we can assume 
that all the cells receive an equal dose of the polymeric gene complex at the same time, 
while in millimetre-scale spheroids, the nanocarriers were obstructed to reach in the 
core parts by ECM or hypoxia phenomena, etc. 
 
 
Figure 3-3. Different in vitro models in 3D cultures. The block with yellow outline (left) 
shows the hanging drop method to produce spheroids [Reproduced from Tung, Y.-C. et 
al. Analyst53 with permission]. The block with the red outline (right) presents 
pre-vascularised tumour spheroids, which are made by co-culture of endothelial cells 
(A1) and tumour cells (A2) growing in fibroblast containing fibrin-gels (A4 and A3). 
The label B shows the endothelial layer (red signals) stained by anti-CD31 and 
GFP-transduced tumour cells (green signals) [Reproduced from Ehsan, S. M. et al. 
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Integrative Biology55 with permission]. 
 
 
3.1.5 Three dimensional reconstructed imaging 
Optical/fluorescence microscopes have been widely applied in different fields for 
a hundred years, but several challenges of 3D-structure imaging still restrict the 
progress of investigation in large biological objects (>100 μm), and in time-lapse 
imaging (time-course experiments), relevant for dynamic penetration studies of 
nanoparticle-treated spheroids. These limitations include the wide point spread 
function (PSF), limits in excitation light penetration, photobleaching, and speed of 
imaging58. In comparison with traditional confocal laser-scanning microscopy (CLSM), 
two-photon microscopy (2PM) utilizes two photons with long wavelength 
(near-infrared) as the excitation energy, allowing high signal to noise rate, low 
photobleaching, and most importantly deep penetration in biological samples. 
Although 2PM has high resolution and high-penetration excitation, there are some 
difficulties in time-lapse imaging by this technique because of low scan speed and 
non-linear photobleaching58,59. The Light-Sheet Fluorescent Microscope (LSFM) uses 
excitation focused on selective planes to illuminate samples and collect emission 
signals from the direction perpendicular to the excitation path (Figure 3-4a). Firstly, in 
view of its sheet-like scanning, the acquisition speed is much higher than 
point-scanning methods (CLSM and 2PM) and occurs with insignificant 
photobleaching or phototoxicity. Another interesting advantage is a rotation-available 
sample holder (Figure 3-4b), which enables LSFM to collect emission signals from 
different directions, which then overcomes limitations of penetration and allows 
reconstruction and multi-view imaging via appropriate software60. The limitations of 
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LSFM include lower spatial resolution and poor light collection, compared to 2PM and 
CLSM (Figure 3-4d). In addition, LSFM has the wide point-spread function (PSF), 
explaining why LSFM has the lower axial resolution of the various 3D imaging 
microscopes. Despite these deficiencies, LSFM is still a valuable tool to investigate 
tissue mimics, such as 3D-spheroid models and zebrafish models. 
  





Figure 3-4. Fluorescence microscopes for 3D-reconstructed images. (a) Optical 
pathway profiles of microscopes for large biological subjects. [Adapted from Fischer, R. 
S. et al. Trends in cell biology58] (b) The LSFM we used in this thesis (Zeiss Z1). 
[Reproduced from Zeiss website, Lightsheet Z1] (c) Multi-view acquisition by rotated 
samples in LSFM [Adapted from Huisken, J. BioEssays60] (d) Comparison with 
effective point-spread function between different microscopes. The scale bar is 0.25 μm. 
[Adapted from Fischer, R. S. et al. Trends in cell biology58, with permission] 
Abbreviations used are the following: CLSM (confocal laser-scanning microscopy); 
iPALM (interferometic photoactivated localization); LSFM (Light-sheet based 
fluorescent microscopy); PALM (photoactivated localization microscopy); 2PM 
(two-photon microscopy); SIM (structured illumination microscopy). 
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3.2 Materials and Methods 
3.2.1 Haemolysis tests 
Rat blood samples were collected in K2E tubes containing EDTA (BD 
Vacutainer®) and were centrifuged at 1000 rcf for 5 min. After washing with PBS three 
times under the same centrifuge conditions, the red blood cells were re-suspended in 
PBS 7.4 and PBS 5.5 at the concentration of 3 %(wt/volume). The erythrocyte solution 
was allocated across 96 wells and incubated with either CA-PPZ:pDNA or 
CA-/6MHA-PPZ:pDNA complexes for 2 hours at 37 ºC under mild shaking. Then, the 
plates were centrifuged and the supernatants transferred to a new plate for colorimetric 
analysis. The absorption of the released haemoglobin was measured in a 96-well plate 
reader at an excitation wavelength of 570 nm. The maximum haemolysis (positive 
control) was established using cells treated with 1 %(v/v) Triton X100 and the 
minimum value was set by treatment with PBS either at pH 7.4 or PBS at pH 5.5. 
 
3.2.2 Confocal imaging on 2D monolayer 
For maintaining cell-lines, U87MG cells were cultured in Dulbecco's Modified 
Eagle Medium (DMEM, Sigma) containing 10 % fetal bovine serum, 2mM Glutamine 
and 100 mg/L penicillin-streptomycin and maintained at 37 ºC under a 5 % CO2 
atmosphere. For intracellular tracking studies, 25K of U87MG cells were attached on 
poly-L-lysine coating 8µ-Slides (Ibidi) in 200 µL growth media for at least 24 hours 
and then treated with polymeric complexes carrying Cy5-labelled pDNA (prepared by 
Label IT® kit from Mirus) for 4 hours. Then the media was changed to fresh growth 
media for further incubation over an additional 20 hours. After this period, treated cells 
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were incubated with 50 nM of Lysotracker-green (Invitrogen) and 5 µg/mL Hoechst 
33342. Finally, confocal images (Leica SP5X) in live cells were taken. 
 
For pDNA release study, the CA-PPZ was been labelled with Cy3-NHS as 
described in Section 2.2. The polymeric complexes of Cy3-CA-PPZ and Cy5-pDNA 
with 6MHA-PPZ were treated in U87MG cells in OptiMEM for 4 hours and then 
incubated in growth media for the desired time. Before confocal imaging, the cells 
were stained with 5 µg/mL Hoechst 33342. Finally, the confocal images (Leica SP5X) 
of live cells were taken. 
 
3.2.3 Transfection and tomographic scanning in a 3D spheroid model 
 For establishing 3D spheroids of U87MG cells, ultra-low attachment 96 well 
round-bottom plates (Corning®) were seeded with 250 - 5000 U87MG cells per well in 
growth media and with six replicates for experimental conditions. The plates were 
centrifuged at 200 rcf for 5 min to cause cell accumulation and stimulate spheroid 
formation. After three days, the spheroids were adjudged ready for transfection studies. 
The spheroids were treated with different polymeric complexes with different 
concentrations for 16 hours in OptiMEM and further incubated in growth media for 80 
hours. GFP expression was quantified from each spheroid at 96 h post-treatment via 
ImageJ (Fiji) analysis directly using built-in histogram functions (Figure 3-10). The 
volume of the spheroids was calculated from phase-contrast microscopic images 
(Nikon Eclipse Ti) using a ImageJ plugin (Fiji package) macro program,61 which 
measured spheroid area (A) from defined regions of interest (ROI). Then, the spheroid 
area was used to determine the radius (R=[A/π]^(1/2)) and calculated the volume 
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assuming the cell aggregates formed an equivalent sphere. To quantify metabolic 
activity in the spheroids, a resazurin reduction assay was performed. Briefly, the 
spheroids were treated with resazurin (60 µM) in the growth media and incubated at 37 
ºC for 4 hours. Following that, the 96-well plate was measured with a FlexStation II 
plate reader set at an excitation wavelength of 530 nm and at an emission of 590 nm. 
The evaluation of membrane integrity in the cell was performed using 7AAD (5 µL per 
well, 50 µg/mL) and fluorescence observed in the mCherry channel (Ex 560/55 and 
filter 630/60) at the fluorescence microscope. 
In Figure 3-10, the quantification of fluorescence intensity in spheroid model was 
selected via ROI and histogram curves of fluorescence intensity (FI) compared with 
the non-treated group as control (media-only). GFP-positive counts were recorded 
when FI were higher than the maximum FI of non-treated groups, whose intensities 
were decided as thresholds (also as negative control) (Eq. 3-1). For GFP-gene 
transferred expression, there is no optimal positive control. For this reason, we 
presented herein the quantification via the percentage of GFP positive pixels. There 
were at least four replicates in each independent experiment and displayed data were 
analysed by Prism software from four to nine independent experiments. 
 
𝐺𝐺𝐺 𝐺𝐿𝑃𝑃𝑃𝑃𝑃𝑃 𝐺𝑃𝑃𝑃𝑃𝑃 % =  
∑𝑃𝑖𝑃𝑃𝐻𝑃(whose FI>threshold) 
∑𝑃𝑖𝑃𝑃𝐻𝑃 
             (Eq 3-1) 
 
For 7AAD, the threshold is defined from the mean of fluorescent intensity (Mean FI) in 
the untreated group as 0% and the mean FI of 0.5 %(v/v) triton X-100 treated group as 
100%. The percentage of 7AAD signals of treated spheroids are expressed as below. 
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 𝑀𝑃𝑝𝑀 𝐺𝐹 𝐿𝑜 7𝐴𝐴𝐴 𝑃𝑃𝐿𝑀𝑝𝑃𝑃 =  ∑𝑝𝑖𝑃𝑃𝐻×𝐹𝐹 
∑𝑃𝑖𝑃𝑃𝐻𝑃 
                   (Eq 3-2) 
 
7𝐴𝐴𝐴 𝐺𝐿𝑃𝑃𝑃𝑃𝑃𝑃 % =  (𝑀𝑃𝑀𝑛 𝐹𝐹 𝑜𝑜 𝑡𝑡𝑃𝑀𝑡𝑃𝑡 𝑃ph𝑃𝑡𝑜𝑖𝑡𝑃) − (𝑀𝑃𝑀𝑛 𝐹𝐹 𝑜𝑜 𝑛𝑜n-tre𝑀𝑡𝑎𝑃𝑛𝑡)
(𝑀𝑃𝑀𝑛 𝐹𝐹 𝑜𝑜 𝑇𝑡𝑖𝑡𝑜𝑛𝑇 𝑡𝑡𝑃𝑀𝑡𝑎𝑃𝑛𝑡) − ( 𝑀𝑃𝑀𝑛 𝐹𝐹 𝑜𝑜 𝑛𝑜n-tre𝑀𝑡𝑎𝑃𝑛𝑡) 
  (Eq 
3-3) 
 
For 3D imaging, spheroid samples were fixed with 4% paraformaldehyde (PFA) first 
and their nucleus stained with DAPI. The fixed spheroids were loaded in appropriate 
glass capillaries with 1% low-melt agarose. The imaging was performed by light sheet 
fluorescent microscopy LSFM (Light-sheet Z.1, Zeiss) and presented in the same 
fluorescence intensity scale using ImageJ software. 
 
3.2.4 GFP/Luciferase transfection in xenografted model 
All in vivo experiments had been approved by the Research Ethics and Animal 
Welfare Committee at the Instituto de Salud Carlos III, Madrid, (PROEX 224/14) in 
agreement with the European Union and national directives. A subcutaneous xenograft 
model of GBM was established as previously described62. Briefly, athymic nude 
Foxn1nu mice were subcutaneously injected with 1 million fresh U87MG cells (in 80 
µL cultured media and 20 µL Matrigel (BD)) on both flanks. When tumour sizes 
reached around 100-150 mm3, polymer complexes with the GFP/Luciferase plasmid 
were injected inside the tumour directly. One week later, before the mice were 
sacrificed, they were treated with Luciferin 50 mg/kg by IP injection. The transfected 
tumours were excised and imaged by In Vivo Imaging System (IVIS®).  
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3.3 Results and discussion 
 
3.3.1 Membrane disruption of binary-polyions complexes 
Many literature reports have emphasized the importance of endosomal escape in 
the process of gene/drug delivery, for which two proposed mechanisms are the “proton 
sponge” effect and membrane disruption due to the acidified endosomal environment10. 
The effects of biomaterials related to membrane disruption are usually assessed in 
assays prior to practical bio-applications by two common methods, i.e. haemolysis of 
red blood cells (RBC) from mammals32,39 and rupture teats of artificial liposomes37. 
Herein, we chose the erythrocyte membrane as a model because the RBC model can 
not only evaluate the endosomolytic effects but also can indicate the potential of other 
cell-material interactions in the body. 
 
The polymer-only and polymeric complex formulations were added to murine 
RBC, as shown in Figure 3-6a and b, respectively. Firstly, either only cationic 
CA-PPZ or only anionic 6MHA-PPZ were incubated with RBC. As expected, CA-PPZ 
polymers caused severe haemoglobin release due to strongly positive charges, similar 
to other cationic polymers, like poly-L-Lysine (PLL)63,64. In comparison to CA-PPZ, 
the anionic polyphosphazene (6MHA-PPZ) presented high compatibility with RBC at 
physiological pH, even when incubated with high concentrations of 6MHA-PPZ and at 
pH 5.5, but the haemolytic capacity of 6HMA-PPZ were still insignificant. For 
nanocomplex formulations, CA-PPZ:pDNA complex caused higher haemolytic effects 
than CA-/6MHA-PPZ:pDNA, triggering pH-independent membrane disruption. On the 
contrary, the CA-/6MHA-PPZ:pDNA showed low haemolysis percentage at 
physiological pH but caused higher haemoglobin release at the endosomal pH (Figure 
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3-6c). There may be several reasons that caused this low pH-induced erythrocytic 
membrane rupture. Firstly, protonated 6MHA-PPZ reduced neutralisation of CA-PPZ 
at the acidic situation, making positively charged CA-PPZ more capable to interfere 
with the cell membranes in a similar manner to the highly-haemolytic CA-PPZ:pDNA 
complexes. Another reason may be that the protonated 6MHA-PPZ presented 
hydrophobic regions able to insert into the phospholipid bilayers of RBC, resulting in 
membrane disruption. In comparison to 6MHA-PPZ only, this system did not cause 
strong haemolysis, but its complex formulation did have haemolytic effects on the 
erythrocytes at pH 5.5. This is likely caused by aggregation of 6MHA-PPZ polymers 
due to protonation, resulting in insignificant interaction with RBC. On the other hand, 
for the 6MHA-PPZ polymers mixed in CA-PPZ complexes, partial protonation and 
surface presentation of the new-hydrophobic side-chains out from the ‘coronae’ of the 
complexes and as ‘suspending status’ may have raised the haemolytic capability of the 
complexes.  
 
In general, the percentages of haemolysis in the assays were calculated from the 
scale between negative control (PBS only) and positive control (Triton-X 100), but this 
scale is directly affected by the initial number of RBC. As a result, a proper ratio of 
formulation to RBC should be considered but it is difficult to ensure consistency in 
complicated practical situations. Normally, the blood cell concentration of nude mice 
(body weight 20-25 g) is around 7×109 to 13×109 RBC/mL,65 and herein we treated the 
same concentration of polymeric complexes with two initial concentrations of RBC; 
one located around the murine blood concentration, and another was 25 % of the 
physiological RBC number. The figures confirmed the CA-/6MHA-PPZ:pDNA can 
stimulate haemoglobin release under slightly acidic conditions (pH 5.5) in both 
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concentrations of RBC, but the percentages of haemolysis were amplified in the assays 
with the lower initial number of RBC. 
 
 
Figure 3-6. Haemolysis evaluation of PPZ-based polyions or nanocomplexes. a) 
haemolysis percentages of either CA-PPZ or 6MHA-PPZ in different concentration 
ranges. b) haemolysis percentages of CA-PPZ complex (CA-PPZ:pDNA, N/P 8:1), 
CA-/6MHA-PPZ:pDNA complex (N/C/P 8:4:1) with different doses incubated with 
murine red blood cells for 2 h for 37 oC. The initial amount of RBC is 1 × 1010 per mL 
and the 100% haemolysis is defined by the absorption value via treatment of 1% Triton 
X100. c) Haemolysis assay in the initial number RBC at 2.5 × 109 per mL.  
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3.3.2 Intracellular distribution of binary-polyions complexes 
 
For deeper understanding of the interaction of CA-PPZ and CA-/6MHA-PPZ 
complexes with tumour cells, internalisation and intracellular trafficking assays of the 
complexes were evaluated by flow cytometry and confocal microscopy, respectively. 
CA-PPZ and CA-/6MHA-PPZ were complexed with Cy5-labelled pDNA and incubated 
with U87MG cells under the same treatment conditions described previously for the 
transfections in 2D monolayers. Confocal micrographs (Figure 3-7a) and flow 
cytometry (Figure 3-7c, d) indicated similar levels of cellular uptake for both 
prototypes. However, there were significant differences in the intracellular distribution 
of Cy5-labeled pDNA for both prototypes in relation to a late endosome / lysosome 
marker (Lysotracker, Invitrogen). At 24h post-treatment, the Cy5-labelled pDNA 
carried by CA-/6MHA-PPZ complexes was more broadly distributed in the cytosol, and 
distal to the green-stained lysosomes. CA-PPZ:pDNA complexes remained inside 
lysosomes, resulting in yellow signals in the confocal merged image (Figure 3-7a, 
bottom). The analysis of fluorescence intensities in the confocal images at 24h 
post-treatment indicated that the co-localization ratios (Manders’ overlap coefficient, 
Figure 3-7c) of Cy5-pDNA to lysosomal markers were different for both prototypes and 
confirmed that the addition of 6MHA-PPZ facilitates escape of the complexes from the 
endosomal compartments. One of the suggested reasons is that 6MHA-PPZ has high 
buffering capacity particularly in the early endosomal pH range (pH 7.4 – 6.0). 
Furthermore, we hypothesized that these results might be related to a capacity of 
6MHA-PPZ to destabilize biological membranes at endosomal pH. At pH 5.5 
CA-/6MHA-PPZ:pDNA complexes showed a clear haemolytic effect similar to those 
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observed for PLL complexes, while CA-/6MHA-PPZ:pDNA complexes showed minor 
haemolysis at physiological pH (Figure 3-6). 
 
After escape from endosomal components, another limitation for 
polycation-mediated delivery is the difficulty to release nucleic acids from 
complexation with the polycation, in order to pDNA to be further delivered to 
nuclei66,67. Herein we tracked the distribution of pDNA and polycations simultaneously 
in the cells, via labelling of polycation CA-PPZ and pDNA with Cy3 and Cy5, 
respectively. In general, the time-course images revealed the high co-localisation 
between pDNA and CA-PPZ in both formulations (Figure 3-8). However, 
CA-/6MHA-PPZ complexes were better able to release pDNA from CA-PPZ 
complexation, especially at 48h post-treatment while compared to CA-PPZ:pDNA. At 
24 h post-treatment, there were some red-orange signals (tiny CA-PPZ co-localized 
with pDNA) in the cells treated with CA-/6MHA-PPZ, probably showing some 
polycations retained with pDNA. Following that, the images of cells treated with 
CA-/6MHA-PPZ complexes clearly showed more released pDNA at 48 h. At 72 h 
post-treatment, the signals of Cy3 and Cy5 were weakened due to proliferation of the 
cells resulting in dilution of total fluorescent intensity. In contrast, the high amount of 
yellow signals in CA-PPZ:pDNA treated cells showed highly correlated co-localisation 
between pDNA and CA-PPZ. This intracellular release evaluation was followed by 
endo/lysosomal localisation studies, in which CA-/6MHA-PPZ complexes were shown 
to be distal to endolysosomal compartments (Figure 3-7b). From both 
confocal-imaging evaluations, it can be concluded that most of the pDNA was still 
condensed in the PPZ complexes, even after endosomal escape and diffusion in the 
cytosol, but the mixing of 6MHA-PPZ with CA-PPZ complexes acted as a 
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pH-controlled trigger for proton-buffering endosomal escape and as a facilitator for 
dissociation of CA-PPZ and pDNA. 
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Figure 3-7. Comparison of the intracellular trafficking of two selected PPZ prototypes. 
(a) Intracellular distribution after 24h of Cy5-labeled pDNA (red) and a late-endosome/ 
lysosome compartment marker (Lysotracker, in green) upon delivery of CA-PPZ:pDNA 
or CA-/6MHA-PPZ:pDNA complexes. (b) Internalisation of both complexes carrying 
Cy5-labeled pDNA after 4h incubation with U87MG cells measured by Fluorescence 
Activated Cell Sorting. (c) Co-localization of pDNA with the late-endosome/ lysosome 
compartment calculated by image analysis (ImageJ, Coloc2 plugin). 
 
 




Figure 3-8. Confocal images of Cy3-CA-PPZ (green) complexes with Cy5-pDNA (red) 
for intracellular dynamic distribution after 24, 48, and 72 h treatments in U87MG cell 
monolayer.  
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3.3.3 Transfection of binary polyionic complex on 3D spheroid model 
Following demonstration of transgene expression in 2D monolayers, we 
established three-dimensional spheroids of U87MG cells as simple mimics of residual 
tumour regions around glioblastoma-margin areas after surgery or radiotherapy.68 The 
cells grew as spheroids (diameter ~250 µm) following a three-day incubation period 
and Light-Sheet Fluorescent Microscopy (LSFM) was used for tomographic scanning 
in this tumour model. PPZ:pDNA complexes were assayed on the spheroids to evaluate 
any inherent toxicity by measuring spheroid size and metabolism through analysis of 
phase-contrast images and resazurin reduction assays (Alamar Blue), respectively, 
following the previously published methods by our group57,61 (Figure 3-9). Spheroids 
treated only with pDNA reduced slightly in volume after 16 hours in OptiMEM media, 
most likely due to some nutrient depletion over this period. Incubation of the spheroids 
with the CA-PPZ:pDNA complexes at 4 μg/mL caused a significant decline in volume 
to 87.4±3.2% of the initial value (P < 0.004), whereas CA-/6MHA-PPZ:pDNA 
complexes did not cause a statistical shrinkage (P = 0.132) at the same dose. In 
resazurin reduction assays, the metabolic activities of CA-/6MHA-PPZ:pDNA treated 
spheroids were slightly higher than the untreated spheroids, whereas CA-PPZ:pDNA 
treated spheroids at both DNA doses (2 µg/mL and 4 µg/mL) showed no significant 
difference in metabolic activity compared to non-treated spheroids. These experiments 
indicated no marked toxicity for the mixed cationic/anionic PPZ complexes. 
 
Further tolerability assays were performed monitoring cell membrane damage 
with 7-Aminoactinomycin D (7AAD) on the previously used spheroid model. These 
experiments were performed in parallel with transgene expression levels of Green 
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Fluorescent Protein (GFP) upon pDNA delivery with different polymer complexes 
(Figure 3-11). CA-/6MHA-PPZ successfully delivered the GFP encoding pDNA as 
demonstrated by the percentage of GFP-positive pixels at the regions of interest (ROIs) 
of spheroid images (56.2 ± 7.9% and 88.9 ± 4.1% for pDNA doses of 2 and 4 μg/mL, 
respectively). Figure 3-10 shows examples of ROI selection and histogram analysis. 
These GFP levels were significantly higher than those obtained with CA-PPZ:pDNA 
and PEI:pDNA. Regarding 7AAD staining, there were no statistic differences between 
polymeric complexes at the same dose, resulting from the strong positive values of the 
spheroids incubated with Triton X-100. In summary, the spheroid model experiments 
indicated that CA-/6MHA-PPZ:pDNA complexes achieved better transfection / 
toxicity ratios than CA-PPZ:pDNA and the laboratory standard PEI:pDNA system. 
 
  





Figure 3-9. Polyphosphazene complex cytotoxicity as measured by spheroid volume 
and metabolic activity in U87MG spheroids. Initial spheroid diameter was ~ 250 µm at 
time 0 (t0) and was measured over time after treatment with polymer complexes with 
pDNA 2 µg/mL in a) and 4 µg/mL in b). Metabolic activity of U87MG spheroids 
treated with different polymer complexes in (c, d). Data is normalized to spheroids 
cultured in media-only group. 
 
 




Figure 3-10. Diagrams showing the region-of-interest (ROI) selection in spheroid 
areas (a) and corresponding analysis via GFP (b) and 7AAD (c) fluorescent intensity 
histograms of spheroids treated with polymeric complexes with pDNA 4 µg/mL. 
 




Figure 3-11. Transfection efficacy and viability of U87MG spheroids treated with 
polymeric complexes at two pDNA doses. (a) Overlay microscopy images showing 
GFP-expression and 7AAD-staining of U87MG-spheroids after treatments by 
CA-PPZ:pDNA (N/P 8:1) and CA-PPZ/6MHA-PPZ:pDNA (N/C/P 8:4:1) at the pDNA 
doses of 2 and 4 μg/mL. (b, c) Quantification of GFP-fluorescence and 7AAD signals 
from the ROIs of spheroids in four independent experiments; spheroids treated with 2 
μg/mL pDNA are analyzed in (b), those treated with 4 μg/mL in (c) (**** represents P < 
0.001 and *** is P < 0.005, analyzed by a one-way ANOVA with a Dunnett’s multiple 
comparison test with a single pooled variance). 
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3.3.4 Tomographic scanning in transfected spheroid in 3D  
 
To gain further insight on the delivery system penetration and gene transfer 
throughout the spheroids, fluorescence tomographic scanning was performed by 
light-sheet fluorescent microscopy (LSFM) (Figure 3-12), and tomographic-scanning 
videos of those transfected spheroids will show in supplemental files [or in the thesis 
presentation]. When the spheroids were treated with complexes at the higher pDNA 
dose (4 μg/mL), homogeneous GFP transfection was apparent even in the core of the 
spheroids treated with CA-PPZ:pDNA and CA-/6MHA-PPZ:pDNA, although GFP 
fluorescence was most intense in the latter system. At the lower pDNA dose (2 µg/mL) 
CA-/6MHA-PPZ:pDNA complexes still provided consistent transfection in most of the 
spheroids, whereas transfection for CA-PPZ:pDNA and PEI:pDNA was clearly weaker 
with low GFP expression (Figure 3-12a). This effect suggests a more efficient gene 
delivery for CA-/6MHA-PPZ:pDNA than CA-PPZ:pDNA and PEI:pDNA systems in 
this 3D model. 
 
These data also indicated that this mixed polycations-DNA-polyanion system had 
a surprising capacity to move through a 3D tumour structure of 250µm-diameter 
spheroids. Maximum intensity projections (Figure 3-12b) indicated strong 
fluorescence throughout the spheroids transfected with the CA-/6MHA-PPZ:pDNA 
complexes and supported our previous observations. The results showed that mixing of 
6MHA-PPZ in CA-PPZ complexes enhanced penetration into this size of spheroids 
and facilitated gene-transfection expression, even in the core of spheroids. Regarding 
to penetration in spheroids, many key factors are involved, including particle size and 
surface charges, type of cell models, treatment concentration, etc. In LSFM images, the 
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higher dose (4 μg/mL) of polymeric complexes demonstrated deeper penetration 
efficacy and higher gene-transferring efficiency than the low dose of treatments (2 
μg/mL). As shown in Figure 3-12, the PEI-complexes and CA-PPZ complexes at 
pDNA dose 2 μg/mL generated only faint green signals through the whole spheroids. 
For this polycation-only pDNA complexes (N/P 8), the minimum pDNA dose for 
transfection in this model has to be 4 μg/mL. In contrast, significant GFP expression 
was found in treatment by the low dose of CA-/6MHA-PPZ complexes. As the dose 
increasing to 4 μg/mL of CA-/6MHA-PPZ complex, significant GFP expression was 
shown throughout the spheroids. The results showed strong dose-dependent 
penetration in spheroid models. 
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Figure 3-12. 3D tomographic images of GFP-transfected spheroids taken by LSFM. a) 
3D section images of CA-PPZ:pDNA complexes (CA-plex) and 
CA-/6MHA-PPZ:pDNA complexes (Mix-plex) treated spheroids (diameter ~250 μm) at 
two pDNA doses of 2 μg/mL and 4 μg/mL. b) Maximum intensity projections along 
Z-axis (XY projection) images of spheroids treated with different polymer:pDNA 
complexes at two doses. The images were taken by LSFM. Blue corresponds to DAPI 
staining; green to GFP fluorescence. The all fluorescence images were analysed by 
ImageJ and processed under the same scale of fluorescence intensity. 
 
In addition, gene transfection was also dependent on size of spheroids. For 
instance, although the small size of spheroids (~250 μm diameter) was chosen for 
suitable screening by LSFM, we also evaluated gene expression in larger (≥ 400 µm 
diameter) spheroids (Figure 3-13) where we found limitation in transport to the 
spheroid cores as compared to those tested previously. This could be explained in two 
ways. First, the nanocarriers were unable to transport to the tumour core due to 
extended distance. Secondly, the tumour cells in the inner core of these large tumour 
spheroids may have been necrotic due to low oxygen tension and lack of nutrients, 
thereby unable to transfect GFP gene and expression, even if CA-/6MHA-PPZ 
complexes clearly diffused to the centre of the spheroids. 
  





Figure 3-13. Transfection by CA-/6MHA-PPZ complexes carrying GFP-encoding 
plasmid in large spheroids (Diameter ≧400μm). 
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3.3.5 GFP/Luciferase transfection in xenograft model 
We next evaluated gene-transfer efficiency of the binary ionic PPZ:nucleic acid 
complexes in centimetre-scale xenograft tumours in vivo. Nude mice were 
subcutaneously implanted with U87MG cells on the flanks, and when the tumours 
attained a size of 100 – 150 mm3, polymeric complexes with the bi-functional plasmid 
(encoding GFP and Luciferase) were injected intra-tumorally (16 µg pDNA for each 
tumour). At the end of the experiment, tumours were excised, sectioned and observed 
by IVIS (Figure 3-14 a, b) and hematoxylin and eosin (H&E) stains (Figure 3-15). 
The data indicated that the tumours were transfected by all the polymeric complexes 
compared with non-treated tumours. ROI quantification of luciferase expression 
(Figure 3-14b) showed that the CA-/6MHA-PPZ:pDNA complexes were similar in 
transfection efficacy to the PEI-DNA complexes and achieved around 1.5-fold higher 
transgene expression than CA-PPZ:pDNA. In GFP-expression images, the 
semi-quantification of polymeric complexes indicated similar results with those of 
luciferase expression. However, either GFP fluorophores (λem = 507 nm) or 
luciferase-reported luminescence (λem = 560 nm) may not the best options for 
evaluation of in vivo gene transfection due to low penetration of light with 
yellow-green wavelength in living tissues69. This may be caused by the large error bars 
in statistical analysis due to technical difficulties, including the depth of tumour to 
inject the complexes, tumour shapes, tumour microenvironments, natural green 
autofluorescence. Here we recommend to choose plasmid encoded mCherry or mPlum 
proteins70 for in vivo gene transfection studies, because their emission wavelengths are 
located in the range of red or near far red, which have better penetration through the 
tissues. The transfected tumours were then sliced and stained by H&E for evaluation of 
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transfection-induced toxicity (Figure 3-15). The H&E stained images showed there 
was no significant toxicity after those in vivo transfection. Compared with transfection 
in 2D monolayer, lower side-effects in gene expression were found in PPZ-complex 
treated 3D spheroids and xenograft tumours of glioblastoma U87MG. Regarding this, 
3D cultures and xenograft tumours can provide a relevant micro-environment limiting 
accessibility of the polymeric carriers, such as ECM impeding drug/carrier 
diffusion61,71,72, and also better able to preserve the properties of tumour stem cells73. In 
the literatures, 3D spheroid models have been employed for investigation of 
chemo-sensitivity in several cancers72,74,75, in which GBM spheroids and their primary 
cell-lines are better able to resist chemotherapeutic alkylating agents (e.g. TMZ) than 
2D traditional cell models47. The data indicated that a lead formulation, 
CA-/6MHA-PPZ carrier improved effectiveness of gene delivery in two bio-relevant 








Figure 3-14. Transfection of polymeric complexes on xenograft tumours of U87MG 
cell-line. a) IVIS images of luciferase/GFP transfected U87MG tumours in nude mice. 
Quantitative analysis in the tumour regions for the luminescence of luciferase 
expression in b) and fluorescence of GFP expression in c). (* P < 0.5, analysed by a 
one-way ANOVA with a Dunnett’s multiple comparison test with a single pooled 
variance) N≧3 expect for GFP expression of CA-/6MHA-PPZ complex. 
 





Figure 3-15. Hematoxylin and eosin (H&E) stains in histology. The H&E stained 
sections of PEI:pDNA complex treated, CA-PPZ complex treated, and 
CA-/6MHA-PPZ complex treated U87MG-xenograft tumours after IVIS imaging. 
 
  





In this chapter, we designed several proof-of-concept experiments for 
6MHA-addition in order to facilitate endosomal escape of polymer-gene complexes as 
well as controlled release of nucleic acids from their complexes. In the confocal 
images, the CA-/6MHA-PPZ complex was demonstrated to be better able to separate 
from the lysosome marker and release in the cytosol regions. Through labelling of Cy3 
in polycations and Cy5 in pDNA, the intracellular distribution analysis provided clear 
evidence for pDNA release, which is one of the major obstacles especially for 
polycation-mediated delivery. However, 6MHA-PPZ mixing with CA-PPZ complexes 
significantly boosted the release of pDNA after 48h treatment. Following the 
optimisation in 2D monolayer, 6MHA-PPZ mixing in CA-PPZ complexes also showed 
higher transfection efficiency in a bio-relevant 3D spheroid model compared to 
CA-PPZ-only complexes. Tomographic scanning images confirmed the transfection 
profile inside the 3D spheroids, indicating penetration and transfection efficiencies are 
dependent on the treatment doses and 6MHA-PPZ addition. Finally, preliminary 
evaluations of in vivo transfection confirmed CA-/6MHA-PPZ complexes can transfer 
gene cargoes and express transgene via local administration in a U87MG xenograft 
model. In the next chapter, we chose this optimal formulation for RNAi therapeutic 
application. 
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RNAi therapy has gained increasing attention in several genetic disorder diseases. 
In terms of glioblastoma cancers, glioblastoma initial cells (GICs) can be induced from 
originally normal brain cells (neural stem cells or astrocytes) via genetic alterations. 
Abundant genetic amplifications and mutations have been linked to GBM recurrence 
after the standard treatment comprising surgery and chemo-/radiotherapies. 
Highly-resistant GICs survive chemo-/radiotherapy and reproduce themselves to form 
relapsed tumours, causing the poor prognosis of this disease, a 5-year survival rate in 
clinical treatments. DYRK1A is dual-specificity tyrosine phosphorylation–regulated 
kinase, contributing to EGFR stability in GIC, imparting them with renewal capability. 
Albeit of their promising cellular activity, EGFR and DYRK1A inhibitors presented 
small benefits in clinical trials. siRNA therapy could achieve a more potent and 
selective down-regulation of this pathway, increasing the therapeutic potential of this 
approach. Herein, we adapted our high-effective polymeric gene nanocarriers, 
previously used with pDNA, for the delivery siRNA against DYRK1A. A first 
evaluation was performed in U87MG neurospheres and consisted on testing the 
capacity of siRNA-loaded nanocarriers to down-regulate DYRK1A and tumour 
self-renewal capacity. Then, the siRNA-complexes were injected intratumorally to 
xenograft mice bearing U87MG cells and co-administration with a low dose of 
temozolomide (5 mg/kg). The mice group treated with an active siRNA and 
temozolomide reduced the tumour size 50% as compared to the group treated with 
temozolomide and scrambled siRNA nanocomplexes. This effect was observed for 
most of the duration and it was significant against the control between the day 7 to the 
day 17 after treatment. Herein we conclude that siRNA delivered by optimized 
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polymeric complexes successfully knocked down endogenous DYRK1A expression 
and delayed xenograft tumour growth rates, indicating an efficient delivery of siRNA 









4.1.1 Glioblastoma and clinical treatments 
The therapeutic goal for the study was to deliver nucleic acids as potential means 
to treat Glioblastoma Multiforme (GBM), a highly aggressive and malignant cancer 
classified as grade IV by the World Health Organization (WHO) in view of its short 
median survival time (14 months) after diagnosis1. Fortunately, some therapies have 
improved overall survival time for GBM patients, specifically radiotherapy. Integrated 
multiple techniques are able to focus precisely the radiation beams on the irregular 
contours of brain tumours, minimizing the side effects on normal brain tissues2. For 
resection of intracranial tumours, the upgraded image-guide and microsurgery 
techniques facilitate neurosurgeons precisely judging tumour boundaries, being 
fluorescence-guided surgery (FGS) with 5-aminolevulinic acid as an example3. 
However, many GBMs are widely infiltrative through neighbour tissues and sometimes 
to distant locations, making impossible to completely remove surgically all GBM cells4. 
As a result, combination therapies are typically applied after surgery for extending 
median survival time. The current first line treatment will typically comprise 
temozolomide (TMZ), an anti-tumour drug that crosses the blood brain barrier and 
presents therapeutic benefits, especially combination treatment with radiotherapy.5,6 
Previously, other chemotherapeutical options have been tested; for instance, 
carmustine-loaded wafers for controlled release of this compound after implantation at 
the resection site was a promising strategy. Although this implantation did not fulfil the 
expected clinical outcomes in terms of median survival time improvements, this 
practical example proposed a sustained release platform for local administration in the 





Despite the therapeutic options and new technologies in clinical trials, GBM is 
still characterized by a high recurrence rate that reflects the resistance of leftover 
tumour clumps containing subpopulations of glioblastoma initiating cells (GICs)7. 
Literatures reported those subpopulations of GICs are more capable to recover and 
proliferate after treatment of chemotherapeutic drugs, as compared with another type 
of lung cancer stem cells8. According to The Cancer Genome Atlas (TCGA), EGFR 
genetic amplification/overexpression and TP53 mutation are the most common genetic 
alterations in GBM1. These genetic mutations enable GICs for resisting chemotherapy 
and endow them with amplified growth rates and modified signalling pathways, 
ultimately leading to tumour survival and relapse. Accordingly, there is dire demand 
for new treatment strategies for GBM, and the delivery of suicide genes or gene 
knockdown by siRNA are two very promising therapeutic options. 
 
4.1.2 Suppression of EGFR in GBM therapy via inhibition of DYRK1A 
 As mentioned previously, TCGA initiated a project for large-scale analysis of 
human cancers in different dimensions, including the grade-IV glioblastoma. The key 
genetic alterations identified for GBM have been: (1) amplification of receptor tyrosine 
kinase genes, for an well-known example overexpression of epidermal growth factor 
receptor (EGFR); (2) activation of pathway of phosphatidylinositol-3-OH kinase; (3) 
dysfunction of tumour suppressor pathway, such as p53 mutation.9 In the aberrations of 
amplified expression in GBM, EGFR families accounted for the most highest frequency 
in the surveyed samples of GBM patients (91/206 cases)9, indicating EGFR signalling 
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pathways play a pivotal role in GBM pathogenesis, relating to wide ranges from the 
early development of tumour and proliferation, to aggressive infiltration, to therapeutic 
resistance10. However, EGFR kinase inhibitors (e.g. bevacizumab, gefitinib and 
erlotinib) did not fulfil the clinical expectations11-14.  
 
Previous studies have shown that inhibition of dual-specificity tyrosine 
phosphorylation–regulated kinase (DYRK1A), which can prevent endocytosis-mediated 
degradation of EGFR by the phosphorylation-required modulator Sprouty-215, causing a 
loss of self-renewal capacity in several primary GBM tumour initial cells (Figure 
4-1).16 One of main functions of DYRK1A is to catalyse autophosphorylation on serine/ 
threonine residues of substrates via formation of a transitory intermediate product in an 
activation loop of the catalytic domains that containing tyrosine residue (Tyr321)17,18. 
Not only phosphorylating Sprouty-2, but also DYRK1A mediated stabilization of 
platelet-derived growth factor receptor (PDGFR), which is another common 
overexpression receptor and associating with tumour cell proliferation. In this chapter, 
we used the commercial available siRNA against DYRK1A to down-regulate GBM 
cells and further suspend renewal capability. 
 




Figure 4-1. The relation pathways between DYRK1A and EGFR stabilisation. 
[Reproduced from Abbassi, R. et al, Pharmacology & therapeutics19 with permission] 
 
4.1.3. RNA interference therapy 
RNA interference (RNAi) therapies are based on the introduction of foreign short 
RNA sequences to the cytosols where inhibit mRNA translation, down-regulating 
targeting gene expression. RNAi was identified by Andrew Fire and Craig C. Mello in 
1998.20 Physiologically, endogenously short double-stranded RNA molecules are 
cleaved and adapted by the enzyme Dicer, forming two single-stranded RNAs: the 
passenger and the guide-strand RNA. The guide-strand RNA will be incorporated into 
RNA-induced silencing complex (RISC), which is a catalytic enzyme that binds to 
mRNA sequences complementary to this guide stand, degrading them, and thus 
repressing translation 20,21. There are several RNA molecules used in RNAi applications, 
including microRNA (miRNA), short interfering RNA (siRNA), short hairpin RNA 
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(shRNA), and Dicer substrate RNA (dsiRNA). The shRNA delivery is frequently used, 
delivered from shRNA-encoding plasmids, transcribed to shRNA in nucleus, and 
cleaved by Dicer where it incorporates in the described RNAi pathway22. dsiRNAs are 
small RNA duplexes with sequences optimized for Dicer incorporation that show 
increased potency. siRNA and miRNA are already processed and can integrate directly 
in RISC for gene silencing (Figure 4-2). In comparison to miRNA, siRNA is usually 
100% complementary to the targeted sequence, inducing mRNA degradation. The RISC 
complex is then free to interact with new mRNA molecules. On the other hand, miRNA 
typically shows small loops and non-complementary regions and ultimately leads to 
inhibition of mRNA. The inhibitory effect of miRNA, therefore, is less potent, but the 
possibility of acting with non-perfect complementarity means that each sequence can 
act on gene clusters23. 
 
 From pharmaceutical perspectives, the key task of RNAi to deliver safely siRNA 
to the cytosol of the targeted cells. Although some nanocarrier-siRNA formulations 
showed promise in clinical trials, such as ALN-TTR02 (Alnylam company), many 
studies still showed a clear demand for efficient delivery systems for siRNA, especially 
for non-targeting organs different from the liver. The critical challenges to address for 
improved RNA delivery are: (i) their very low bioavailability non-parenteral 
administration, (ii) their poor stability in physiological media, (iii) their difficulty to 
arrive at the targeted cells and (iv) their inefficient intracellular delivery24. Herein, we 
designed the mixed polyphosphazene derivative polymeric complexes to deliver siRNA 
against DYRK1A to GBM cells and reported here their therapeutic efficacy both in vitro 
and in vivo. 
 





Figure 4-2. RNAi pathways. The red arrows indicated import of RNA molecules. 
[Reproduced from Bobbin, M. L. et al. Annual review of pharmacology and toxicology 
21 with permission] 
 
  




4.2.1 Down-regulation efficiency and clonogenic assays 
 Complexes of polymers with siRNA for DYRK1A (ON-TARGETplus Human 
DYRK1A, Dharmacon) were prepared using the same ratios previously studied for 
polymeric complexes loaded with pDNA and added to U87MG (75K cells per well) in 
12-well plates. The polymeric complex suspension was incubated with the cells for 4 
hours, and then replaced by standard cell medium and maintained in culture for 24 
hours. The DYRK1A silencing efficiency following siRNA delivery was then 
measured by qRT-PCR. Cells treated with siRNA against DYRK1A (siDYR) or a 
scramble sequence (siCtrl) were collected for mRNA extraction by a High-pure RNA 
isolation kit (from Roche) and mRNAs were trapped by on a glass fibre fleece in filter 
tubes. After elution of mRNA, the reverse transcription of 200 ng mRNA was 
performed by PrimeScriptTM RT kit (from TaKaRa). The transcribed cDNA was mixed 
with Sybr-green and either primers of DYRK1A (Forward 5’-3’: 
GCAATTTCCTGCTCCTCTTG; Reverse 5’-3’: TTACCCAAGGCTTGTTGTCC) or 
primers of HPRT (Forward 5’-3’: TGACACTGGCAAAACAATGCA; Reverse 5’-3’: 
GGTCCTTTTCACCAGCAAGCT), used as a reference (housekeeping gene). Gene 
expression was quantified by RT-PCR (Lightcycler-480 II, Roche).  
 
For self-renewal assays, the silenced cells were de-attached and left in a 
serum-free media, Neurobasal (Fisher-Scientific) supplemented with B27 (1:50), EGF 
(40 ng/ml) and FGF (20 ng/ml) (Peprotech) for three days to form spheroids. Then, the 
spheroids were dissociated by Accumax (Millipore) and the serum-starved cells were 
seeded on 96-well plates (250 cells/ well) for 7-10 days in the same serum-free media. 
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The numbers of secondary spheroids formed were counted, considering a spheroid any 
group with more than 4 cells clumped together.  
 
4.2.2 Intracranial-implanted model of siDYRK1A-treated GBM cells 
All in vivo therapeutic studies had been approved by the Research Ethics and 
Animal Welfare Committee at the Instituto de Salud Carlos III, Madrid, (PROEX 
224/14) in agreement with the European Union and national directives. An 
intracranial-implanted model of GBM was established as previously described.16 To 
investigate in vivo renewal ability of glioblastoma cells in orthotopic xenograft models, 
we implanted intracranially the silenced U87MG cells in cerebrum of athymic Foxn1 
nude mice (Harlan Iberica)16. Firstly, U87MG cells were treated with the 
nanocomplexes at a dose of 1 µg siRNA per 100K cells for 4 h. The cells were then left 
in growth media for 24 hours. The treated cells in 2 µL cultured media (75K 
cells/mouse) were collected and injected intracranially in the nude mice using 
Hamilton syringe via a stereotactically guided injection system. The location of the 
implantation was coordinated at A-P, –0.5 mm; M-L, +2 mm; D-V, –3 mm; related to 
Bregma), and the animals were sacrificed at the onset of symptoms. 
 
4.2.3 Combination of siDYR and TMZ in xenograft model in vivo 
To investigate the therapeutic effectiveness of DYRK1A-silenced gene delivery in 
vivo, a subcutaneous xenograft model was established as the method in chapter 3.2.4. 
When tumour sizes reached around 100-150 mm3, the polymeric complexes were 
injected intratumorally with 4 µg siDYR or the same amount of the scrambled 
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sequence (siCtrl) for each tumour/day and treated over four consecutive days (total 16 
µg siRNA for each tumour). On those same days, the mice were also administered 5 
mg/kg temozolomide (TMZ) by intraperitoneal injection (total dose 20 mg/kg each 
mice). The tumour sizes were measured by a calliper and calculated by Volume= 
W×W×L/2, in which W represents width and L is length (here, W < L). 
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4.3 Results and discussion 
 
4.3.1 Characterisation of polymer siRNA complexes 
As a therapeutic transgene, we chose a small-interfering RNA to silence 
DYRK1A (siDYR), a gene implicated in the stability of EGFR presentation and in 
tumour renewal16,19. The polymers/siRNA complex formulations were made using the 
same composition ratio (N/C/P 8:4:1) used for the polymer/pDNA complexes in 
previous two chapters. Particle characterization showed that substitution of pDNA by 
siRNA did not induce a large modification in nanocarrier size and surface charges 
(Figure 4-3a). However, there are still some slight differences between 
siRNA-complexes and pDNA-complexes in polydispersity index (PDI) and total 
derived counts (KCPs) from DLS measurement. CA-PPZ is capable to condense 
siRNA to form nanocomplexes yet they had lower KCPs than CA-PPZ:pDNA 
analogue. The KCPs value is related to the intensity of light scattered, which is related 
to several conditions, including particle concentration, particle density, etc. From 
nanoparticle tracking analysis (NTA) measurement, we observed that the concentration 
of CA-PPZ:siRNA (7.17×1010 ± 6.66×109 /mL) is one order of magnitude lower than 
CA-PPZ:pDNA (6.99×1011 ± 6.66×1010 /mL). The tendency was reproduced in other 
formulation where particle concentration for CA-/6MHA-PPZ:siRNA and 
CA-/6MHA-PPZ:pDNA were 9.78×1010 ± 6.62×109 /mL and 4.81×1011 ± 5.24×109 
/mL, respectively. The reason is likely that the short and low molecular weight of 
siRNA makes this molecule less efficient for condensation than pDNA25,26. This 
difficulty also caused a slightly higher polydispersity index in the particular 
distribution in CA-PPZ complex groups, but not found in CA-/6MHA-PPZ complexes  





Figure 4-3. Comparisons of particle characterization data for CA-PPZ complexes and 
CA-/6MHA-PPZ complexes carrying either pDNA or siRNA. Particle size and surface 
charges are shown in a); total derived counts (KCPs) and polydispersity index (PDI) in 
b). 
 
4.3.2 Down-regulation efficiency and clonogenic assays 
The DYRK1A silencing efficiency was measured by qRT-PCR of DYRK1A 
mRNA in U87MG cells in 2D cultures (Figure 4-4a). CA-/6MHA-PPZ:siDYR 
complexes were able to silence DYRK1A expression by 70%, while the same 
prototype carrying a scrambled siRNA sequence (siCtrl) did not change DYRK1A 
expression compared to non-treated cells. In addition, CA-/6MHA-PPZ:siDYR 
efficacy was higher than the positive control PEI:siDYR complexes. On the other hand, 
CA-PPZ:siDYR complexes did not show a therapeutic effect. As a therapeutic effect of 
this DYRK1A reduction, tumorigenic capability was examined by a self-renewal test, 
which was calculated by formation of secondary neurospheres of the treated tumour 
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cells (clonogenic assays). The renewal capabilities of U87MG were diminished by the 
treatment with CA-/6MHA-PPZ:siDYR complexes, as evaluating the formation of 
secondary spheroids in Figure 4-4b. This effect on the ability to form secondary 
spheroids was also clear in microscopy images (Figure 4-4 c, d, e). Logically, none of 




Figure 4-4. In vitro silencing efficacy of polymer:siDYR complexes. a) DYRK1A 
silencing effect of different polymer:siRNA complexes in 2D monolayer of U87MG 
cells measured by qRT-PCR. b) Clonogenic ability (formation of secondary spheroids) 
of U87MG cells after treatment with different polymer:siRNA complexes. Micrographs 
in (c, d, e) show images of secondary spheroids after treatment with 
CA-PPZ/6MHA-PPZ complexing either a therapeutic (siDYR) or a scrambled siRNA 
(siCtrl) or media only group (non-treatment). 




4.3.3 Intracranial-implanted model of siDYRK1A-treated GBM cells 
After the evaluation of the self-renewal capacities, we further implanted those 
siRNA-treated cells into the striatum of nude mice for the evaluation of 
silencing-efficiency in an orthotopically xenograft model. However, the data showed 
there is no statistical difference in the Kaplan-Meier curves between survival ratios of 
mice explanted CA-/6MHA-PPZ:siDYR-treated and CA-/6MHA-PPZ:siCtrl-treated 
cells in cerebrum (Figure 4-5). As shown in the figure, siDYR-treatment did not delay 
tumour formation and growth in this aggressive U87MG orthotopic model. However, 
this result might attribute to an inadequate study design. Indeed, the orthotopically 
explanted mice in both treatments survived for longer than 20 days after explanation. 
In the literature, the maximum effective silencing periods for siRNA inside tumour 
cells is only approximately 72 hours 27,28. In light of this, the silencing effects of the 
gene therapy might have been lost during initial lag phase of tumour growth, making 
unfeasible that the gene medicines can benefit survival rates in this therapeutic setting. 
In comparison, Pilar Sánchez group has shown that GBM cells with constitutive gene 
silencing of DYRK1A was significantly delayed in tumour growth in the same 
orthotopic xenotransplantation model16, but this constitutive gene silencing was 
achieved by shRNA-loaded lentiviral vectors. The advantage of shRNA delivered via 
viral vectors over siRNA/polymer vehicles is the gene-silencing effective time, but the 
viral vectors may be not an appropriate feature for the clinical applications. Taken 
together, albeit we obtained negative results, this study provided two important 
suggestions for the following studies. Firstly, it illustrated that it is necessary to 
provide multiple siRNA treatments in cancer therapy. Another is that siRNA only can 
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down-regulate expression of tumour cells, causing them to be more sensitive to 
chemo-/radiotherapy.29,30 This could be used to combine siRNA treatments with other 
anticancer agents (e.g. Temozolomide, TMZ) during gene silencing time window. 
 
 
Figure 4-5. The Kaplan-Meier curve of orthotopic xenograft mice models. Polymeric 
siRNA complex-treated U87MG cells were intracranially injected into the cerebrum of 




4.3.4 Combination of siDYRK1A and TMZ in xenograft models 
After the functional experiments in vitro and in vivo, a heterotopical xenograft 
model was prepared for multiple injections of siRNA formulation combined with the 
first-line chemotherapeutic agent for GBM (e.g. TMZ). The same U87MG-xenograft 
tumour model implanted on both flanks used in previous chapter (Chapter 3.3.5) was 
treated here with an intratumoral injection of CA-/6MHA-PPZ:siRNA (4µg) together 
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with an intraperitoneal injection of TMZ (5 mg/kg) once per day for 4 consecutive 
days (Figure 4-6a, red arrows). Two siRNA treatment groups were tested, including 
the therapeutic sequence (siDYR) and the scrambled sequence (siCtrl), both in 
combination with TMZ. Tumour growth started to be significantly delayed by 
CA-/6MHA-PPZ:siDYR complexes from day 10 to day 17 as compared to the 
CA-/6MHA-PPZ:siCtrl group (Figure 4-6 a, b). This reduction in tumour growth rate 
can be better appreciated by comparing the size of the treated tumours and those of the 
controls on the same day (Figure 4-6 b); tumours treated with 
CA-/6MHA-PPZ:siDYR were around 50% smaller than those of the control. This data 
underscores the therapeutic superiority when combining the first line treatment TMZ 
with CA-/6MHA-PPZ:siDYR complexes in relation to TMZ with the placebo (siCtrl).  
 
 
Figure 4-6 a) Relative tumour volume in a U87MG xenograft tumour model treated 
with CA-PPZ/6MHA-PPZ complexing either a therapeutic (siDYR) or a scrambled 
(siCtrl) siRNA (4 µg per tumour) and co-therapy with an intraperitoneal injection of 
TMZ 5 mg/kg. This treatment was repeated for 4 consecutive days (red arrows). b) 
Delayed tumour growth rate (size of siDYR treated tumours divided by the size of siCtrl 
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treated tumours) at different time points in the same in vivo experiment (n=4). *** 










In this chapter, we introduced siRNA in the optimal binary polyionic 
(CA-PPZ/6MHA-PPZ) complex for silencing DYRK1A expression, which targets the 
EGF pathway and GBM reinitiation. We prepared complexes using the same 
composition ratios (N/C/P 8:4:1) used previously with pDNA and confirmed that this 
substitution causes only marginal differences in physicochemical properties. 
CA-/6MHA-PPZ:siDYR was able to efficiently silence the expression of DYRK1A in 
cell culture, and though this effect inhibit tumour reproducible capacity and formation, 
indicating a promising therapeutic effect. In a in vivo xenograft model, the 
administration of multiple injections of CA-/6MHA-PPZ:siRNA resulted in a 50% 
reduction in tumour growth rate for one week as compared to the same treatment 
loaded with a scrambled siRNA sequence. Overall, it has been shown that 
CA-/6MHA-PPZ can successfully deliver siDYR to U87MG cells in vitro and in vivo, 
as well as generating a therapeutic effect. However, the largest therapeutic benefits 
were only achieved with multiple injections of siRNA and in combined with a 
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Polyphosphazenes have been considered promising materials for gene delivery 
since they combine biodegradability and great chemical flexibility. It was envisaged 
that such flexibility would be ideal for generating combinatorial chemistry screens to 
optimize polymer structure. Still, their application for gene delivery has remained 
relatively scarce because the main synthetic route for polymer modification, the 
nucleophilic substitution of the precursor poly(dichlorophosphazene), is problematic 
for most derivatives of interest. The reason is that functional groups with several 
nucleophilic centres (i.e. amines, hydroxides, carboxylic acids, etc.) used in gene 
therapy will crosslink the precursor polymer. Recently the side groups of allylamine 
and propargylamine have reported the introduction of click handles in PPZs for 
thiol-ene or thiol-yne addition1,2, inspiring more possibilities for this polymer. In this 
thesis, we demonstrated that introduction of a vinyl group through the formation of a 
secondary polymer precursor, allylamino-poly(phosphazene) (AAPPZ), enables its 
simple modification with functional groups of interest for gene delivery using a 
thiol-ene addition reaction. By this method, PPZs with primary amines can be 
synthesized without any protection/deprotection reaction, and a small library of other 
derivatives with tertiary amines or carboxylic acid pendent groups. The streamlined 
synthetic process has drawn interesting structure/performance relationships. For 
example, PPZs substituted with tertiary amines were found to be less toxic yet more 
inefficient for cell transfection than those substituted with primary amines. 
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One of the most important findings derived from this screening has been the 
identification of 6MHA-PPZ, to be used as gene delivery enhancer. This polymer 
performs five different functions in the gene nanocarriers: (i) improving interpolymer 
complexation in the cationic PPZ/pDNA system, (ii) promoting the release of 
polynucleotides in the presence of a competitor, (iii) reducing polycation-caused 
toxicity, (iv) benefits in intracellular gene delivery, and (v) improving intratumoral 
penetration of nanocomplex in 3D tissue models. The capacity of anionic PPZs to 
enhance interpolymer complexation has been confirmed by comparing CA-PPZ:pDNA 
(8: 1 N/P ratio) and CA-/6MHA-PPZ:pDNA (8:4:1 N/C/P ratio) by dynamic light 
scattering and TEM imaging. Dynamic light scattering showed almost one order of 
magnitude increase in derived count rate in systems when 6MHA-PPZ is added 
(Figure 2-13). TEM images showed that CA-/6MHA-PPZ:pDNA had more compact 
morphology than CA-PPZ:pDNA complexes (Figure 2-15). The nanoparticle tracking 
assay further confirmed 6MHA-PPZ added to CA-PPZ:pDNA results in denser 
complexes rather than in a higher number of them (Figure 2-14).  
 
Many standard polymers used for gene delivery are typically used in excess with 
the polynucleotide. For instance, only an N/P ratio of 3 is necessary to complex pDNA 
with PEI, but usually larger proportions are used for improving in vitro transfection 
efficiency, yet resulting in weakly bound or unbound PEI.3,4 However, there are 
concerns on the fate and side effect of these unbound polymers when these systems are 
administered in vivo. The dense network of the CA-/6MHA-PPZ:pDNA complexes 
suggest that all critical elements of the preparation might be delivered together to the 
target cells. A most remarkable observation of the function of 6MHA-PPZ in the 
nanocomplexes has been its capacity to increase their efficacy/toxicity ratio over one 
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order of magnitude, reaching efficacies similar to the gold standard PEI:pDNA in 2D 
monolayer of U87MG cells (Figure 2-19a) and above them in a clinically relevant 
glioblastoma primary cell line (GBM1, Figure 2-20). Indeed, we observed that the 
introduction of any of the polyanionic-PPZs developed in the complex reduced the 
cellular toxicity of the prototype. Therefore, this is likely a toxicity reduction driven by 
charge neutralization. On the other hand, most polyanionic PPZ failed to enhance 
nanocomplex gene delivery efficacy with the exception of 6MHA-PPZ (Figure 2-19a). 
This is likely caused by the specific capacity of 6MHA-PPZ structure in proton 
buffering. When analysing the mechanism behind this improved delivery, our studies 
have shown that presence of 6MHA-PPZ in the nanocomplex results in lower 
co-localisation with the endosomal compartments (Figure 3-7). This efficient 
endosomal escape is most probably linked to the capacity of 6MHA-PPZ to rupture 
lipid membranes in the acid environment of the endosomes as we have confirmed by 
haemolysis tests (Figure 3-6). Herein, the complexes integrating 6MHA-PPZ were the 
only ones that presented negligible haemolytic effect at neutral pH, but a haemolytic 
effect comparable to poly-L-lysine (PLL) at the acidic pH. This membrane rupturing 
effect could be mediated by hydrophobization of 6MHA-PPZ as this polymer loses 
charges by protonation. Indeed, of all the polyanionic PPZs synthesized, 6MHA-PPZ is 
the only one that shifts most its charge ratio between physiological and endosomal pH 
(Table 2-3, Figure 2-12); this could be the reason why this was the only derivative to 
show pH-sensitive enhancing endosomal escape and high transfection efficiency. It is 
interesting to note that 6MHA-PPZ seems also capable of improving cell transfection 
in combination with standard polycations with low endosomal escape properties such 
as PLL, although the combination with CA-PPZ seems to be particularly efficient 
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(Figure 2-20), which likely attributed to our reasonable optimization of cationic PPZ 
platform in chapter 2. 
 
Another effect that could contribute to improving cell transfection in 
CA-/6MHA-PPZ:pDNA complexes, and in combination with endosomal escape as 
discussed above, is a modulation of polynucleotide binding. Complexes should bind 
polynucleotides tightly enough that the drug is not release prematurely, but without 
compromising its release in the cytosol or cell nucleus. In this sense, we have observed 
that CA-PPZ/6MHA-PPZ:pDNA complexes present more efficient polynucleotide 
release upon incubation with the competitor heparin that the reference CA-PPZ 
complexes (Figure 2-16). Moreover, intracellular tracking images of polycation and 
pDNA also provided evidence that CA-/6MHA-PPZ complexes dissociate better in the 
cytosol (Figure 3-8). Both results might translate in a more efficient intracellular 
unpacking of the polynucleotides for the CA-/6MHA-PPZ vs. the CA-PPZ system. 
Similar mechanisms were the presence of a polyanion helping for polynucleotide 
unpacking has been previously reported by Sullivan groups5 and L. Han groups6. 
 
Traditional two-dimensional cell monolayer model has been widely used for 
optimization of formulations but also have been questioned for validity and ability to 
represent physiologically relevant situations. Three-dimensional cultures are better 
able to provide tissue-like architecture (e.g. extracellular matrix, cell interactions)7, 
fundamental tumour microenvironment traits such as nutrient and oxygen gradients8, 
and also gene expression profiles alike those of clinical tumours9. To date very few 
studies have investigated nucleic acid delivery in tumour spheroids despite of the fact 
that they are perfectly suited as preliminary studies before in vivo and that they can 
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provide critical information regarding nanocomplex tumour penetration, nowadays 
considered one of the most important barriers in cancer drug delivery10,11. As observed 
by tomographic fluorescence imaging, CA-/6MHA-PPZ:pDNA complexes provided 
higher transfection in GBM spheroids as compared to CA-PPZ:pDNA and the 
reference PEI:pDNA complexes; this was particularly remarkable at low pDNA doses 
(Figure 3-12). This improved efficacy was also accompanied by minimizing 
gene-transfer toxicity. These studies found that CA-/6MHA-PPZ:pDNA complexes 
were able to induce clear transgene expression in the core of ~250 µm spheroids, 
which contrasted with the poor transfection observed for the CA-PPZ:pDNA and 
PEI:pDNA complexes under the same dose (2 µg/mL) (Figure 3-11). Overall, this 
results showed an unexpectedly high transfection efficacy and tumour penetration 
capacity for the CA-/6MHA-PPZ:pDNA formulation. This observation could be 
related to the physicochemical properties of CA-/6MHA-PPZ:pDNA complexes, with 
their partially neutralized cationic charges at physiological pH, that might shield the 
system from indiscriminate binding to the extracellular matrix in tumour spheroids. 
Although the data was more complicated to interpret due to inhomogeneous 
transfection levels between injection and distal sites, these results were in agreement 
with those from the in vivo gene delivery experiment (Figure 3-14).  
 
Glioblastoma initiating cells are considered to be responsible of tumour 
recurrence 12, and therefore, their suppression is essential for any medicine intended to 
provide mid- or long-term survival benefits. In the past, we have shown that controlled 
release implants can deliver glioblastoma initiating cell suppressing molecules and 
provide a therapeutic benefit in advanced in vivo models13,14. In this work, following 
the pilot in vivo study of GFP-pDNA transgene expression, we applied the same 
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optimized formulation to deliver a siRNA sequence with known activity against 
glioblastoma initiating cells (siRNA against DYRK1A, siDYR)15. 
CA-/6MHA-PPZ:siDYR complexes presented physicochemical properties similar to 
those of CA-/6MHA:pDNA complexes, and were able to silence its target protein 
(DYRK1A) in a more consistent fashion than CA-PPZ:siDYR and PEI:siDYR (Figure 
4-4). We confirmed that this protein silencing observed for cells treated with 
CA-/6MHA-PPZ:siDYR resulted in a reduction in the clonogenic index in a secondary 
spheroid formation assay, indicating the abrogation of the “initiating cell” phenotype 
of the target cells. The CA-/6MHA-PPZ:siDYR formulation was evaluated in U87MG 
xenograft mice, in a therapeutic scheme including co-delivery of first-line treatment 
drug temozolamide. The experiment found a significant delay in tumour progression in 
the arm receiving TMZ and CA-/6MHA-PPZ:siDYR vs. the arm receiving TMZ and 
CA-/6MHA-PPZ complexed with a scrambled siRNA sequence (Figure 4-6). 
Therefore, our results are consistent with an additional therapeutic benefit in 
combining the CA-/6MHA-PPZ:siDYR gene therapy with the standard 
pharmacological GBM treatment. Further studies will be needed to elucidate the 
possible clinical impact of this co-therapy in more advanced models and performing 








A synthetic strategy for the simple preparation of a small library of 
polyphosphazenes of interest for gene delivery was developed based on the generation 
of a precursor polymer with click handles, and further derivation by thiol-ene additions. 
This strategy has allowed us to test a variety of compounds and draw structure/function 
relationships. Based on the screenings, a primary amine-containing polymer (CA-PPZ) 
and an anionic polyphosphazene analogue (6MHA-PPZ) were selected for plasmid 
DNA gene delivery. These binary polyion/gene complexes displayed significantly 
higher transfection efficiency than the parent polycation-only system in 2D monolayers, 
3D spheroids of U87MG cells and in a subcutaneous xenograft model, due to improved 
tumour transport and intracellular trafficking characteristics. This optimized prototype 
also showed indications of superior performance compared to the gold standard PEI 
complexes, particularly in 3D tumour models. When used for RNAi therapy, 
CA-/6MHA-PPZ complexes efficiently delivered siRNA against DYRK1A in U87MG 
cells, inducing a significant reduction of their self-renewal capability in vitro and a 
significant anti-tumoural effect in a glioblastoma model in vivo. Overall, the data 
established a new versatile, biodegradable polymeric gene delivery based on 
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Annex I:  
A Di-Functional Responsive Biodegradable Block-Copolymer 
Polyethylene Glycol-co-Polydisulfide for Gene Delivery Application 
 
Abstract 
We synthesized a novel block-copolymer Polyethylene Glycol-co-Poly(α-LiPoic 
Acid) (PEG-PLPA) containing a PEG block, effective for protecting drugs and labile 
biopharmaceuticals, and a PLPA block for controlled degradation in the tumor tissue. 
Besides the bio-functions, this PEG-PLPA copolymer is designed to be pH- and 
redox-sensitive, facilitating programmed delivery of drugs or associated nanocarriers at 
targeting sites. In this preliminary study, PEG-PLPA was synthesized by ring-opening 
polymerization of lipoic acids and then characterized by NMR, DOSY, GPC, and 
potentiometric titration. In formulation screening for gene delivery carriers, PEG-PLPA 
mixing with protamine:pDNA complexes formed of nanoscale complexes. In a 
redox-sensitive test, once incubated with 10 mM DTT, PEG-PLPA/protamine:pDNA 
complexes underwent a significant increase in particle size, even aggregating and 
shifting towards positive surface charge. These data indicated the loss of PEG-stealth 
functions likely because disulfide bonds of PLPA segments have been broken. Overall, 
this novel bi-functional PEG-PLPA represents approach over PEGylation dilemma 






1. Introduction and background 
In non-viral gene delivery, one of the commonest fashions to facilitate gene cargo 
entering live cells is polymeric-mediated gene delivery1-3. This delivery system has 
been designed as complexes of positively charged polymers with negatively charged 
nucleic acids. However, there is a ‘trade-off’ between strong electrostatic associations 
needed to protect the nucleic acids during delivery with a loose association required for 
release at targeting sites. In this work, we design a novel negatively-charged di-block 
copolymer to provide adequate ionic interaction for complex formation as well as 
pH-sensitive and redox-induced dissociation for release inside targeting cells. One of 
the major problems in the design of gene therapies or other drug delivery modalities is 
what is often termed the “PEG dilemma”.4 On one hand, coating of the drug or the 
nanocarrier with a protective PEG layer is often essential to prevent: (i) instantaneous 
aggregation in physiological media, (ii) unwanted interactions with proteins and blood 
components, (iii) rapid clearance from the bloodstream mediated by the phagocytic 
system, and (iv) potential toxicity mediated by unspecific interactions with blood or 
non-targeted cells5-7. On the other hand, this same PEG coating is known to reduce the 
interaction of the nanocarriers with the targeted cells, and in the specific case of gene 
carriers, will reduce the efficacy of the transfection process. In this context, the 
generation of PEG-coatings that de-associate once the therapeutic cargo has reached 
the targeting site (“programmed delivery systems”) are of high interest. In the past, 
several chemistries have been described that can cleave the PEG layer by either 
reacting to the acidic environment typical of physiological regions such as tumors, or 
less often, by changes in the redox potential. Here we present a new PEG-based 






2. Materials and Methods 
Lipoic acid (PLPA), PEG-SH (Mw 5000), iodoacetamide, and 1,4-Dithiothreitol 
(DTT) were all purchased from Sigma-Aldrich and used as received. Protamine sulfate 
was obtained from Yuki Gosei Kogyo Co., Ltd (Tokyo, Japan).  
PEG-PLPA was synthesized by ring-opening “disulfide exchange” polymerization. 
Briefly, 30 mg of PEG-SH (5000 Da) was added into 100 mg of lipoic acid in 0.6 mL 
methanol. NaOH 2N (50 µL) was added into the reactor for acceleration of disulfide 
exchange and incubated for 3 days. For termination of reaction, excess iodoacetamide 
(90 mg in 0.5 mL water) was added and incubated for another 4 hours. After that, the 
raw product was precipitated in cold ethyl ether and purified by dialysis against pure 
water. Finally, the purified products were lyophilized and stocked in freezer for future 
use. 
For complexation of PEG-PLPA/protamine:pDNA, protamine was dissolved in 
HEPES pH 5.5 firstly, and complexed with polyanions (pDNA and PEG-PLPA) in 
HEPES pH 8.2 with different mass ratios of protamine to pDNA and with mole ratio of 
carboxylic acids on PLPA and phosphate on DNA. The complexation was performed 
by intense vortex for 30 sec and incubated for 2 hours in room temperature. For the all 
characterizations, the analysis methods are same with the chapter 2 in this thesis. 
 
3. Results and discussions 




initiator PEG-thiol to exchange to the disulfide bonds of lipoic acids, growing polymer 
chains. In light this, this polymerization is also called disulfide-exchange 
polymerization. After that, iodoacetamide can be used as terminator for suspending the 
polymerization8. The main structure of this co-polymer is shown in Figure 1, which 
composes of a PEG segment and several repeating units of lipoic acid (PLPA). The 
segment of PEG provides a stealth property for in-vitro and in-vivo stability. On the 
other hand, the segment of PLPA offers negative charges for electrostatic-driven 
association with drugs or other polyionic complexes. The polymer structure was 
identified by proton-NMR spectra for each specific functional group (Figure 2) and 
proton-DOSY confirmed high purity of the final product. The number average 
molecular weight (Mn) of PEG-PLPA is 15404 Da from proton-NMR, which is similar 
to the result (Mn: 15285 Da) from DOSY spectra with known molecular weight of 
PEG standards. However, the GPC measurement of the same PEG-PLPA polymer 
showed around 8000 Da with PI < 1.3, which is also calibrated by PEG standards. 
Regarding this inconsistency, this may be caused by the hydrophobicity of PLPA 
segments, which is easy to form “micelles”, especially at high concentration of the 
polymer samples and aqueous elution phase at pH close to or lower than the pKa of the 
polymer. In addition to structure characterization, this polymer possesses an apparent 
pKa around pH 6.3, expressing their potential buffering capacity in the endosomal pH 
range (Figure 3), but also the potential for coating decoupling in the acidic 
















































Figure 2. Polymer characterization. (a) Proton-NMR characterization and DOSY of 







Figure 3. Potentiometric titration curves and protonation curves of PEG-PLPA in three 
different concentrations. 
 
 In formulation of gene delivery carriers, we chose a cationic protein, protamine 
sulfate as polycation and complexed pDNA to form a nanoscale gene carrier. The 
particle size and surface charge of protamine/pDNA complexes are shown in Figure 4. 
The diameters of complexes are around 90-100 nm and distribution in size of the 
nanoparticles is of low polydispersity. The surface charge of protamine:pDNA is 
inverted to positive values as the mass ratio of protamine to pDNA goes from 0.5 to 
approximately 0.66, indicating that protamine dominates the charge of polymeric 
complexes and excess cationic charges present on the particle surface. Here, we 
decided the mass ratio of protamine to pDNA 2:1 for the following studies. 
 
After formation of polycationic complex (protamine:pDNA), PEG-PLPA is mixed 
into this complex. The PEG-PLPA not only facilitates ionic complex formation and 




glutathione-rich environment typical of tumor cell interior. The decoupling and 
polymer degradation of the polymer could also occur in the extracellular environment, 
induced by the proteins disulfide isomerase. In Figure 5, the size of PEG-PLPA mixing 
protamine complexes remain in the nanoscale range when stably suspended in 
physiological ionic strength (NaCl 150 mM). More interestingly, once the complexes 
incubated with 10 mM DTT (a reducing agent), the PLPA section is cleaved and the 
PEG segments dissociate from the nanocomplexes. As a result of the loss of the 
stabilizing PEG layer, the complexes are destabilized by free ions, causing aggregation 
(Figure 5c). It should be noted that the PEG-PLPA can shield positive surface charges 
of the nanocomplexes dependent on the ratio of polymer to DNA, but after incubation 
in 10mM DTT, the surface charges return from negative to positive due to the 






Figure 4. Particle characterization (a) and TEM images (b) of protamine:pDNA 
complex.  (c) Gel retardation of protamine:pDNA complexes against different mass 
ratios of heparin. 
  
 
Figure 5. (a) TEM images of PEG-PLPA mixing in protamine/pDNA complex. (b) 
PEG-PLPA/protamine:pDNA in physiological pH 7.4 and endosomal pH 5. Particles 
size (c) and zeta potential (d) of PEG-PLPA/protamine:pDNA complex in different 
media and at different ionic strength buffer, and in the same media but in the presence 








The chemical composition of the polymer is simple and novel, and can be 
synthesized following concepts of ‘green’ chemistry. This smart polymer PEG-PLPA is 
sensitive by two physiological stimuli (pH and redox potential), which could be used 
for programmed delivery of active components or associated nanocarriers to cancer 
cells, for instance in polyplex tumor delivery. This copolymer acts as an excipient 









Annex II: Ethical permissions 
I. Animal Studies: 
1. Xenotrasplanted glioma cells in the flank of immunodeficient mice 
2. Intracranial-implantation of siDYRK1A-treated GBM cells 
All the protocols with animals were reviewed and approved by the Research Ethics and 
Animal Welfare Committee at our Institution (Instituto de Salud Carlos III, Madrid) 
(PROEX 244/14), in agreement with the European Union and national directives. 
 
II. Primary cell-line, GBM1 cells 
The primary cell line GBM1 was obtained from Dr. MD. Bernard Rogister’s laboratory 
at the University of Liege, who obtained it from the original source Dr. Vincent Bours’ 
laboratory. The derivation of such cell is already public knowledge and reported in the 
following papers. [Kroonen, J., et al. International Journal of Cancer 129, 574-585 
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To whom it may concern, 
 
This letter certifies that Wei-Hsin Hsu made stayed in the lab I direct from March to 
June of 2017. During that time, he performed in vitro and in vivo studies with glioma 
cells. These experiments were part of his PhD work, financed by the “Nanofar, Erasmus 
Mundus Joint Doctorate in Nanomedicine and Pharmaceutical”. For the in vivo studies, 
we xenotrasplanted glioma cells in the flank of immunodeficient mice. When tumors 
became visible, animals were treated with intratumoral injections of polyphosphazene 
complexes, for effective delivery of interfering DYRK1A RNAs (twice a week) in the 
presence or in the absence of temozolomide (conventional chemotherapy for glioma 
patients). Tumor size was measured afterwards for two weeks. All these procedures 
were done under my supervision and all the protocols with animals were reviewed and 
approved by the Research Ethics and Animal Welfare Committee at our Institution 
(Instituto de Salud Carlos III, Madrid) (PROEX 244/14), in agreement with the European 
Union and national directives. 
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